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*Legislative Background vi 
The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). 
This public law directed ATSDR to prepare toxicological profiles for hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List and that pose the most 
significant potential threat to human health, as determined by ATSDR and the EPA. The 
availability of the revised priority list of 275 hazardous substances was announced in the Federal 
Register on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see 
Federal Register notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); 
October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17,199O (55 FR 
42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 
1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of 
ATSDR to prepare a toxicological profile for each substance on the list. 
___________________________________________________________________________ 
___________________________________________________________________________ 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
 
Toxicological Profiles are a unique compilation of toxicological information on a given 
hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, 
and interpretation of available toxicologic and epidemiologic information on a substance. Health 
care providers treating patients potentially exposed to hazardous substances will find the 
following information helpful for fast answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: 
The Public Health Statement can be a useful tool for educating patients about possible 
exposure to a hazardous substance. It explains a substance’s relevant toxicologic 
properties in a nontechnical, question-and-answer format, and it includes a review of the 
general health effects observed following exposure. 
Chapter 2: Health Effects: 
Specific health effects of a given hazardous compound are reported by route of exposure, 
by type of health effect (death, systemic, immunologic, reproductive), and by length of 
exposure (acute, intermediate, and chronic). In addition, both human and animal studies 
are reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in 
the clinical setting. Please refer to the Public Health Statement to identify general 
health effects observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child 
health issues: 
Section 1.6 How Can (Chemical X) Affect Children? 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 
Section 2.6 Children’s Susceptibility 
Section 5.6 Exposures of Children 
Other Sections of Interest: 
Section 2.7 Biomarkers of Exposure and Effect 
Section 2.10 Methods for Reducing Toxic Effects 
ATSDR Information Center 
Phone: l-800-447-1544 (to be replaced by 1-888-42-ATSDR in 1999) 
or 404-639-6357 Fax: 404-639-6359 
E-mail: atsdric@,cdc.nov Internet: http://atsdrl.atsdr.cdc.nov:8080 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History-The importance of taking 
an exposure history and how to conduct one are described, and an example of a thorough 
exposure history is provided. Other case studies of interest include Reproductive and 
Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting 




Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III-
MedicalManagement Guidelines for Acute Chemical Exposures-is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (‘ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Centerfor Environmental Health (NCEH) 
focuses on preventing or controlling disease, injury, and disability related to the 
interactions between people and their environment outside the workplace. 
Contact: NCEH, Mailstop F-29,4770 Buford Highway, NE, Atlanta, GA 30341-3724 • 
Phone: 770-488-7000 •  FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) 
conducts research on occupational diseases and injuries, responds to requests for 
assistance by investigating problems of health and safety in the workplace, recommends 
standards to the Occupational Safety and Health Administration (OSHA) and the Mine 
Safety and Health Administration (MSHA), and trains professionals in occupational 
safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 
2020 1 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft 
Laboratory, Mailstop C-19,4676 Columbia Parkway, Cincinnati, OH 45226-1998 • 
Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) 
is the principal federal agency for biomedical research on the effects of chemical, 
physical, and biologic environmental agents on human health and well-being. Contact: 
NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • 
Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) 
has developed a network of clinics in the United States to provide expertise in 
occupational and environmental issues. Contact: AOEC, 10 10 Vermont Avenue, NW, #5 
13, Washington, DC 20005 l Phone: 202-347-4976 l FAX: 202- 347-4950 • 
e-mail: aoec@,dgs.dnsys.com • AOEC Clinic Director: http://occ-envmed. 
mc.duke.edu/oem/aoec.htm. 
The American College of Occupational and Environmental Medicine (ACOEM)
 is an association of physicians and other health care providers specializing in the field of 
occupational and environmental medicine. Contact: ACOEM, 55 West Seegers Road, 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
 
1.	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and 
classifying end points. 
2 . Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific minimal risk levels (MRLs), reviews the health effects database of each 
profile: and makes recommendations for derivation of MRLs. 
3 . Data Needs Review. The Research Implementation Branch reviews data needs sections to





A peer review panel was assembled for 3,3’-dichlorobenzidine. The panel consisted of the 
following members : 
1. Dr. Herbert Cornish, Private Consultant, 830 W. Clark Rd., Ypsilanti, MI 48 198; 
2. Dr. Arthur Gregory, Private Consultant, 1 Gregory Lane, Luray, VA 22835; 
3. Dr. Philip Leber, Private Consultant, 1344 Jefferson Ave., Akron, OH 443 13; and 
4. Dr. Robert Rubin, Johns Hopkins School of Public Health, Environmental Health Sciences,
    Baltimore, MD 21205. 
These experts collectively have knowledge of 3,3’-dichlorobenzidine’s physical and chemical 
properties, toxicokinetics, key health end points, mechanisms of action, human and animal 
exposure, and quantification of risk to humans. All reviewers were selected in conformity with 
the conditions for peer review specified in Section 104(1)( 13) of the Comprehensive 
Environmental Response, Compensation, and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed 
the peer reviewers’ comments and determined which comments will be included in the profile. A 
listing of the peer reviewers’ comments not incorporated in the profile, with a brief explanation of 
the rationale for their exclusion, exists as part of the administrative record for this compound. A 
list of databases reviewed and a list of unpublished documents cited are also included in the 
administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the 











1. PUBLIC HEALTH STATEMENT
 
This public health statement tells you about 3,3’-dichlorobenzidine and the effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities. 3,3’-Dichlorobenzidine has been found in at least 32 of the 
1,467 current or former NPL sites. However, the total number of NPL sites evaluated for this 
substance is not known. As more sites are evaluated, the sites at which 3,3’-dichlorobenzidine is 
found may increase. This information is important because exposure to this substance may harm 
you and because these sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it. You may be 
exposed by breathing, eating, or drinking the substance or by skin contact. 
If you are exposed to 3,3’-dichlorobenzidine, many factors determine whether you’ll be harmed. 
These factors include the dose (how much), the duration (how long), and how you come in 
contact with it. You must also consider the other chemicals you’re exposed to and your age, sex, 
diet, family traits, lifestyle, and state of health. 
1 .l WHAT IS 3,3’-DICHLOROBENZIDINE? 
3,3’-Dichlorobenzidine is a gray-to-purple colored crystalline solid. It changes from a solid to a 
gas very slowly. 3,3’-Dichlorobenzidine salt, the major form in actual use, is a stable, off-white 
colored crystalline solid that does not evaporate. Neither 3,3’-dichlorobenzidine nor its salt occur 
naturally in the environment. They are manufactured for use in the production of pigments for 
printing inks, textiles, plastics and enamels, paint, leather, and rubber. Whether 3,3’­
dichlorobenzidine or the salt is present as such depends on the acidity of the soil or water as well 
as other 
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factors. In most environmental samples, such as water and soils, 3,3’-dichlorobenzidine would be 
expected to exist in the free amino form, not as the salt. For more information, see Chapters 3 
and 4. 
1.2 WHAT HAPPENS TO 3,3’-DICHLOROBENZIDINE WHEN IT ENTERS THE 
ENVIRONMENT? 
3,3’-Dichlorobenzidine breaks down rapidly when exposed to natural sunlight. In air and 
sunshine, it is estimated that half of the chemical breaks down within 9.7 hours. In water exposed 
to natural sunlight, 3,3’-dichlorobenzidine is expected to break down rapidly, with half being 
removed in approximately 90 seconds. In soil, where no sunlight is present, the compound may 
last for several months. Under certain conditions, 3,3’-dichlorobenzidine can break down in soil 
to form another compound, benzidine, which is toxic. For more information, see Chapter 5. 
1.3 HOW MIGHT I BE EXPOSED TO 3,3’-DICHLOROBENZIDINE? 
3,3’-Dichlorobenzidine is used to make pigments (substances used to give color to something, for 
example, paint). You are most likely to be exposed to 3,3’-dichlorobenzidine if you work inside 
plants where the chemical is manufactured or used. However, employers have limited workers’ 
exposure to the chemical by using closed systems for processing as well as other methods for 
reducing its concentration in the air to very low levels and by requiring workers to wear 
protective clothing and use special equipment. If you were exposed in such a workplace, it would 
probably be by breathing in the dust or by getting the chemical on your skin. Careless handling or 
accidental spillage of the chemical could result in exposure to potentially hazardous levels of 
3,3’-dichlorobenzidine. People may be exposed to the chemical if they live or work near land 
where plant wastes have been stored or buried, or close to lakes, streams, or rivers near where 
plants discharge process water or store wastes. Most people do not live near a source of the 
chemical. The Canadian government has published calculations that show that exposure of the 
Canadian general population to 3,3’-dichlorobenzidine in air, soil, or water is extremely low. If 
you do live in areas near a source of the chemical (such as a hazardous waste site that contains 
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dye or pigment manufacturing wastes), some exposure could occur if you or a child accidentally 
or purposely ingested small amounts of contaminated soil, drank contaminated water, or ate fish 
caught in waters near the source. However, studies of water and fish taken from locations near 
dye-manufacturing plants did not find the chemical. 
3,3’-Dichlorobenzidine has no agricultural or food chemical uses, so exposure to it by eating 
contaminated food is not likely. More information about the presence of 3,3’-dichlorobenzidine in 
our environment and how it disappears by being broken down by other chemicals and processes 
can be found in Chapter 5. 
1.4 HOW CAN 3,3’-DICHLOROBENZIDINE ENTER AND LEAVE MY BODY? 
In the workplace, 3,3’-dichlorobenzidine may enter the body when workers breathe dust 
contaminated by 3,3’-dichlorobenzidine and through skin contact. You are not likely to be 
exposed to 3,3’-dichlorobenzidine unless you drink water or eat dirt contaminated with 
3,3’-dichlorobenzidine in the vicinity of a hazardous waste site where 3,3’dichlorobenzidine has 
been stored and leakage has occurred. When 3,3’-dichlorobenzidine does enter the body, very 
little of it leaves the body unchanged. Most of it (over 90%) is changed to related chemical 
substances called metabolites, which leave the body, mainly in urine and to a lesser extent in 
feces, within 72 hours after exposure. More information can be found in Chapter 2. 
1.5 HOW CAN 3,3’-DICHLOROBENZIDINE AFFECT MY HEALTH? 
Some workers exposed to the salt form of 3,3’-dichlorobenzidine complained of sore throat, 
respiratory infections, stomach upset, headache, dizziness, caustic burns, and dermatitis (an 
inflammation of the skin). However, with the exception of dermatitis, it is not certain that 
3,3’-dichlorobenzidine causes these health effects because the workers were also exposed to other 
chemicals at the same time. There is no evidence that 3,3’-dichlorobenzidine affects the nervous 
system, the ability to fight disease, or the ability of people to have children. 
3,3’-DICHLOROBENZIDINE 4 
1. PUBLIC HEALTH STATEMENT
 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests. 
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary. Animal testing may 
also be used to identify health effects such as cancer or birth defects. Without laboratory animals, 
scientists would lose a basic method to get information needed to make wise decisions to protect 
public health. Scientists have the responsibility to treat research animals with care and 
compassion. Laws today protect the welfare of research animals, and scientists must comply with 
strict animal care guidelines. 
Death has occurred in laboratory animals that ate very high levels of 3,3’-dichlorobenzidine 
mixed in their food for short periods of time. Laboratory animals exposed to moderate levels of 
3,3’-dichlorobenzidine mixed with food for a long time suffered mild injury to the liver. 
Studies show that 3,3’-dichlorobenzidine caused cancer of the liver, skin, breast, bladder, and 
tissues that form blood (leukemia), and other sites in laboratory animals that ate 3,3’­
dichlorobenzidine in their food. There is no evidence that 3,3’-dichlorobenzidine has caused 
cancer in people who worked with it or who were exposed to it unknowingly or by accident for a 
short or long time. However, because of the many types of cancer that 3,3’-dichlorobenzidine has 
caused in different tissues of many types of laboratory animals, 3,3’-dichlorobenzidine should be 
thought of as probably capable of causing human cancer if exposure to the chemical is 
sufficiently high. 
The Environmental Protection Agency (EPA) has determined that 3,3’-dichlorobenzidine is a 
“probable human carcinogen.” The U.S. Department of Health and Human Services (DHHS) has 
determined that 3,3’-dichlorobenzidine and its salt may reasonably be expected to be 
cancercausing substances (carcinogens). The International Agency for Research on Cancer 
(IARC) has determined that 3,3’-dichlorobenzidine is possibly carcinogenic to humans. More 
information can be found in Chapter 2. 
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1.6 HOW CAN 3,3’-DICHLOROBENZIDINE AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans. Potential effects on children resulting from exposures of 
the parents are also considered. 
Children might be exposed to 3,3’-dichlorobenzidine if they eat small amounts of soil 
contaminated with 3,3’-dichlorobenzidine. However, studies suggest that it is very difficult to 
release 3,3’-dichlorobenzidine once it becomes attached to soil. Exposure via contaminated soil 
may occur if they live in an area near a source of the chemical (such as a hazardous waste site that 
contains 3,3’-dichlorobenzidine). Children can also be exposed if the parents work at chemical 
facilities where 3,3’-dichlorobenzidine is handled and bring home contaminated clothing or tools 
or if they do not shower before coming home. There are no known unique exposure pathways for 
children. 
There have been no studies of health effects in children exposed to 3,3’-dichlorobenzidine. We 
have no information on whether 3,3’-dichlorobenzidine causes birth defects in children. It is 
unknown whether birth defects would occur in the offspring of pregnant animals that breathed or 
eaten 3,3’-dichlorobenzidine, or had it on their skin. In studies in which pregnant mice were 
injected with high amounts of 3,3’-dichlorobenzidine under the skin, the kidneys of their babies 
did not develop properly and some babies developed renal tumors. However, it is highly unlikely 
that humans will encounter such exposure conditions. 
There is no information to determine whether children are different in their sensitivity to the 
health effects of 3,3’-dichlorobenzidine from adults. There is indirect evidence that 3,3’­
dichlorobenzidine or its breakdown products can cross the placenta, but we do not know for 
certain whether it can be transferred to the young via the mother’s breast milk. Sometimes when 
children have been exposed to chemicals before they are born, the chemical or its breakdown 
products can be found in amniotic fluid, meconium, cord blood, or neonatal blood; however, no 
information 
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about such measurements was found for 3,3’-dichlorobenzidine. More information regarding 
children’s health and 3,3’-dichlorobenzidine can be found in Section 2.6. 
1.7 	HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO
       3,3’-DICHLOROBENZIDINE? 
If your doctor finds that you have been exposed to significant amounts of 3,3’-dichlorobenzidine, 
ask your doctor if children may also be exposed. When necessary your doctor may need to ask 
your state Department of Public Health to investigate. 
3,3’-Dichlorobenzidine has no agricultural or food chemical uses, so exposure to it by eating 
contaminated food is not likely. It is sometimes possible to carry 3,3’-dichlorobenzidine from 
work on your clothing, skin, hair, tools, or other objects removed from the workplace. This has 
happened in factories that produce 3,3’-dichlorobenzidine. In this way, you may contaminate 
your car, home, or other locations outside work where children might be exposed to 3,3’­
dichlorobenzidine.  You should know about this possibility if you work with 3,3’­
dichlorobenzidine. 
Your occupational health and safety officer at work can and should tell you whether chemicals 
you work with are dangerous and likely to be carried home’on your clothes, body, or tools. Ask 
if you should shower and change clothes before you leave work, store your street clothes in a 
separate area of the workplace, or launder your work clothes at home separately from other 
clothes. The Occupational Safety and Health Administration (OSHA) requires Material Safety 
Data Sheets (MSDSs) for many chemicals used at your place of work. MSDS information should 
include chemical names and hazardous ingredients, and important information such as fire and 
explosion data, potential health effects, how you get the chemical(s) in your body, how to 
properly handle the materials, and what to do in the case of emergencies. Your employer is 
legally responsible for providing a safe workplace and should freely answer your questions about 
hazardous chemicals. U.S. OSHA or your state OSHA-approved occupational safety and health 
program can answer any further questions and help your employer identify and correct problems 
with hazardous substances. OSHA or your state OSHA-approved occupational safety and health 
program will listen to your formal complaints about workplace health hazards and inspect your 
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workplace when necessary. Employees have a right to seek safety and health on the job without 
fear of punishment. More information regarding exposure to 3,3’-dichlorobenzidine can be found 
in Sections 5.5, 5.6, and 5.7. 
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
      EXPOSED TO 3,3’-DICHLOROBENZIDINE? 
Exposure to 3,3’-dichlorobenzidine can be determined by finding the chemical or its metabolites 
in urine. The test is not commonly available to the general population, but it is available to 
workers who may be exposed to potentially hazardous levels of the chemical in the workplace 
(for example, by careless handling or accidental spills). The test is accurate and provides evidence 
that exposure has occurred. However, since 3,3’-dichlorobenzidine does not remain long in the 
body, the test must be performed very soon after the possible exposure. Also, measured urine 
levels of 3,3’-dichlorobenzidine or its metabolites do not tell you whether it will affect your 
health. More information can be found in Chapter 6. 
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
       PROTECT HUMAN HEALTH? 
Federal agencies that develop regulations for toxic substances include the Environmental 
Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA). Recommendations provide valuable guidelines to protect 
public health but cannot be enforced by law. Federal organizations that develop recommendations 
for toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and 
the National Institute for Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals; then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
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Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for 3,3’-dichlorobenzidine include the 
following: 
EPA has determined that 3,3’-dichlorobenzidine is a “probable human carcinogen” and has 
placed several limits on the chemical in the environment to protect human health. Under the 
Clean Water Act of 1977, EPA controls discharges of 3,3’-dichlorobenzidine to industrial waste 
waters. The agency has listed 3,3’-dichlorobenzidine as a hazardous waste and requires that any 
spill of one pound or more be reported to the National Response Center. 
Although the FDA has classified 3,3’-dichlorobenzidine as a carcinogen, no regulatory guidelines 
have been enacted. The FDA has concluded that the food supply is not in danger from 
3,3’-dichlorobenzidine. 
3,3’-Dichlorobenzidine is one of a number of compounds regulated by OSHA. To control 
exposures to 3,3’-dichlorobenzidine in workplace air and to protect the health of workers, 
OSHA’s regulatory standards provide strict guidelines for handling, using, and storing the 
compound. They also include the requirements for personal protective equipment, training, 
labeling, and posting and engineering controls. OSHA also requires that initial medical screening 
and regular medical examinations be made available to any employee who is exposed to 3,3’-
dichlorobenzidine at potentially hazardous levels. 
NIOSH considers 3,3’-dichlorobenzidine a “potential occupational carcinogen” and recommends 
workplace practices and controls to reduce exposures to the lowest possible level. NIOSH 
defines potential occupational carcinogens as substances which may cause an increased incidence 
of benign and/or malignant neoplasm, or a substantial decrease in the latency period between 
exposure and onset of neoplasms in humans. 
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1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or: 













ATSDR can also tell you the location of occupational and environmental health clinics. These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
* To order toxicological profiles, contact: 
National Technical Information Service
 
5285 Port Royal Road
 
Springfield, VA 22 16 1
 




2. HEALTH EFFECTS 
2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, 
and other interested individuals and groups with an overall perspective of the toxicology of 3,3’­
dichlorobenzidine. It contains descriptions and evaluations of toxicological studies and 
epidemiological investigations and provides conclusions, where possible, on the relevance of 
toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this 
profile. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working 
near hazardous waste sites, the information in this section is organized first by route of exposure-
inhalation, oral, and dermal; and then by health effect--death, systemic, immunological, 
neurological, reproductive, developmental, genotoxic, and carcinogenic effects. These data are 
discussed in terms of three exposure periods-acute (14 days or less), intermediate (15-364 days), 
and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated 
in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or 
lowest-observedadverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used 
in the studies. LOAELS have been classified into “less serious” or “serious” effects. “Serious” 
effects are those that evoke failure in a biological system and can lead to morbidity or mortality 
(e.g., acute respiratory distress or death). “Less serious” effects are those that are not expected to 
cause significant dysfunction or death, or those whose significance to the organism is not entirely 
clear. ATSDR acknowledges that a considerable amount of judgment may be required in 
establishing whether an end point should be classified as a NOAEL, “less serious” LOAEL, or 
“serious” LOAEL, and that in some cases, there will be insufficient data to decide whether the 
effect is indicative of significant dysfunction. However, the Agency has established guidelines 
and policies that are used to classify these end points. ATSDR believes that there is sufficient 
merit in this approach to warrant an attempt at distinguishing between “less serious” and 




distinction between “less serious” effects and “serious” effects is considered to be important 
because it helps the users of the profiles to identify levels of exposure at which major health 
effects start to appear.  LOAELs or NOAELs should also help in determining whether or not the 
effects vary with dose and/or duration, and place into perspective the possible significance of 
these effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables 
and figures may differ depending on the user’s perspective. Public health officials and others 
concerned with appropriate actions to take at hazardous waste sites may want information on 
levels of exposure associated with more subtle effects in humans or animals (LOAEL) or 
exposure levels below which no adverse effects (NOAELs) have been observed. Estimates of 
levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may be of interest to 
health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of 3,3’­
dichlorobenzidine are indicated in Table 2- 1 and Figure 2- 1. Because cancer effects could occur 
at lower exposure levels, Figure 2-1 also shows a range for the upper bound of estimated excess 
risks, ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
A User’s Guide has been provided at the end of this profile (see Appendix B). This guide should 
aid in the interpretation of the tables and figures for Levels of Significant Exposure. 
2.2.1 Inhalation Exposure 
3,3’-Dichlorobenzidine is not a volatile chemical. In the air, it may exist as dust particles or 
bound to particulate matter. The absorption of 3,3’-dichlorobenzidine from such respirable 
particles into the body depends, in part, on the size of the particle. Large particles tend to deposit 
in the upper airways and are subsequently cleared by ciliary action with little absorption across 
lung tissues. However, the ciliary action transports the particles to the epiglottis where they are 
often swallowed, leading to gastrointestinal absorption. Smaller particles can penetrate more 





No studies were located regarding lethal effects in humans or animals after inhalation exposure to 
3,3’-dichlorobenzidine. No fatalities were observed in rats observed for 14 days following a 
l-hour exposure to an unspecified concentration of 3,3’-dichlorobenzidine dihydrochloride dust 
(Gerarde and Gerarde 1974). No deaths were reported in male rats exposed to 23,700 mg/m3 
3,3’-dichlorobenzidine base (dust) for 2 hours per day for 7 days (Gerarde and Gerarde 1974). 
2.2.1.2 Systemic Effects 
No studies were located regarding cardiovascular, hematological, musculoskeletal, hepatic, renal, 
endocrine, dermal, ocular, body weight, or metabolic effects in humans or animals after 
inhalation exposure to 3.3’-dichlorobenzidine. 
Respiratory Effects. Upper respiratory infection and sore throat were listed among several 
principal reasons for visits to a company’s medical clinic by workers handling 
3,3’-dichlorobenzidine dihydrochloride (Gerarde and Gerarde 1974). However, there is no 
conclusive evidence that these effects were due to inhalation of 3,3’-dichlorobenzidine 
dihydrochloride. 
No adverse health effects were observed in male rats exposed by inhalation to 
3,3’- dichlorobenzidine free base (23,700 mg/m3) 2 hours per day for 7 days (Gerarde and 
Gerarde 1974). In another study, 10 rats were exposed to an unspecified concentration of 
3,3’-dichlorobenzidine dihydrochloride dust particles for 1 hour and then observed for 14 days. 
Slight-to-moderate pulmonary congestion and one pulmonary abscess were observed upon 
necropsy (Gerarde and Gerarde 1974). The effects observed in the study using the ionized 
(hydrochloride) form of 3,3’-dichlorobenzidine may have been due to the irritative properties of 
hydrochloric acid released from the salt in combination with particulate toxicity. 
Gastrointestinal Effects. Gastrointestinal upset was one of the symptoms reported by employees 
who worked with 3,3’-dichlorobenzidine dihydrochloride (dihydro salt of 3,3’-dichlorobenzidine) 
(Gerarde and Gerarde 1974). However, there is no conclusive evidence that the gastrointestinal 





No studies were located regarding gastrointestinal effects in animals following inhalation 
exposure to 3,3’-dichlorobenzidine. 
2.2.1.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans or animals after inhalation 
exposure to 3,3’-dichlorobenzidine. 
2.2.1.4 Neurological Effects 
The only relevant information regarding neurological effects in humans exposed to 
3,3’-dichlorobenzidine was found in an early study which reported that headache and dizziness 
were among several principal reasons why employees working with 3,3’-dichlorobenzidine in a 
chemical manufacturing plant visited the company medical clinic (Gerarde and Gerarde 1974). 
However, there is no conclusive evidence that these symptoms were caused specifically by 
3,3’-dichlorobenzidine since there was exposure to other chemicals as well. No further 
information was provided. 
No studies were located regarding neurological effects in animals after inhalation exposure to 
3,3’-dichlorobenzidine. 
No studies were located regarding the following effects in humans or animals after inhalation 
exposure to 3,3’-dichlorobenzidine: 
2.2.1.5 Reproductive Effects 
2.2.1.6 Developmental Effects 
2.2.1.7 Genotoxic Effects 





Several epidemiological studies have investigated cancer incidences among workers 
occupationally exposed to 3,3’-dichlorobenzidine (Gadian 1975; Gerarde and Gerarde 1974; 
MacIntyre 1975; Myslak et al. 1991).  Exposure may have been by both inhalation and dermal 
routes. 
Due, in part, to structure-activity considerations, epidemiological studies of potential cancer 
effects of occupational exposure to 3,3’-dichlorobenzidine have been particularly concerned with 
bladder tumors, since 3,3’-dichlorobenzidine is structurally similar to benzidine, a chemical 
which is known to be a human bladder carcinogen. The possible role of benzidine-based azodyes 
as a carcinogenic risk factor for painters in a major industrial area of Germany was investigated 
by Myslak et al. (1991). The cohort consisted of 403 male patients (case group) treated in the 
period 1984-1987 for urological tumors: 290 had a diagnosis of bladder carcinoma and 113 had a 
diagnosis of bladder papilloma. The mean duration of employment was 29 years (range 2-48 
years). A comparison group (reference group) of 426 patients with benign prostate disease was 
also included in the study. Cases and controls responded to questionnaires regarding employment 
history. Questionnaires were analyzed for occupational categories. A painter was defined as a 
person employed in this occupation for at least 6 months at any time of his working history and 
who had never been employed in another occupation known to be causally associated with 
bladder cancer. Of the bladder tumor patients, 21 were painters; among referents, 8 were painters. 
This difference among the groups was statistically significant; the relative risk of painters to be 
associated with bladder tumor was 2.76 (p<0.01). Occupation as painter (primarily house painter) 
was far more frequent among bladder tumor patients than would be expected from census data. 
The relative risk of bladder tumors for current smokers and ex-smokers was 1.13, which led 
Myslak et al. (1991) to suggest that the risk of smoking for bladder tumors was less than the 
occupational risk for the painters. The authors noted that a large number of benzidine-based 
azodyes were manufactured in Germany in the past. During that time it was usual for painters to 
prepare the paints themselves, allowing for possible exposure to dyes and pigments derived from 
benzidine, 3,3’-dichlorobenzidine, 3,3’-dimethylbenzidine (o-tolidine), 3,3’-dimethoxybenzidine 
(o-dianisidine), and 2-naphthylamine (Myslak et al. 1991). While the results of this study suggest 
that occupational exposure to benzidine-like chemicals is associated with an increased incidence 




No other epidemiological studies have found either bladder tumors or excess tumors at other sites 
that were associated with 3,3’-dichlorobenzidine (Gadian 1975; Gerarde and Gerarde 1974; 
MacIntyre 1975).  However, these studies were conducted with workers who were exposed to 
3,3’-dichlorobenzidine for less than 20 years. Since a period of 5 to 50 years may follow the 
exposure to bladder carcinogens and the diagnosis of bladder cancer by a physician (Badalament 
1998), an adequate latency period for 3,3’-dichlorobenzidine-induced tumors may not have 
elapsed for some individuals. Also, the number of workers examined in these studies was 
relatively small, thus limiting the statistical power to detect a significant increase in bladder 
cancer mortality (incidence). Finally, the possibility that 3,3’-dichlorobenzidine is a human 
carcinogen under certain undefined exposure conditions cannot be totally ruled out. 
In one of these reports, no bladder tumors were found in a group of 35 workers who handled only 
3,3’-dichlorobenzidine; in the same dyestuff plant, bladder tumors occurred in 3 out of 14 
workers exposed to both benzidine and 3,3’-dichlorobenzidine. The investigator reported a total 
exposure time of 68,505 hours, equivalent to nearly 140 full-time working years (Gadian 1975). 
No cases of bladder tumors were found in an epidemiology study of 259 workers exposed to dry 
and sernidry 3,3’-dichlorobenzidine base and hydrochloride. Cytological analyses of the urine 
(Papanicolaou tests) were negative. Workers were exposed to an average of less than 16 years 
each to 3,3’-dichlorobenzidine, which means that an adequate exposure duration and/or the latent 
period following exposure may not have been reached for tumor expression (MacIntyre 1975). 
In a retrospective epidemiological study of workers employed in a dye and pigment 
manufacturing plant that used 3,3’-dichlorobenzidine as chemical precursor, no bladder tumors 
were observed in a cohort of 207 workers, most of whom had been exposed for up to 15 years 
(Gerarde and Gerarde 1974). However, in this study there was no evidence that any valid system 
of medical surveillance of workers ever existed during the years that 3,3’-dichlorobenzidine was 
used at the plant. A number of employees had not been followed up for 15 years or more 
(Gerarde and Gerarde 1974). Other limitations of this study included using data from a very small 
and incomplete sample of workers; focusing solely on the occurrence of bladder tumors; and 
using data that may have been misleading and, at times, apparently inaccurate. 
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2. HEALTH EFFECTS 
No studies were located regarding cancer effects in animals after inhalation exposure to 
3,3’-dichlorobenzidine.  However, cancer effects have been observed in animal studies where 
3,3’-dichlorobenzidine was administered orally or by other routes. See Sections 2.2.2.8 and 2.5 
for further information. 
2.2.2 Oral Exposure 
Indirect gastrointestinal tract exposure may occur from breathing contaminated airborne dust in 
the workplace. The respiratory deposition pattern of inhaled 3,3’-dichlorobenzidine depends 
primarily on the mass median aerodynamic diameter (MMAD) of the particles. The mucociliary 
clearance mechanism moves most particulates with a MMAD of l-5 µm out of the lower 
respiratory tract, thus allowing their passage into the gastrointestinal tract. Larger particles 
(>5 µm) impacting in the nasopharyngeal region would also be eventually ingested. Oral 
exposure may potentially occur in the general environment by drinking contaminated 
groundwater. Occupational exposure by the oral route is not expected to be significant. Exposure 
through eating food is unlikely since 3,3’-dichlorobenzidine has never had an application as an 
agricultural or food chemical. Children may be exposed to 3,3’-dichlorobenzidine if they 
consume contaminated soil; however, the bioavailability of 3,3’-dichlorobenzidine from soil is 
quite low. All of the available data on the effects of 3,3’-dichlorobenzidine following oral 
exposure are derived from studies in experimental animals. Table 2- 1 and Figure 2- 1 summarize 
available data. 
2.2.2.1 Death 
No studies were located regarding lethal effects in humans after oral exposure to 
3,3’-dichlorobenzidine. 
In rats, the acute-duration oral LD50 (lethal dose, 50% kill) for 3,3’-dichlorobenzidine free base 
administered in pure olive oil was estimated to be 7,070 mg/kg, whereas the LD50 for a 20% 
suspension of the dihydrochloride salt in corn oil was 3,820 mg/kg (Gerarde and Gerarde 1974). 
The cause of death was not discussed. Given this high LD50 acute lethality in humans following 
oral exposure is unlikely. Both oral LD50 values for 3,3’-dichlorobenzidine are shown in Table 










2.2.2.2 Systemic Effects 
No studies were located regarding respiratory, hematological, hepatic, renal, or body weight 
effects in humans after oral exposure to 3,3’-dichlorobenzidine. No studies were located 
regarding cardiovascular, gastrointestinal, musculoskeletal, endocrine, dermal, ocular, or 
metabolic effects in humans or animals after oral exposure to 3,3’-dichlorobenzidine. 
The highest NOAEL values and all LOAEL values for oral exposure from each reliable study for 
systemic effects in each species and duration category for 3,3’-dichlorobenzidine are shown in 
Table 2-1 and plotted in Figure 2- 1. 
Respiratory Effects. Dyspnea was observed in 1 of 6 female dogs exposed to 10.4 mg/kg/day 
3,3’-dichlorobenzidine for 6.6 years, which probably resulted as a secondary effect of liver 
disease, that this dog was experiencing. No respiratory effects were observed in any other dogs, 
including controls (Stula et al. 1978). 
Hematological Effects. Although hematological effects may not be sensitive indicators for 
3,3’-dichlorobenzidine toxicity, hemoglobin adducts have been detected in female Wistar rats 
orally administered single 127 or 253 mg/kg doses of 3,3’-dichlorobenzidine (Birner et al. 1990) 
or with repeated doses between 0.3 and 5.8 mg/kg/day (Joppich-Kuhn et al. 1997). It was 
suggested that metabolically formed nitroso derivatives and the formation of a sulfinic acid amide 
with cysteine residues in hemoglobin may be the mechanism of adduct formation (Birner et al. 
1990). Hydrolysis yielded mainly 3,3’-dichlorobenzidine; N-acetylated 3,3’-dichlorobenzidine 
was also detected. The more recent study found that adduct formation was dose-related (Joppich-
Kuhn et al. 1997). It was further observed that at low doses of 3,3’-dichlorobenzidine, N-acetyl­
3,3’-dichlorobenzidine adducts and 3,3’-dichlorobenzidine adducts were formed at similar levels, 
but at the highest dose level tested (5.8 mg/kg/day) the dichlorobenzidine adduct was 
predominant, suggesting saturation of the acetylation pathway at high dose (Joppich-Kuhn et al. 
1997).  While hemoglobin adduct formation does not imply altered or abnormal hemoglobin 
function, adduct formation may be a suitable biomarker of human exposure to 
3,3’-dichlorobenzidine (see Section 2.7).  Hematological variables (erythrocyte count, 
hemoglobin concentration, hematocrit, and leucocyte count) were found to be normal in dogs 




Hepatic Effects. Limited animal evidence suggests that chronic-duration oral exposure to 
3,3’-dichlorobenzidine results in mild-to-moderate liver injury. Six female dogs exposed to 
3,3’-dichlorobenzidine (10.4 mg/kg/day) all had modestly elevated plasma glutamic-pyruvic 
transaminase (GPT) during the first 3 years of a 7-year treatment period (Stula et al. 1978). 
Thereafter, GPT levels returned to normal in three of the experimental animals, two remained 
elevated for the duration of the study. Elevated GPT levels may have been due to the test 
chemical that caused chronic hepatic injury to these dogs that ultimately led to development of 
liver tumors. One of the six dogs, sacrificed after 42 months of the test, showed a marked 
fatty change in the liver. It should be noted that the study is limited by use of one dose level, 
precluding dose-response evaluations. It should be mentioned, however, that none of the six 
control dogs exhibited adverse liver effects. 
Renal Effects. Urinary parameters (blood urea nitrogen, pH, osmolality, volume, protein, sugar, 
and sediment) were normal in female dogs exposed to 3,3’-dichlorobenzidine (10.4 mg/kg/day) 
throughout a 7-year study in which female dogs were exposed to 10.4 mg/kg/day 
3,3’-dichlorobenzidine. At necropsy, no histological effects to the kidneys were reported in any of 
the dogs (Stula et al. 1978). 
Body Weight Effects. In a study in which female dogs were exposed to 10.4 mg/kg/day 
3,3’-dichlorobenzidine for 7 years, there were no significant differences in body weight between 
treated and control dogs during the study period (Stula et al. 1978). 
2.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and/or lymphoreticular effects in humans or 
animals after oral exposure to 3,3’-dichlorobenzidine. 
2.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to 3,3’-
dichlorobenzidine. 
In a 3,3’-dichlorobenzidine carcinogenicity study, 1 of 6 dogs exhibited convulsions after 21, 28, 





at 42 months revealed slight neuronal degeneration; although the specific location was not 
indicated, histological examination was performed on the brain and spinal cord. No neurological 
effects were observed in any other dogs, including controls. This LOAEL value for neurological 
effect for oral exposure to 3,3’-dichlorobenzidine is shown in Table 2- 1 and plotted in 
Figure 2- 1. 
2.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans or animals after oral exposure 
to 3,3’-dichlorobenzidine. 
2.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans or animals after oral 
exposure to 3,3’-dichlorobenzidine. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans after oral exposure to 
3,3’-dichlorobenzidine. 
Genotoxic effects have been reported in animals treated with 3,3’-dichlorobenzidine. A single 
dose of 3,3’-dichlorobenzidine (1,000 mg/kg) administered to male and pregnant female mice 
induced micronuclei in polychromatic erythrocytes in the bone marrow of the males and in the 
liver of the fetuses, but not in bone marrow of the dams (Cihak and Vontorkova 1987). A 
micronucleus test is performed to detect a chemical’s ability to induce chromosomal aberrations. 
However, the relevance of micronuclei formation to human health is not known. The reason for 
the lack of effect of 3,3’-dichlorobenzidine on bone marrow micronuclei formation in the mothers 
is unclear, but it may be related to deficiencies in the metabolic activation of 
3,3’-dichlorobenzidine in female mice. The relative importance of pregnancy is unknown since 
the study did not evaluate nonpregnant females. In another study, an increase in unscheduled 
deoxyribonucleic acid synthesis (UDS) was observed in cultured liver cells from male mice 
previously pretreated orally with single doses of ≥ 500 mg/kg 3,3’-dichlorobenzidine; no 




3,3’-Dichlorobenzidine was also shown to bind extensively to tissue deoxyribonucleic acid 
(DNA) in rats and mice. Single oral administration of 20 or 100 mg/kg radiolabeled 
3,3’-dichlorobenzidine to male Sprague-Dawley rats and Swiss-Webster mice resulted in 
extensive binding of the compound to tissue (liver, bladder, and intestine) DNA at 12, 24, or 96 
hours, and 9 or 14 days after treatment (Ghosal and Iba 1990). 
The UDS assay is used to measure the repair that follows DNA damage. However, the relevance 
of UDS to human health is not known. While results were positive in two assay in animals, 
sufficient data are not available from more predictive indicator assays to adequately characterize 
the genotoxic potential for 3,3’-dichlorobenzidine in humans. Other genotoxicity studies are 
discussed in Section 2.5. 
2.2.2.8 Cancer 
There are no epidemiological studies linking cancer in humans to oral exposure to 
3,3’-dichlorobenzidine.  However, based on the findings of oral studies in animals, 
3,3’-dichlorobenzidine may be regarded as a chemical that would probably induce cancer in 
humans given sufficient exposure to the agent. An IARC review of the existing cancer toxicity 
data for 3,3’-dichlorobenzidine concluded that, although no case report on exposure to 
3,3’-dichlorobenzidine was available, because 3,3’-dichlorobenzidine and benzidine may be made 
in the same plant, it is not possible to exclude 3,3’-dichlorobenzidine’s contribution to the 
incidence of bladder cancer attributed to benzidine (IARC 1982a). Studies in animals 
demonstrated that 3,3’-dichlorobenzidine is carcinogenic in rats, hamsters, mice and dogs (see 
below). 
A statistically significant increased incidence of hepatomas was observed in male ICR/JCL mice 
exposed to 0.1% 3,3’-dichlorobenzidine in the diet (170 mg/kg/day) at 6 months (8 of 8 treated as 
opposed to 0 of 5 controls) and 12 months (18 of 18 treated as opposed to 2 of 2 1 controls) 
(Osanai 1976). Hepatic tumors were observed in 4/l 8 strain D mice exposed to 11.2-l 1.9 mg 
3,3’-dichlorobenzidine/kg/day in the diet for 10 months (Pliss 1959). 
No bladder carcinomas were observed in rats exposed to 0.03% 3,3’-dichlorobenzidine in the diet 
(27 mg/kg/day) for 4 or 40 weeks (Ito et al. 1983), nor were any mammary tumors observed in 
rats administered approximately 49 mg 3,3’-dichlorobenzidine dihydrochloride/kg/day by gavage 




In a study in which rats were exposed to 10-20 mg 3,3’-dichlorobenzidine per day (120 
mg/kg/day) in feed 6 days per week for 12 months, tumors were observed at a variety of sites, 
including the Zymbal gland (7 of 29 animals), mammary gland (7/29), bladder (3/29), 
hematopoietic system (3/29), skin (3/29), ileum (2/29), connective tissue (2/29), salivary gland 
(2/29), liver (l/29), and thyroid (l/29) (Pliss 1959). No tumors were reported in 130 control 
animals. In a later study, the same investigator reported that oral administration of an unspecified 
dose (in the range of 125-500 mg/kg) of 3,3’-dichlorobenzidine by gavage to rats for 10-13 
months resulted in the development of tumors of the skin, sebaceous and mammary glands, and 
papillomas of the urinary bladder (Pliss 1963). Because the frequency of administration of the 
compound was not provided, a daily dose could not be estimated. 
In another rat study, 3,3’-dichlorobenzidine was administered to 50 male (70 mg/kg/day) and 50 
female (80 mg/kg/day) Sprague-Dawley rats, in a standard diet for up to 16 months (Stula et al. 
1975). In rats fed 3,3’-dichlorobenzidine in the diet for a total of 349 days (females) and 353 days 
(males), histopathological evaluations revealed mammary adenocarcinoma (16% incidence), 
malignant lymphoma (14%) granulocytic leukemia (20%), carcinoma of the Zymbal gland (18%) 
in males, and mammary adenocarcinoma (59%) in females. These tumors were either totally 
absent or occurred statistically less frequently in untreated controls. The authors noted that most 
of these tumors appeared to arise in the bone marrow and hematopoietic foci in the spleen and 
liver with subsequent metastasis to other organs. Only one dose level was used in the study, 
however, and information on the purity of the test substance was not provided. 
In a subsequent study by this investigator, hepatocellular carcinomas (67% incidence) and 
papillary transitional cell carcinomas of the urinary bladder (83%) were observed in female dogs 
fed approximately 10.4 mg/kg/day orally in gelatin capsules over a period of 6.6-7.1 years (Stula 
et al. 1978). These tumors were absent in untreated controls. Although a small number of dogs (6) 
were evaluated, and only one sex and one dose were used, the significant increase in tumor rate in 
this group of dogs demonstrates unequivocally the carcinogenicity of this chemical in this 
species. 
Transitional cell bladder carcinomas and liver cell and cholangiomatous tumors were observed in 
hamsters fed a diet containing 0.3% 3,3’-dichlorobenzidine (300 mg/kg/day) (Sellakumar et al. 





benzidine (59-64 mg/kg/day) fed to Syrian golden hamsters for their lifetimes did not cause 
significant carcinogenic effects or changes in bladder pathology (Saffiotti et al. 1967). 
A synergistic role for 3,3’-dichlorobenzidine in the development of bladder cancer has been 
suggested. This was proposed in a study in which no carcinomas were found in any rats 
administered one of the following: 0.03% 3,3’-dichlorobenzidine in the diet, 0.001% BBN 
(N-butyl-N-(hydroxybutyl)nitrosamine) in drinking water, 0.0005% 2-acetylaminofluorene 
(2-AAF) in the diet, or 0.04% N-[4-(5nitro-2-furyl)-2-thiazolyllformamide (FANFT) in the diet 
for a period of 40 weeks (Ito et al. 1983). However, when BBN plus 3,3’-dichlorobenzidine were 
fed together at the same dose levels as above, there was a marked increase in the presence of 
papillary or nodular hyperplasia in the rat bladder, and the appearance of one papilloma. 
Based on these findings, the authors suggested that 3,3’-dichlorobenzidine had a synergistic effect 
on the carcinogenicity of BBN. In rats sequentially administered BBN (0.0l%), FANFT (0.15%), 
2-AAF (0.025%), and 3,3’-dichlorobenzidine (0.03%) for 4 weeks each, the incidence of bladder 
cancer after administration of the 4 chemicals was no different than after administration of the 
first 3, suggesting no interactive effect of any type for 3,3’-dichlorobenzidine (Ito et al. 1983). 
The Cancer Effect Level (CEL), (i.e., lowest dose that produced a tumorigenic response for each 
species) and the duration category of exposure to 3,3’-dichlorobenzidine are shown in Table 2-l 
and plotted in Figure 2-l. Based on the increased incidence in mammary adenocarcinomas in rats 
reported in the Stula et al. (1975) study, EPA calculated a q1* of 0.45 (mg/kg/day)-1. Doses 
corresponding to risk levels ranging from 10-4 to 10-7 are 2.2x10-4 to 2.2x10-7 mg/kg/day, 
respectively, as indicated in Figure 2-l. 
2.2.3 Dermal Exposure 
Because of large particle size and increased usage of closed systems and protective clothing, 
dermal absorption is expected to be minimal in occupational environments. Conditions of high 
humidity and high temperature are known to enhance dermal absorption of chemicals following 
skin contact. 
2.2.3.1 Death 
No studies were located regarding lethal effects in humans after dermal exposure to 3,3’-
dichlorobenzidine. The minimum dermal lethal dose for 3,3’-dichlorobenzidine (free base) for 




albino rabbits with skin intact was reported to be greater than 8,000 mg/kg (Gerarde and Gerarde 
1974). The cause of death was not discussed. No discernible skin irritation was observed when 
3,3’-dichlorobenzidine dihydrochloride was applied to the intact or abraded skin of rabbits; the 
dose was not provided (Gerarde and Gerarde 1974). This minimum dermal lethal dose in female 
New Zealand albino rabbits is shown in Table 2-2. Dermal exposure is not likely to cause death in 
humans. 
2.2.3.2 Systemic Effects 
No information was located regarding cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, body weight, or metabolic effects in animals or 
humans following dermal exposure to 3,3’-dichlorobenzidine. 
Very limited data were found regarding the effects of dermal exposure to 3,3’-dichlorobenzidine. 
The highest NOAEL value and all LOAEL values for dermal exposure for this study are shown in 
Table 2-2. 
Respiratory Effects. Although no respiratory effects have been reported in humans following 
dermal exposure exclusively to 3,3’-dichlorobenzidine, upper respiratory infection and sore throat 
were among the principal reasons for visits to a company’s medical clinic by workers who 
handled 3,3’-dichlorobenzidine (Gerarde and Gerarde 1974). However, there is no conclusive 
evidence that these effects were due specifically to 3,3’-dichlorobenzidine exposure. Workers 
may have been exposed to this and/or other agents by both inhalation and dermal routes. 
No studies were located regarding respiratory effects in animals after dermal exposure to 
3,3’-dichlorobenzidine. 
Dermal Effects. Dermatitis was cited as the only verified health problem encountered by workers 
in contact with the free base of 3,3’-dichlorobenzidine in a dichlorobenzidine manufacturing plant 
(Gerarde and Gerarde 1974). 
There was no discernable skin irritation when 3,3’-dichlorobenzidine dihydrochloride (at an 
unstipulated dose) was applied to the intact and abraded skin of rabbits (Gerarde and Gerarde 





aqueous suspension of 3,3’-dichlorobenzidine instilled intradermally into rats at a dose of 700 
mg/kg did not produce adverse effects (Gerarde and Gerarde 1974). 
Ocular Effects. No studies were located regarding the ocular effects of 3,3’-dichlorobenzidine in 
humans. 
No effects were reported in rabbits when 100 mg of dichlorobenzidine (free base) was placed in 
the conjunctival sac of the eye (Gerarde and Gerarde 1974). It should be noted that the authors 
did not report the duration of exposure or the vehicle used. However, 0.1 mL of 
3,3’-dichlorobenzidine dihydrochloride in a 20% corn oil suspension produced erythema, pus, 
and cornea1 opacity, giving a 76% score in the Draize test within an hour when placed in the 
conjunctival sac of the eye of the rabbit (Gerarde and Gerarde 1974). This response is very likely 
associated with the release of hydrochloric acid following the salt’s contact with the moist surface 
of the eye. 
No studies were located regarding the following effects in humans or animals after dermal 
exposure to 3.3’-dichlorobenzidine: 
2.2.3.3 Immunological and Lymphoreticular Effects 
2.2.3.4 Neurological Effects 
2.2.3.5 Reproductive Effects 
2.2.3.6 Developmental Effects 
2.2.3.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.5. 
2.2.3.8 Cancer 
Several epidemiological studies have investigated cancer incidences among workers 
occupationally exposed to 3,3’-dichlorobenzidine and other arylamines (Gadian 1975; Gerarde 
and Gerarde 1974; MacIntyre 1975; Myslak et al. 1991). Exposure may have been by both 
inhalation and dermal routes. These studies are discussed in greater detail under Section 2.2.1.8 




Due, in part, to structure-activity considerations, epidemiological studies of potential cancer 
effects of occupational exposure to 3,3’-dichlorobenzidine have been particularly concerned with 
bladder tumors since benzidine is a known human carcinogen in which the bladder is the primary 
target. While one studyfound an excess incidence of bladder tumors among German painters who 
may have been exposed to 3,3’-dichlorobenzidine (Myslak et al. 1991), the causality is equivocal 
largely because it had been common for painters to prepare the paints themselves, allowing for 
possible exposure to other carcinogenic dyes and pigments derived from benzidine, 
3,3’-dichlorobenzidine, 3,3’-dimethylbenzidine (o-toluidine), 3,3’-dimethoxybenzidine 
(o-dianisidine), and 2-naphthylamine (Myslak et al. 1991). 
A more recent study found an association between bladder cancer and exposure to arylamines 
(Ouellet-Hellstrom and Rench 1996). This study examined the cancer incidence in a cohort of 
704 workers employed at a Connecticut chemical plant between 1965 and 1989. The plant 
produced a variety of chemicals including arylamines such as 3,3’-dichlorobenzidine, o-tolidine, 
and o-dianisidine, but not benzidine; benzidine production ceased prior to mid-1965. Skin contact 
was found to be the main route of exposure. Only workers never exposed to benzidine were 
selected to participate and only confirmed cancer cases were considered in the analysis. As a 
result of a worker survey, the information on follow-up yielded 8,624 person-years of observation 
for a follow-up rate of 97% for male employees and 1,660 person-years for a follow-up rate of 
97% for female employees. There were a total of 27 cancer cases, 23 in males and 4 in females. 
Three of the 23 male cases were non-melanoma skin cancers and were not included in the 
analysis. There were 7 cases of bladder cancer, all in males; two were diagnosed in workers first 
employed after 1972, four in workers first employed at the age of 40 or older, and five in 
workers who worked at least 5 years or more. All bladder cancers had a follow-up period of 8 
years or more. The standardized incidence ratio (observed/expected, SIR) for bladder cancer was 
8.3 (C.I. 3.3-17.0). In addition, the association between bladder cancer cases and exposure to 
arylamines increased with cumulative exposure. One bladder cancer case was a current smoker 
and the other six were former smokers. The authors (Ouellet-Hellstrom and Rench 1996) 
recognized that the study could not evaluate cancer risks for specific arylamines, but as indicated 
above, the results supported an association between bladder cancer and arylamine exposure. They 
also indicated that although smoking is known to increase the risk of bladder cancer by a factor of 
two, it is unlikely that smoking alone explains the eight-fold increase in bladder cancer risk 




No studies were located regarding carcinogenicity in animals following dermal exposure to 
3,3’-dichlorobenzidine. 
2.3 TOXICOKINETICS 
Very limited studies exist on the toxicokinetics of 3,3’-dichlorobenzidine in humans. Most of the 
available information is on urinary elimination of the compound following occupational 
exposure. Evidence from animal studies suggest that 3,3’-dichlorobenzidine is rapidly absorbed 
from the gastrointestinal tract.  Animals administered a single oral dose of 
[14C]-3,3’-dichlorobenzidine showed highest concentrations of radioactivity in the liver, kidney, 
lung, spleen, heart, pancreas, and testes. In rats, a major step in the elimination of 
3,3’-dichlorobenzidine is metabolic transformation. N-Acetyl metabolites (N-acetyl-
3,3’-dichlorobenzidine and N,N-diacetyl-3,3’-dichlorobenzidine) have been detected in urine of 
rats. N-acetyl metabolites are formed in vivo by hepatic N-acetyltransferase(s). In humans, some 
isozyme(s) of N-acetyltransferase show marked polymorphic differences; it is thus possible that 
the proportion of the dose of 3,3’-dichlorobenzidine converted to its N-acetyl metabolites in 
humans may vary widely between individuals. The metabolites undergo rapid excretion primarily 
in urine and to a lesser extent in feces. Unchanged 3,3’-dichlorobenzidine occurs as a minor 
urinary excretion product. 
2.3.1 Absorption 
There is no information regarding absorption of 3,3’-dichlorobenzidine in children by any route 
of exposure. 
2.3.1.1 Inhalation Exposure 
3,3’-Dichlorobenzidine has been detected in the urine of workers in 3,3’-dichlorobenzidine-
handling plants under conditions which favored inhalation of 3,3’-dichlorobenzidine-bound 
particulate matter (Handke et al. 1986; London and Boiano 1986; Meigs et al. 1954). Under these 
conditions, it is reasonable to expect that some of the 3,3’-dichlorobenzidine found in the urine 
could have come from inhalation exposure. However, conditions in the plants were also 
conducive to dermal exposure. Therefore, some of the 3,3’-dichlorobenzidine dose found in the 
urine could have come from dermal exposure. In addition, since the mucocilliary clearance 




the gastrointestinal tract, it is reasonable to expect that some gastrointestinal dose was received as 
well. No information was located on absorption in animals following inhalation exposure. 
2.3.1.2 Oral Exposure 
No quantitative data were located on the absorption of 3,3’-dichlorobenzidine following oral 
exposure in humans. However, a study in volunteers found acetylated metabolites in the urine 24 
hours after a single 250 mg oral dose of 3,3’-dichlorobenzidine, which suggested that the 
compound is absorbed (Belman et al. 1968). 
In animals, absorption of 3,3’-dichlorobenzidine from the gastrointestinal tract is rapid. Following 
a dose of 40 mg/kg, the plasma level of unchanged 3,3’-dichlorobenzidine attained a peak 
concentration of 1.25 µg/mL at 4 hours in Sprague Dawley rats. Further, about 90% of the 
administered radioactivity was excreted in feces (via bile) and urine within 72 hours largely as 
metabolites, indicating a high bioavailability, typical of primary arylamines. The elimination is 
biphasic, with half-lives of 6 hours and 14 hours in plasma for the rapid and slow phases, 
respectively (Hsu and Sikka 1982). 
2.3.1.3 Dermal Exposure 
No studies were located regarding absorption of 3,3’-dichlorobenzidine following dermal 
exposure in humans. Because of large particle size and increased usage of closed systems and 
protective clothing, dermal absorption is minimized. In animals, dermally applied 
3,3’-dichlorobenzidine (in acetone) is moderately absorbed. Based on the amount of radioactivity 
remaining at the site of application, the extent of dermal absorption of applied 
[14C]-3,3’-dichlorobenzidine to the shaved skin of rats at 1, 8, and 24 hours following the 
application was estimated to be 6, 23, and 49%, respectively (Shah and Guthrie 1983). 
2.3.2 Distribution 
There is no information regarding distribution of 3,3’-dichlorobenzidine or metabolites in 
children after exposure by any route. 
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2.3.2.1 Inhalation Exposure 
No studies were located regarding distribution in humans or animals after inhalation exposure to 
3,3’-dichlorobenzidine. 
2.3.2.2 Oral Exposure 
No studies were located regarding distribution of 3,3’-dichlorobenzidine in humans after oral 
exposure. 
In animals, orally absorbed 3,3’-dichlorobenzidine is widely distributed. In a study in which 
3,3’-dichlorobenzidine was orally administered to female Wistar rats in single doses of 0.25 mL 
3,3’-dichlorobenzidine in propylene glycol at 0.5 or 1 mmol/kg (127 or 253 mg/kg) by gavage, 
hemoglobin adducts of 3,3’-dichlorobenzidine were isolated from the blood of the animals 
(Birner et al. 1990). Similar results were obtained in rats dosed with 0.3-5.8 mg 
3,3’-dichlorobenzidine/kg/day for 4 weeks (Joppich-Kuhn et al. 1997). The distribution of 
radioactivity in rat tissues after the oral administration of [14C]-3,3’-dichlorobenzidine 
has been studied (Hsu and Sikka 1982). Twenty-four hours after a single oral dose, the highest 
levels of radioactivity were found in the liver, followed by the kidney, lung, spleen, heart, 
pancreas, and testes, in that order. This pattern did not depend on dose. After 96 hours, tissues 
that retained 0.02% or more of the administered radioactivity were liver (1.48%), muscle 
(0.37%), kidney (0.19%), and lung (0.02%). Erythrocytes retained more of the radioactivity than 
lung, but attention was not paid to the hematopoietic system in this study (Hsu and Sikka 1982). 
The effect of repetitive 3,3’-dichlorobenzidine administration on tissue levels of radioactivity was 
also studied by Hsu and Sikka (1982). Radioactivity in tissues of animals that received six daily 
doses of 3,3’-dichlorobenzidine was generally three to four times as high as the radioactivity in 
tissues of animals that received a single dose. Similarly, the rate of decline of radioactivity in 
tissues was generally higher in animals that received a single dose than in those treated with 
multiple doses of the compound. The authors concluded that repeated dosing with 
3,3’-dichlorobenzidine did not result in a substantial retention of 14C, and the compound may be 
considered to have a fairly low tendency to accumulate in tissues following repetitive dosing 
(Hsu and Sikka 1982). Overall, bioaccumulation of this chemical in rats is considered to be 




There is indirect evidence that 3,3’-dichlorobenzidine or metabolites can cross the placenta. A 
study that examined the potential genotoxic effects of 3,3’-dichlorobenzidine found that oral 
administration of 3,3’-dichlorobenzidine to pregnant rats induced micronuclei in the liver of 
fetuses (Cihak and Vontorkova 1967). There is no information regarding accumulation of 
3,3’-dichlorobenzidine or metabolites in breast milk or its potential transfer to offspring via breast 
milk. 
2.3.2.3 Dermal Exposure 
No studies were located regarding distribution of 3,3’-dichlorobenzidine in humans following 
dermal exposure. The distribution of [14C]-3,3’-dichlorobenzidine in rat tissues following dermal 
application was studied by Shah and Guthrie (1983). Tissues retaining >0.1% of the administered 
radioactivity 24 hours after application were liver (4.09%), blood (0.75%) and lung (0.45%). The 
level in the lung was the same at the 8- and 24-hour time points. Differences in the tissue 
distribution pattern of total radioactivity between the oral and dermal routes of 
3,3’-dichlorobenzidine administration may be presumed to reflect differences in the rates of 
absorption from these sites. These differences suggest that the target organ in which 
3,3’-dichlorobenzidine exerts an adverse effect may depend on the route of exposure to the 
compound. Organ toxicity can be better evaluated in comparative studies designed to test tissue 
distribution and persistence exposure. 
2.3.3 Metabolism 
No studies were located regarding metabolism in humans or animals after inhalation exposure to 
3,3’-dichlorobenzidine. 
Information from a study in which 4 volunteers ingested a single 250 mg dose of 
3,3’-dichlorobenzidine suggests that this chemical undergoes N-acetylation and that metabolites 
may be excreted in the urine either free or as glucuronides (Belman et al. 1968). N-Acetylation 
appears to be the major path for the metabolism of 3,3’-dichlorobenzidine in mammals (Lazear et 
al. 1979; Reid et al. 1984; Tanaka 1981).  Studies in animals also indicate that 
3,3’-dichlorobenzidine is extensively metabolized. Bile and urine of rats given single oral doses 
of [14C]-3,3’-dichlorobenzidine (40 mg/kg/day) contained 5 metabolites of 3,3’-dichlorobenzidine 
in addition to the parent compound. None of the metabolites were identified, but a majority were 
reported to be conjugates (Hsu and Sikka 1982). A 24-hour urine sample of rats given a 
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single oral dose of 3,3’-dichlorobenzidine (50 mg/kg/day) contained unchanged 
3,3’-dichlorobenzidine, N,N’-diacetyl 3,3’-dichlorobenzidine, and N-acetyl 3,3’-dichlorobenzidine in 
a ratio of 1:3:10 (Tanaka 1981). Indirect evidence for the formation of nitroso derivatives was found 
in a study in which 3,3’-dichlorobenzidine was administered to female Wistar rats by gavage (Bimer 
et al. 1990). Hemoglobin adducts were detected by the release of  3,3’-dichlorobenzidine after alkaline 
hydrolysis. The authors stated that the most likely process by which the adducts were formed was a 
reaction between a nitroso derivative of 3,3’-dichlorobenzidine and sulfhydryls in cysteine residues of 
hemoglobin. 
No studies were located regarding the metabolism of 3,3’-dichlorobenzidine in humans following 
dermal exposure. In a 24-hour urine sample of rats given a single dermal application of 
3,3’-dichlorobenzidine (50 mg/kg/day), N,N ‘-diacetyl 3,3’-dichlorobenzidine (but not N-acetyl 3,3’­
dichlorobenzidine or the unchanged chemical) was detected (Tanaka 1981). Since the utagenicity of 
diacetylated product is much less than either the monoacetylated or parent compound (Lazear et al. 
1979; Reid et al. 1984; Tanaka 198l), diacetylation may be a detoxification reaction for 3,3’­
dichlorobenzidine (see also Sections 2.4.1 and 2.4.2). 
There is no information regarding the metabolism of 3,3’-dichlorobenzidine in children. However, N-
acetylation (as discussed above) in humans is likely done by one of two families of N­
acetyltransferases.  One of these families, NAT2, is developmentally regulated (Leeder and Keams 
1997). Some enzyme activity can be detected in the fetus by the end of the first trimester. Almost all 
infants exhibit the slow acetylator phenotype between birth and 2 months of age. The adult phenotype 
distribution is reached by the age of 4-6 months, whereas adult activity is found by approximately l-3 
years of age. Also, UDPglucuronosyltransferase, responsible for the formation of glucuronide 
conjugates, seems to achieve adult activity by 6-18 months of age (Leeder and Kearns 1997). These 
data suggest that metabolism of 3,3’-dichlorobenzidine by infants will differ from that in adults in 
extent, rate, or both. 
The metabolism of several 3,3’-dichlorobenzidine-based pigments has been studied in animal 
experiments to determine if they are metabolized to 3,3’-dichlorobenzidine. In a study where rats were 
exposed by inhalation to Pigment Yellow 17 (230 mg/m3 air) for 4 hours, 3,3’-dichlorobenzidine was 
not detected in either urine or blood during the following 14 days (Hofmann and Schmidt 1993). No 
detectable residues of 3,3’-dichlorobenzidine were found in urine samples of hamsters administered a 
single dose of 100 mg/kg purified Yellow 12 (NCTR 1979; Nony et al. 1980). Similarly, 




urine samples of rats fed 3,3’-dichlorobenzidine-derived pigments (C.I. Pigment Yellow 12, 16, 
and 83) in the diet at concentrations of 0.1% (1,000 ppm), 0.3% (3,000 ppm), and 0.9% (9,000 
ppm) for 104 weeks (Leuschner 1978). Based on the results of these studies, there is no evidence 
for the metabolic cleavage of tested pigments to 3,3’-dichlorobenzidine in test animals (Hoffman 
and Schmidt 1993; Leuschner 1978; NCTR 1979; Nony et al. 1980). 
2.3.4 Elimination and Excretion 
There is no information regarding the elimination and excretion of 3,3’-dichlorobenzidine or 
metabolites in children following any route of exposure. 
2.3.4.1 Inhalation Exposure 
Less than 0.2 ppb 3,3’-dichlorobenzidine was detected in urine samples of 36 workers exposed to 
3,3’-dichlorobenzidine-derived pigments (Hatfield et al. 1982). However, the authors did not 
clearly identify specific pigments. While the authors did not report exposure route, it was 
presumed to have been by inhalation. Dermal exposure may have also occurred. 
No studies were located regarding excretion in animals after inhalation exposure to 
3,3’-dichlorobenzidine. 
2.3.4.2 Oral Exposure 
Very limited information was located regarding excretion of 3,3’-dichlorobenzidine and/or 
metabolites in humans after oral exposure. In 4 volunteers who ingested a single 250 mg dose of 
3,3’-dichlorobenzidine, the percentage of N-hydroxyacetyl compound excreted free in the urine 
in 24 hours ranged from 0.32 to 1.55%, whereas the percentage of  N-hydroxyacetyl compound 
excreted as glucuronide in 24 hours ranged from 0.11 to 0.45% (Belman et al. 1968). Studies on 
the fate of 3,3’-dichlorobenzidinederived pigments fail to provide conclusive evidence that these 
pigments are broken down to release free 3,3’-dichlorobenzidine in humans. 
Results from animal studies show that 3,3’-dichlorobenzidine administered by gavage is excreted 





benzidine (40 mg/kg), the elimination from plasma appeared to be biphasic, with half-lives of 
about 6 and 14 hours for the rapid and slow phases, respectively (Hsu and Sikka 1982). 
Elimination of 3,3’-dichlorobenzidine-derived radioactivity from liver, kidneys, and lungs also 
exhibited rapid and slow phases, with half-lives of 5.8 and 77 hours for the liver, 7.1 and 139 
hours for the kidneys, and 3.8 and 43.3 hours for the lungs. Approximately 58-72% of the 
administered dose was recovered in bile and feces and 23-33% in urine (Hsu and Sikka 1982). 
Most of the material found in bile and feces consisted of conjugated metabolites, while most of 
the material in urine consisted of unconjugated metabolites. No detectable residues of 
3,3’-dichlorobenzidine were found in urine samples of hamsters administered a single dose of 100 
mg/kg purified Yellow 12 (NCTR 1979; Nony et al. 1980). Similarly, 3,3’-dichlorobenzidine was 
not detected in urine samples of rats fed 3,3’-dichlorobenzidine-derived pigments (C.I. Pigment 
Yellow 12, 16, and 83) in the diet at concentrations of 0.1% (1,000 ppm), 0.3% (3,000 ppm), and 
0.9% (9,000 ppm) for 104 weeks (Leuschner 1978). 
2.3.4.3 Dermal Exposure 
No studies were located regarding the excretion of 3,3’-dichlorobenzidine in humans following 
dermal exposure. Fecal excretion in rats at 24 hours following 3,3’-dichlorobenzidine exposure 
was 19% of the administered dose, while urinary excretion accounted for 8% (Shah and Guthrie 
1983). Fifty-one percent of the administered dose was unabsorbed from the site of application at 
24 hours. The remaining 49% was distributed throughout the body, feces and urine. 
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the 
uptake and disposition of chemical substances to quantitatively describe the relationships among 
critical biological processes (Krishnan et al. 1994). PBPK models are also called biologically 
based tissue dosimetry models.  PBPK models are increasingly used in risk assessments, 
primarily to predict the concentration of potentially toxic moieties of a chemical substance that 
will be delivered to any given target tissue following various combinations of route, dose level, 
and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic (PBPD) 
models use mathematical descriptions of the dose-response function to quantitatively describe the 




PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and 
target tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses 
(Andersen and Krishnan 1994; Andersen et al. 1987). These models are biologically and 
mechanistically based and can be used to extrapolate the pharmacokinetic behavior of chemical 
substances from high to low dose, from route to route, between species, and between 
subpopulations within a species. The biological basis of PBPK models results in more meaningful 
extrapolations than those generated with the more conventional use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation 
(Krishnan and Andersen 1994). In the early 1990s validated PBPK models were developed for a 
number of toxicologically important chemical substances, both volatile and nonvolatile (Krishnan 
and Andersen 1994; Leung 1993). PBPK models for a particular substance require estimates of 
the chemical substance-specific physicochemical parameters, and species-specific physiological 
and biological parameters. The numerical estimates of these model parameters are incorporated 
within a set of differential and algebraic equations that describe the pharmacokinetic processes. 
Solving these differential and algebraic equations provides the predictions of tissue dose. 
Computers then provide process simulations based on these solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable 
for many biological processes. A simplified scheme reduces the magnitude of cumulative 
uncertainty. The adequacy of the model is, therefore, of great importance, and model validation is 
essential to the use of PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify 
the maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and 
Krishnan 1994).  PBPK models provide a scientifically sound means to predict the target tissue 
dose of chemicals in humans who are exposed to environmental levels (for example, levels that 
might occur at hazardous waste sites) based on the results of studies where doses were higher or 
were administered in different species.  Figure 2-2 shows a conceptualized representation of a 





benzidine exist, the overall results and individual models are discussed in this section in terms of 
their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
No PBPK modeling studies were located for 3,3’-dichlorobenzidine. 
2.4 MECHANISMS OF ACTION 
2.4.1 Pharmacokinetic Mechanisms 
No information was located for the mechanism of inhalation, oral, or dermal absorption of 
3,3’-dichlorobenzidine in humans or animals. Also, no information was located for the 
mechanism by which 3,3’-dichlorobenzidine is transported in the blood. However, a studies in 
rats have shown that 3,3’-dichlorobenzidine forms adducts with hemoglobin (Birner et al. 1990; 
Joppich-Kuhn et al. 1997), indicating that at least a small amount of the chemical is associated 
with red blood cells. 
3,3’-Dichlorobenzidine induces liver microsomal enzymes in a pattern similar to 
3-methylcholanthrene.  Liver microsomes from male Sprague-Dawley rats pretreated 
intraperitoneally with 3,3’-dichlorobenzidine yielded information to suggest that the induction 
pattern of P-450 isozymes by 3,3’-dichlorobenzidine resembles that of 3-methylcholanthrene. 
3,3’-Dichlorobenzidine significantly induced ethoxy-coumarin O-deethylase, p-nitrophenetole 
O-deethylase, and arylhydrocarbon hydrolase by 5-, 6-, and 5-fold, respectively (Iba et al. 1983). 
Another study also found that 3,3’-dichlorobenzidine induces P-450 isozymes in a pattern similar 
to 3-methylcholanthrene (i.e., induces P-450c) (CYP2B l), and P-450d (CYPlA2) but mainly 
P-450c (CYP2Bl) (Iba and Thomas 1988). The same authors also conducted studies to identify 
the isozymes involved in NADPH-dependent activation of 3,3’-dichlorobenzidine by rat hepatic 
microsomes to mutagens in the Ames test. 3,3’-Dichlorobenzidine activation was unaffected by 
monoclonal antibodies to P-450b (CYPIAI) or P-450c (CYP2Bl) but was inhibited by 69% by 
polyclonal antibodies to P-450d (CYPlA2). 3,3’-Dichlorobenzidine activation was also inhibited 
46% by antibody specific to NADPH-cytochrome P-450 reductase. Also, addition of 
methimazole, a high affinity substrate for the flavin-containing monooxygenase, reduced the 
residual mutagenicity in the systems containing antibody to P-450b (CYPlA2) and cytochrome 
P-450 reductase to 9% and 19%, respectively, of the appropriate control values. Based on these 




(CYPlA2) contributes to the majority of the P-450-dependent activation of 3,3’-dichlorobenzidine in 
hepatic microsomes. 
If 3,3’-dichlorobenzidine is activated to a mutagenic intermediate by CYPlA2, this would have 
relevance to exposure in utero and in neonates. Human fetal liver does not contain appreciable 
amounts of CYPlA2 (Leeder and Kearns 1997). Adult levels of CYPlA2 are reached at about 
4 months of age and may be exceeded in 1-2-year-old children. CYPlA2 levels subsequently decline 
and reach adult levels at the end of puberty. 
2.4.2 Mechanisms of Toxicity 
Although, data from the existing human and animal studies indicate that 3,3’-dichlorobenzidine is 
minimally toxic, its mechanism of toxicity appears to be well defined, deriving mainly from adduction 
of DNA. The available data suggest that the metabolism of 3,3’-dichlorobenzidine begins with the 
formation of nitroso derivatives which yield a sulfinic acid amide with hemoglobin in erythrocytes. 
This has been suggested to be a mechanism for adduct formation. However, N-oxidation at one of the 
two nitrogens could occur in the parent diamine, the monoacetyl, or the diacetyl derivative. 
N-hydroxy-dichlorobenzidine and N-hydroxyhr-acetyl-dichlorobenzidine could arise from either 
direct N-oxidation of the amino group or by deacetylation of the hydroxamic acid. Peroxidative 
activation of 3,3’-dichlorobenzidine will yield 3,3’-dichlorobenzidine diimine which causes DNA 
damage in bladder which might be responsible for tumor formation in this target in dogs and possibly 
humans. In rodents, N-oxidation of the monoacetyl derivative is an important step of metabolic 
activation (Birner et al. 1990). 
Results from a recent study suggest that cytochrome P-450 (specifically CYP4B 1) activity may 
contribute to the initiation of carcinogenesis in rat and mouse bladder by activation of 
3,3’-dichlorobenzidine to mutagenic compounds (Imaoka et al. 1997). The authors demonstrated the 
presence of CYP4B 1 in rat and mouse bladder microsomes by immunoblotting and 
immunohistochemistry. Furthermore, tissue-staining showed that CYP4Bl was present in epithelial 
cells of the bladder. It was also shown in that study that mouse bladder microsomes activated 3,3’­
dichlorobenzidine, although not to the degree observed with renal microsomes and purified CYP4B 1. 
3,3’-Dichlorobenzidine activation was judged by a gene expression test in Salmonella typhimurium 
NM2009 that detects DNA damage. Rat CYP4Bl produced very high mutagenic activity for 
3,3’-dichlorobenzidine. 
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The genotoxicity of 3,3’-dichlorobenzidine is derived from DNA adduction, as suggested by 
positivereverse mutation results in Salmonella typhimurium TA98 strain, since this strain of 
S. typhimurium detects reverse (histidine revertants) mutation in both activated and direct-acting base-
pair substitution and frameship mutagens (Vithayathil et al. 1983). The extent of covalent binding of a 
compound to DNA and the persistence of the resulting adducts are considered important determinants 
of cancer initiation by genotoxic carcinogens (Ghosal and Iba 1990). As a direct-acting mutagen, 
3,3’-dichlorobenzidine is an effective inducer of its own activation (Iba 1987a). 
It has been suggested that some of the toxicity (carcinogenicity and non-cancer) of polyhalogenated 
aromatics (such as 3,3’-dichlorobenzidine) may be related to the abilities to induce cytochrome 
P-448-mediated (CYPlA2) monooxygenase activities. Therefore, it is reasonable to expect that the 
hepatocarcinogenicity of 3,3’-dichlorobenzidine may be due, at least in part, to the induction of 
hepatic cytochrome P-448 which would have the impact of producing higher amounts of reactive 
metabolites (Iba et al. 1983). The demonstration that 3,3’-dichlorobenzidine both increases lipid 
peroxidation and decreases antioxidant content in vivo in one study may have a bearing on the 
carcinogenicity of this substance because antioxidants protect against the acute and long-term effects 
of lipid peroxidation (Iba 1987b) which may be an important determinant in carcinogenesis. 
There are data to suggest that 3,3’-dichlorobenzidine may act synergistically with other carcinogens. 
No carcinomas were found in any rats administered one of the following in the diet for a period of 40 
weeks: 0.03% 3,3’-dichlorobenzidine in the diet, 0.001% BBN in drinking water, 0.0005% 2-AAF in 
the diet, or 0.04% FANFT (Ito et al. 1983). However, when BBN and 3,3’-dichlorobenzidine were fed 
together at the same dose levels as above, there was a marked increase in papillary or nodular 
hyperplasia in the rat bladder and the appearance of one papilloma. The authors suggested a 
synergistic effect of 3,3’-dichlorobenzidine on the carcinogenicity of BBN. 
2.4.3 Animal-to-Human Extrapolations 
Information on the toxicity of 3,3’-dichlorobenzidine for humans and animals is limited, 
particularly regarding noncancer end points. Therefore, an attempt to discuss potential 
interspecies differences or similarities in 3,3’-dichlorobenzidine noncancer toxicity based on the 
limited information available seems speculative at this time. 3,3’-Dichlorobenzidine is 




Sellakumar et al. 1969; Stula et al. 1975, 1978). There is no conclusive evidence of carcinogenicity of 
3,3’-dichlorobenzidine in humans (Gadian 1975; Gerarde and Gerarde 1974; MacIntyre 1975; Myslak 
et al. 1991; Ouellet-Hellstrom and Rench 1996); however, there is concern about occupationally 
exposed subjects because of 3,3’-dichlorobenzidine’s structural similarity with the known human and 
animal carcinogen benzidine. However, unless a cohort exposed only to 3,3’-dichlorobenzidine is 
identified and adequate epidemiological studies on such a cohort are conducted, the question will 
remain unsolved. 
2.5 RELEVANCE TO PUBLIC HEALTH 
Overview. 
Most of the information on human health effects of 3,3’-dichlorobenzidine is derived from 
several reports of exposure in the workplace, in which the inhalation and dermal routes represent 
the most likely routes of exposure. Significant exposure to 3,3’-dichlorobenzidine, would impact 
the health of the general population, seems unlikely. The available occupational studies have 
limitations, including lack of precise exposure data and presence of other compounds, as well as 
other confounding factors. No organ or system could be identified as a target for 3,3’­
dichlorobenzidine toxicity in the available studies in humans.  Results from cancer studies in 
humans were inconclusive because of possible co-exposure to other chemicals. Studies in animals 
showed that 3,3’-dichlorobenzidine is a multi-site carcinogen in various species following oral 
administration; no data were available following inhalation or dermal exposure.  There is some 
evidence, however, of carcinogenicity in rats after subcutaneous injection of 3,3’­
dichlorobenzidine, and in the offspring of mice after subcutaneous dosing to the dams during 
pregnancy. Systemic effects in animals were limited to reports of formation of adducts with proteins 
such as hemoglobin and with DNA and minor liver effects after chronic oral dosing. Also, ocular 
effects were reported in rabbits after direct instillation of the hydrochloric salt of the compound to the 
eye. In most studies in animals, the animals were exposed to levels of 3,3’-dichlorobenzidine several 
orders of magnitude higher than those found in the environment. Almost nothing is known about the 
toxicokinetics of 3,3’-dichlorobenzidine in humans. 3,3’-Dichlorobenzidine has been identified in the 
urine from workers or volunteers exposed to it; therefore, it is absorbed by humans. The primary route 
of absorption could not be ascertained, but it is assumed to have been inhalation and/or dermal. 
Animals can absorb 3,3’-dichlorobenzidine through ingestion or dermal contact with the chemical; no 
information was located regarding inhalation exposure.  Based on limited data regarding 




living near hazardous waste sites is the dermal route. Under these circumstances, assuming that 
3,3’-dichlorobenzidine is present in surrounding environmental media, this route may be of 
concern since animal studies have shown that 3,3’-dichlorobenzidine is absorbed by this route. 
Issues relevant to children are explicitly discussed in Section 2.6, Children’s Susceptibility, and 
Section 5.6, Exposures of Children. 
Minimal Risk Levels for 3,3’-Dichlorobenzidine. 
Inhalation MRLs. 
No acute-duration inhalation MRL was calculated for 3,3’-dichlorobenzidine due to the 
inadequate data. The information provided in the single relevant study in animals that is available 
(Gerarde and Gerarde 1974) is severely limited by lack of detailed reporting of the results. 
Included among the limitations are lack of information concerning exposure concentration and 
failure to use control groups. No intermediateduration inhalation MRL was calculated for 
3,3’-dichlorobenzidine because no intermediate-duration studies in humans or animals were 
located. No chronic-duration inhalation MRL was calculated for 3,3’-dichlorobenzidine because 
the available human studies do not provide quantitative exposure information (Gadian 1975; 
Gerarde and Gerarde 1974; MacIntyre 1975; Myslak et al. 1991). No chronicduration inhalation 
studies in animals were located. 
Oral MRLs. 
No acute-duration oral MRL was calculated for 3,3’-dichlorobenzidine because the available 
studies did not identify appropriate NOAELs or LOAELs (Ashby and Mohammed 1988; Birner 
et al. 1990; Cihak and Vontorkova 1987; Ghosal and Iba 1990). No intermediate-duration oral 
MRL was calculated for 3,3’-dichlorobenzidine because the available studies did not identify 
relevant noncancer effects (Ito et al.1983; Osanai 1976; Pliss 1959, 1963). No chronic-duration 
oral MRL was calculated for 3,3’-dichlorobenzidine because there were no NOAELs identified 
below the lowest available serious LOAEL for convulsions and slight neuronal degeneration in 
dogs (Stula et al. 1978). 
Death.  No deaths were reported in humans from inhalation, oral, or dermal exposure to 
3,3’-dichlorobenzidine.  In animals, 3,3’-dichlorobenzidine caused no deaths in rats exposed by 
the inhalation route in concentrations as high as 23,700 mg/m3 for 2 hours per day for 7 days 




addition, the estimated acute oral LD50 for rats (7,070 mg/kg for the free base and 3,820 mg/kg for 
thedihydrochloride salt) and the minimum dermal lethal dose for male and female New Zealand albino 
rabbits (>8,000 mg/kg) for 3,3’-dichlorobenzidine suggested that the lethal toxicity of 
3,3’-dichlorobenzidine is minimal (Gerarde and Gerarde 1974). Consequently, it is unlikely that death 
will occur in humans exposed to 3.3’-dichlorobenzidine at the levels at which it occurs at hazardous 
waste sites. 
Systemic Effects.  Dermatitis appears to be the only effect of 3,3’-dichlorobenzidine (free base) 
exposure for which evidence exists in humans (Gerarde and Gerarde 1974). Gastrointestinal upset and 
upper respiratory tract infections have also been reported by workers, but the role of 
3,3’-dichlorobenzidine was uncertain. 3,3’-Dichlorobenzidine has not been found to cause these 
effects in experimental animals. 
Respiratory Effects.  Upper respiratory infection and sore throat were among several principal reasons 
for frequent visits to a company’s medical clinic by workers handling 3,3’-dichlorobenzidine 
dihydrochloride (dihydro salt of 3,3’-dichlorobenzidine) (Gerarde and Gerarde 1974). However, data 
from animal studies are equivocal regarding the etiology of these symptoms (Gerarde and Gerarde 
1974). While it is possible that these symptoms were due to exposure to 3,3’-dichlorobenzidine 
hydrochloride, the irritant effects of HCl from the compound in combination with particulate toxicity 
could have been responsible for the observed effects in these studies. Therefore, it is not likely that 
respiratory ailments will occur in humans exposed to 3,3’-dichlorobenzidine at hazardous waste sites. 
Cardiovascular Effects. Reports of cardiovascular effects in humans or animals after exposure to 3,3’­
dichlorobenzidine by any route were not found in any of the existing epidemiological and animal 
studies, suggesting that the cardiovascular system is not a target of 3,3’-dichlorobenzidine toxicity. It 
is unlikely that cardiovascular effects will occur in humans exposed to 3,3’-dichlorobenzidine at levels 
found at hazardous waste sites. 
Gastrointestinal Effects.  Gastrointestinal upset was one of the symptoms reported by employees who 
worked with 3,3’-dichlorobenzidine dihydrochloride (dihydro salt of 3,3’-dichlorobenzidine) (Gerarde 
and Gerarde 1974). However, there is no conclusive evidence that 3,3’- dichlorobenzidine caused 
these gastrointestinal upsets since there was exposure to other chemicals as well. In addition, 
3,3’-dichlorobenzidine has not been found to cause any of these effects in experimental animals. 




that exposure to 3,3’-dichlorobenzidine at hazardous waste sites will cause gastrointestinal effects in 
humans. 
Hematological Effects. No studies were located regarding hematological effects in humans after 
inhalation, oral, or dermal exposure to 3,3’-dichlorobenzidine. Although hematological effects may 
not be sensitive indicators for 3,3’-dichlorobenzidine toxicity, hemoglobin adducts were observed in 
animal studies following single oral exposures to 127 or 253 mg/kg 3,3’-dichlorobenzidine (Bimer et 
al. 1990) and repeated exposures to 0.3 mg/kg/day for up to 4 weeks (Joppich-Kuhn et al. 1997). 
Birner et al. (1990) suggested that metabolically formed nitroso derivatives and the formation of a 
sulfinic acid amide with cysteine residues in hemoglobin may be the mechanism of adduct formation. 
No hematological abnormalities were found in dogs exposed to 10.4 mg/kg/day 
3,3’-dichlorobenzidine for 7 years (Stula et al.1978). Therefore, it is unlikely that blood abnormalities 
will occur in humans exposed to 3,3’-dichlorobenzidine at levels found at hazardous waste sites. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans or 
animals after exposure to 3,3’-dichlorobenzidine by any route. However, since this effect was not 
reported in any of the existing epidemiological and animal studies, it is unlikely that musculoskeletal 
effects will occur in humans exposed to 3,3’-dichlorobenzidine at levels found at hazardous waste 
sites. 
Hepatic Effects. No studies were located regarding hepatic effects in humans after exposure to 
3,3’-dichlorobenzidine. Information from animal studies on the liver effects of exposure to 
3,3’-dichlorobenzidine suggests that exposure to sufficiently high levels of thecompound could cause 
liver injury as indicated by modest elevation in serum transaminase activity, fatty liver (Stula et al. 
1978), decrease in hepatic vitamin E, and lipid peroxidation (Iba 1987a; Iba and Lang 1988; Iba and 
Thomas 1988). Some of these effects may contribute to the liver tumors induced. However, it is not 
known whether these liver injuries will occur in humans exposed to 3,3’-dichlorobenzidine at levels at 
which it occurs at hazardous waste sites since these effects were not reported in any worker studies in 
which exposures are significantly higher. 
Renal Effects. No studies were located regarding renal effects in humans after exposure to 
3,3’-dichlorobenzidine by any route. No effects to the kidneys or urinary parameters monitored were 
observed in dogs exposed to 10.4 mg/kg/day for up to 7 years (Stula et al. 1978). Based on these data, 
it is unlikely that 
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kidney effects will occur in humans exposed to 3,3’-dichlorobenzidine at levels found at 
hazardous waste sites. 
Endocrine Effects.  No studies were located regarding endocrine effects in humans or animals 
after exposure to 3,3’-dichlorobenzidine by any route. However, since this effect was not reported 
in any of the existing epidemiological and animal studies, it is unlikely that endocrine effects will 
occur in humans exposed to 3,3’-dichlorobenzidine at levels found at hazardous waste sites. 
Dermal Effects.  Dermatitis was cited as the only verified health problem encountered by workers 
in contact with the free base of 3,3’-dichlorobenzidine in a dichlorobenzidine manufacturing plant 
(Gerarde and Gerarde 1974). There was no discernable skin irritation when 3,3’­
dichlorobenzidine dihydrochloride (at an unstipulated dose) was applied to the intact and abraded 
skin of rabbits (Gerarde and Gerarde 1974).  Similarly, an aqueous suspension of 
3,3’-dichlorobenzidine instilled intradermally into rats at a dose of 700 mg/kg did not produce 
adverse effects (Gerarde and Gerarde 1974). The observations in humans may have been allergic 
dermatitis, and specific protocols are required to make these determinations in laboratory 
animals. 
Ocular Effects. No studies were located regarding ocular effects in humans after exposure to 
3,3’-dichlorobenzidine by any route. No adverse effects on the eye were noted when 
dichlorobenzidine (isomer unspecified, free base) was directly placed in the conjunctival sac of 
the eye of rabbits (Gerarde and Gerarde 1974). However, 0.1 mL 3,3’-dichlorobenzidine 
dihydrochloride (dihydro salt of 3,3’-dichlorobenzidine) in a 20% corn oil suspension produced 
erythema, pus, and cornea1 opacity, giving a 76% score in the Draize test within an hour when 
placed in the conjunctival sac of the eye of the rabbit (Gerarde and Gerarde 1974). Apparently, 
the irritant effects of hydrochloric acid from the salt-compound contributed to the observed 
effects. Based on these data, it is not probable that adverse effects to the eye will occur in 
humans exposed to 3,3’-dichlorobenzidine at levels at which it occurs at hazardous waste sites. 
Body Weight Effects. No studies were located regarding body weight effects in humans after 
exposure to 3,3’-dichlorobenzidine by any route. No significant difference in body weight was 
observed in dogs exposed to 10.4 mg/kg/day for up to 7 years (Stula et al. 1978). Based on these 
data, it is unlikely that body weight effects will occur in humans exposed to 




Metabolic Effects.  No studies were located regarding metabolic effects in humans or animals after 
exposure to 3,3’-dichlorobenzidine by any route. However, since this effect was not reported in any of 
the existing epidemiological and animal studies, it is unlikely that metabolic effects will occur in 
humans exposed to 3,3’-dichlorobenzidine at levels found at hazardous waste sites. 
Immunological and Lymphoreticular Effects. No studies were located regarding immunological 
and/or lymphoreticular effects in humans or animals following exposure to 3,3’-dichlorobenzidine by 
any route of exposure. The immune system does not appear to be a sensitive target of 
3,3’-dichlorobenzidine toxicity. Consequently, immune system disruptions are not expected in humans 
exposed to 3,3’-dichlorobenzidine at the levels at which it occurs at hazard waste sites. 
Neurological Effects.  Workers exposed to 3,3’-dichlorobenzidine and possibly to other chemicals in a 
chemical manufacturing plant reported headache and dizziness at the company clinic (Gerarde and 
Gerarde 1974). No further information indicated neurological effects in humans following exposure to 
3,3’-dichlorobenzidine. In animal studies, 1 of 6 dogs exhibited convulsions after 21, 28, and 42 
months of oral treatment with 10.4 mg/kg/day 3,3’-dichlorobenzidine for 3.5 years. A necropsy of the 
dog at 42 months revealed slight neuronal degeneration at unspecified sites in the brain and/or spinal 
cord (Stula et al. 1978). In view of the fact that only one dog developed the lesion, direct causality 
cannot be inferred. In addition, based on its chemical structure, 3,3’-dichlorobenzidine does not 
appear to be a neurotoxicant.  The information available suggests that at the levels found in the 
environment, 3,3’-dichlorobenzidine is unlikely to constitute a neurological hazard for humans. 
Reproductive Effects.  No studies were located regarding reproductive effects in humans or animals 
following exposure to 3,3’-dichlorobenzidine by any route of exposure. Consequently, reproductive 
system disruptions are not expected in humans exposed to 3,3’-dichlorobenzidine at the levels at 
which it occurs at hazard waste sites. 
Developmental Effects.  No studies were located regarding developmental effects of 
3,3’-dichlorobenzidine in humans following brief or long-term exposure by any route. Abnormal 
growth was observed in kidneys explanted from fetuses of pregnant mice treated subcutaneously daily 
during the last week of pregnancy at an average daily dose of approximately 421 mg/kg (Shabad et al. 
1972). Similarly, in subcutaneous-injection studies in BALB/C mice, hyperplastic foci and 




observed in kidneys of offspring of dams administered 2 mg 3,3’-dichlorobenzidine (about 93.5 
mg/kg) 4 or 5 times throughout gestation (Golub 1970). In a study of similar design, by the same 
group of investigators, subcutaneous injection of 3,3’-dichlorobenzidine during pregnancy to mice 
resulted in the induction of tumors in the progeny (Golub et al. 1975). Because the pups were nursed 
by the dams, it is unknown whether these effects may have been caused by transplacental transfer of 
the active principle, through nursing, or both. The significance of these findings to human health is 
unclear, particularly because of the irrelevant route of exposure and the high doses used. 
Genotoxic Effects. Studies in several test systems show 3,3’-dichlorobenzidine to be genotoxic in vivo 
and in vitro (see Tables 2-3 and 2-4). It has been suggested that genotoxicity of 
3,3’-dichlorobenzidine mediates the carcinogenicity of the compound (Imaoka et al. 1997; Ghosal and 
Iba 1990). 
In vivo, micronuclei were induced in polychromatic erythrocytes of the liver of fetal mice exposed 
transplacentally to the compound, and in liver cells of adult male mice treated orally with the 
compound at a maximum tolerated dose reported to be 1,000 mg/kg (Cihak and Vontorkova 1987). A 
sex difference in the genotoxicity of the compound is suggested, since adult male mice, but not 
pregnant females developed erythrocyte micronuclei following 3,3’-dichlorobenzidine exposure. 
However, whether this differential effect extends to carcinogenic effects is unclear. Positive chromatid 
exchange findings in an in vitro test system provide supportive evidence for 3,3’-dichlorobenzidine-
induced cytogenetic changes. In a study using type I, II, and III Bloom Syndrome (BS) 
B-lymphoblastoid cell lines, 3,3’-dichlorobenzidine induced sister chromatid exchanges (SCEs) in all 
three types (Shiraishi 1986). However, the induction of SCE was variable among the three types. 
Exposure of BS type II and type III cells to 3,3’-dichlorobenzidine (1x10-8 to 1.3x10-3 M) caused an 
increase in SCEs (120-140/cell) over baseline levels (70/cell) at the highest concentration 
(1.3x10-3 M). BS type II cells required metabolic activation, while BS type III cells were sensitive 
with and without activation. The frequency of SCEs in BS type I cells was lower than in II and III. 
The genotoxic effect of 3,3’-dichlorobenzidine is further supported by positive responses in bacterial 
assays employing Sulmonella tester strains TA1538 and TA98 in the absence of liver activating 
systems (Garner et al. 1975; Iba 1987a; Iba and Thomas 1988; Lazear et al. 1979; Savard and Josephy 
1986). In another study, 3,3’-dichlorobenzidine exhibited both direct and hydrogen peroxide-
dependent mutagenicity in S. thyphimurium strain TA98, but not Tal00 or TA102, leading the authors 






endogenous to the tester strain TA98 may play a role in the activation of 3,3’-dichlorobenzidine 
(Lang and Iba 1987). A mixture containing Arochlor-induced rat liver homogenate and 10 µg 
3,3’-dichlorobenzidine was positive for reverse mutation in S. typhimurium strain TA98 
(histidine revertants) (Vithayathil et al. 1983). A recent study reported DNA damage in S. 
typhimurium NM2009 after incubation with 3,3’-dichlorobenzidine activated by mouse kidney or 
bladder rnicrosomes or rat liver microsomes (Imaoka et al. 1997). 
3,3’-Dichlorobenzidine is an effective inducer of its own activation (Iba 1987a). The enhancing 
effect of 3,3’-dichlorobenzidine pretreatment on the in vitro liver activation of the chemical to 
mutagens has been associated with the induction of cytochrome P-450d (CYPlA2) (Iba and 
Thomas 1988). This action may result in the compound enhancing its own genotoxicity and 
carcinogenicity. 3,3’-Dichlorobenzidine was also shown to be a potent inducer of hepatic 
microsomal enzymic activities mediated by cytochrome-P-448 (CYPlA2) and P-450 in other 
animal studies (Iba and Sikka 1983; Iba and Thomas 1988). In another study to evaluate the 
P-450 induction pattern of 3,3’-dichlorobenzidine, intraperitoneal administration of 20-120 mg/kg 
3,3’-dichlorobenzidine to male Sprague-Dawley rats induced P-450 isozymes in a pattern similar 
to 3-methylcholanthrene (i.e., induced P-450c) (CYP2Bl), and P-450d (CYPlA2) but mainly 
P-450c (CYP2Bl). 3,3’-Dichlorobenzidine activation was unaffected by monoclonal antibodies to 
P-450b (CYPlAl) or P-450c (CYP2Bl) but was inhibited by 69% by polyclonal antibodies to 
P-450d (CYPlA2).  3,3’-Dichlorobenzidine activation was also inhibited by 46% by antibody 
specific to NADPH-cytochrome P-450 reductase. Based on these results, it was concluded that 
P-450d (CYPlA2) is mainly responsible for the activation of 3,3’-dichlorobenzidine to mutagens 
in the Ames test by rat hepatic microsomes (Iba et al. 1983). 
Results of in vivo tests show that 3,3’-dichlorobenzidine induced dose-dependent unscheduled 
DNA synthesis in the liver of male rats treated orally (Ashby and Mohammed 1988). In vitro 
evidence for the genotoxicity of 3,3’-dichlorobenzidine includes the induction of UDS in HeLa 
cells at a concentration range of 10m-7 to 10-4M (Martin et al. 1978), and transformation of high 
passage rat embryo cells infected with the Rauscher leukemia virus (Freeman et al. 1973). In the 
latter system, an effect was observed at 2x10-7 M 3,3’-dichlorobenzidine, but not at 4x10-8 M. 
Also, 3,3’-dichlorobenzidine transformed BHK21 cells (hamster kidney cells) in vitro in the 
presence of metabolic activation (Styles 1978). The UDS assay is used to measure the repair that 
follows DNA damage. However, the relevance of UDS to human health is not known. While 




more predictive indicator assays to adequately characterize the genotoxic potential for 3,3’­
dichlorobenzidine in humans. 
3,3’-Dichlorobenzidine formed adducts with calf thymus DNA when incubated with rat liver S9 
(Bratcher and Sikka 1982), or horseradish peroxidase (Tsuruta et al. 1985) in vitro. 
3,3’-Dichlorobenzidine was also shown to bind extensively to tissue DNA in rats and mice. Single 
oral administration of 20 or 100 mg/kg radiolabeled 3,3’-dichlorobenzidine to male Sprague-Dawley 
rats or Swiss-Webster mice resulted in extensive binding of the compound to tissue (liver, bladder, 
and intestine) DNA 12, 24, or 96 hours, and 9 or 14 days after treatment (Ghosal and Iba 1990). 
Results from in vitro studies in rats and mice indicated that 3,3’-dichlorobenzidine formed tissue 
DNA-binding derivatives of 3,3’-dichlorobenzidine (Ghosal and Iba 1990). However, the relevance of 
DNA adduct formation to the genotoxicity and carcinogenicity of the compound and to human health 
is not yet established. Therefore, the genotoxicity consequences of  3,3’-dichlorobenzidine in humans 
remain uncertain. 
Cancer. Due, in part, to structure-activity considerations, epidemiological studies of potential cancer 
effects of occupational exposure to 3,3’-dichlorobenzidine have focused upon bladder tumors since 
benzidine is a known bladder carcinogen. One study found an excess incidence of bladder tumors 
among German painters who were exposed to various dyes and pigments derived from benzidine, 
3,3’-dichlorobenzidine, 3,3-dimethylbenzidine (o-tolidine), 3,3-dimethoxybenzidine (o-dianisidine), 
and 2-naphthylamine (Myslak et al. 1991). Because of the potential exposure of the painters to 
multiple chemicals (including some known bladder carcinogens), the role of 3,3’-dichlorobenzidine in 
the increased incidence of bladder tumors, if any, is unknown. A more recent study found a significant 
increase in the incidence of bladder cancers among a group of about 700 employees employed at a 
Connecticut chemical plant (Ouellet-Hellstrom and Rench 1996). In this case there was no exposure to 
benzidine, but the workers were also exposed to several arylamines other than 3,3’-dichlorobenzidine, 
therefore risks from specific chemical exposures could not be evaluated. 
No other epidemiological studies have found bladder tumors or excess tumors at other sites 
(Gadian 1975; Gerarde and Gerarde 1974; MacIntyre 1975). Cancer effects have not been 
satisfactorily investigated in these studies of occupationally exposed workers. These studies were 
conducted with workers who were exposed to 3,3’-dichlorobenzidine for less than 20 years. Since 
the latency period for chemically induced bladder cancer in humans ranges from 5 to 50 years 




3,3’-dichlorobenzidine-induced tumors may not have elapsed for some individuals. Also, the number 
of workers examined in these studies was relatively small, thus limiting the statistical power to detect 
a significant increase in bladder cancer mortality (incidence). 
Some have speculated that 3,3’-dichlorobenzidine may have contributed to the incidence of bladder 
cancer attributed to benzidine in dye industry workers who handled both benzidine and 
3,3’-dichlorobenzidine (Gadian 1975; IARC 1982a). No bladder tumors were observed in a group of 
workers who handled only 3,3’-dichlorobenzidine; in the same plant, bladder tumors were found 
among workers who handled both benzidine and 3,3’-dichlorobenzidine. The investigator reported a 
total exposure time of 68,505 hours for the study population, equivalent to nearly 140 full-time 
working years (Gadian 1975). Cytodiagnostic tests produced no indication of tumors of the bladder in 
an epidemiological study of 259 workers who had been exposed for a total of less than 16 years to 
3,3’-dichlorobenzidine (MacIntyre 1975). In a retrospective epidemiological study, no bladder tumors 
were observed in a cohort of 207 workers, most of whom had been exposed for up to 15 years 
(Gerarde and Gerarde 1974). However, in this study there was no evidence that any valid system of 
medical surveillance of workers ever existed during the years that 3,3’-dichlorobenzidine was used at 
the plant (Gerarde and Gerarde 1974). A number of other inadequacies noted by reviewers of the 
study severely limit the study’s usefulness. 
In animal studies, 3,3’-dichlorobenzidine has been found to cause neoplasia in a variety of target 
organs in several species. The compound produces hepatocellular carcinomas and urinary bladder 
carcinomas in dogs and hamsters (Sellakumar et al. 1969; Stula et al. 1978). Liver cell tumors were 
demonstrated in mice exposed to 3,3’-dichlorobenzidine in the diet (Osanai 1976; Pliss 1959). In rats, 
mammary gland tumors, Zymbal gland tumors, urinary bladder tumors, and leukemias were 
attributable to 3,3’-dichlorobenzidine exposure (Pliss 1959, 1963; Stula et al. 1975). One cancer study 
of dogs which evaluated one sex and used one dose level (precluding dose-response evaluation) shows 
a sufficient number of animals survived to develop tumors (Stula et al. 1978). The results of a study in 
rats suggested that 3,3’-dichlorobenzidine may have a synergistic effect on the bladder carcinogenicity 
of other chemicals (Ito et al. 1983). 
Because of the increased use of closed systems and protective clothing, dermal absorption of 
3,3’-dichlorobenzidine probably represents a relatively minor route of exposure (EPA 1980b). 
However, there is experimental evidence that under certain environmental conditions favoring moist 





humans may be enhanced (Meigs et al. 1954). Studies have not been located which investigate 
the carcinogenic potential of 3,3’-dichlorobenzidine following dermal exposure in laboratory 
animals. 
Further evidence of the carcinogenic potential of 3,3’-dichlorobenzidine is provided by studies 
where 3,3’-dichlorobenzidine was administered subcutaneously. Following subcutaneous 
administration in rats for 10 to 13 months, the compound was found to cause tumors of the skin, 
sebaceous and mammary glands, and urinary bladder (Pliss 1963). These sites were in addition to 
tumors of the hematopoietic tissues and Zymbal gland which were observed following oral 
exposure (Pliss 1959). Pliss (1963) further indicated that oral exposure to 3,3’-dichlorobenzidine 
resulted in a higher incidence of tumors in rats than after subcutaneous injection of the 
compound. Pliss (1963) also noted that the introduction of chlorine into the benzidine molecule 
resulted in an increased carcinogenic response in the skin and the urinary bladder.  Local 
subcutaneous sarcomas and liver tumors were observed in 13/28 strain D mice following 
subcutaneous administration of 3,3’-dichlorobenzidine for 11 months (Pliss 1959). 
In subcutaneous injection studies, induction of tumors in the progeny of BALB/c mice 
administered 2 mg 3,3’-dichlorobenzidine (about 93.5 mg/kg) 4 or 5 times during the last week of 
pregnancy suggest that the chemical may be a transplacental carcinogen (Golub et al. 1975). 
There was an increased incidence of lymphatic leukemias (7 of 24, 29%), lung adenomas 
(5 of 24, 20%), and adenocarcinomas of the mammary gland (4 of 11 female offspring, 36%) in 
the treated group. Lung tumors (3 of 30 offspring, 10%) and mammary gland tumors 
(3 of 19 female offspring, 16%) were observed in untreated controls (Golub et al. 1975). It should 
be noted that since the offspring were nursed by the treated dams, transfer of 
3,3’-dichlorobenzidine to the offspring through maternal milk may have also occurred. 
3,3’-Dichlorobenzidine is an effective inducer of its own metabolic activation (Iba 1987a). The 
enhancement of 3,3’-dichlorobenzidine mutagenesis has been associated with the induction of 
cytochrome P-450d (Iba and Thomas 1988), and may result in the elevation of its carcinogenicity. 
In other animal studies, 3,3’-dichlorobenzidine was also shown to be a potent inducer of hepatic 
microsomal enzymic activities mediated by cytochrome-P-448 and P-450 (Iba and Sikka 1983; 
Iba and Thomas 1988).  Consequently, it has been suggested that the hepatocarcinogenicity of 





While concordance between tumor sites in experimental animals and humans cannot be assumed, the 
occurrence of tumors in multiple organs in several species of experimental animals should be regarded 
as evidence for the potential carcinogenicity of 3,3’-dichlorobenzidine to humans. 
The Environmental Protection Agency (EPA) has determined that 3,3’-dichlorobenzidine is a probable 
human carcinogen. The U.S. Department of Health and Human Services (DHHS) has determined that 
3,3’-dichlorobenzidine and its dihydrochloride salt may reasonably be expected to be carcinogens. 
IARC (1987) has determined that 3,3’-dichlorobenzidine is possibly carcinogenic to humans. 
2.6 CHILDREN’S SUSCEPTIBILITY 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. 
Potential effects on offspring resulting from exposures of parental germ cells are considered, as well 
as any indirect effects on the fetus and neonate due to maternal exposure during gestation and 
lactation. Relevant animal and in vitro models are also discussed. 
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 5.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there 
is a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or 
less susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both pre-natal and post-natal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s). 
Damage may not be evident until a later stage of development. There are often differences in 
pharmacokinetics and metabolism between children and adults. For example, absorption may be 
different in neonates because of the immaturity of their gastrointestinal tract and their larger skin 
surface area in proportion to body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal 
absorption of lead is greatest in infants and young children (Ziegler et al. 1978). Distribution of 




their bodies as extracellular water and their brains and livers are proportionately larger (Altman and 
Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 
1964). The infant also has an immature blood-brain barrier (Adinolfi 1985; Johanson 1980) and 
probably an immature blood-testis barrier (Setchell and Waites 1975). Many xenobiotic metabolizing 
enzymes have distinctive developmental patterns and at various stages of growth and development, 
levels of particular enzymes may be higher or lower than those of adults and sometimes unique 
enzymes may exist at particular developmental stages (Komori 1990; Leeder and Kearns 1997; NRC 
1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the child more or less 
susceptible also depends on whether the relevant enzymes are involved in activation of the parent 
compound to its toxic form or in detoxification. There may also be differences in excretion, 
particularly in the newborn who has a low glomerular filtration rate and has not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility while others 
may decrease susceptibility to the same chemical. For example, the fact that infants breathe more air 
per kilogram of body weight than adults may be somewhat counterbalanced by their alveoli being less 
developed, so there is a disproportionately smaller surface area for absorption (NRC 1993). 
No studies were located that specifically addressed the health effects of exposure to 
3,3’-dichlorobenzidine in children. Limited data in adults are mostly derived from occupational 
studies with limitations including lack of precise exposure data and presence of other compounds. As 
a result, no organ or system has been identified as a target for 3,3’-dichlorobenzidine in humans, 
although dermatitis caused by skin contact with the free base was reported in one study (Gerarde and 
Gerarde 1974). It is reasonable to assume that the same effect would be seen in children similarly 
exposed. Because of the structural similarity of 3,3’-dichlorobenzidine with the known human bladder 
carcinogen benzidine, special attention has been paid to the incidence of bladder cancer among 
subjects occupationally exposed to 3,3’-dichlorobenzidine. Thus far, largely because of study 
limitations, there is no conclusive evidence that exposure to 3,3’-dichlorobenzidine increases the risk 
of bladder cancer in humans (Gadian 1975; Gerarde and Gerarde 1974; Myslak et al. 1991; 




No studies were available that provided information on possible adverse developmental effects in 
humans exposed to 3,3’-dichlorobenzidine. The few available studies in animals were inadequate 
since they used parenteral administration of high doses of 3,3’-dichlorobenzidine 
(Golub 1970; Golub et al. 1975; Shabad et al. 1972). 
There is no information regarding pharmacokinetics of 3,3’-dichlorobenzidine in children nor it is 
known whether 3,3’-dichlorobenzidine can be stored and excreted in breast milk. Although there 
have been no direct measurements to determine whether 3,3’-dichlorobenzidine can cross the 
placenta, there is some indirect evidence that it or its metabolites do. The evidence is based on the 
results of a study in which oral administration of 3,3’-dichlorobenzidine to pregnant mice resulted 
in the induction of micronuclei in the liver of fetuses (Cihak and Vontorvoka 1987). The results 
of another study in which subcutaneous administration of 3,3’-dichlorobenzidine to pregnant 
mice induced abnormal growth of the kidneys explanted from the fetuses also suggest that 
3,3’-dichlorobenzidine or a metabolite can cross the placenta (Shabad et al. 1972). There is no 
information on whether 3,3’-dichlorobenzidine can be stored in maternal tissues and be mobilized 
during pregnancy or lactation, or whether it can reach parental germ cells. 
There is no information on the metabolism of 3,3’-dichlorobenzidine in children. Limited data in 
humans suggest that N-acetylation is an important metabolic pathway (Belman et al. 1968), and a 
detoxification mechanism. N-Acetylation in humans is likely done by one of two families of 
N-acetyltransferases. One of these families, NAT2, is developmentally regulated 
(Leeder and Kearns 1997). Some enzyme activity can be detected in the fetus by the end of the 
first trimester. Almost all infants exhibit the slow acetylator phenotype between birth and 2 
months of age. The adult phenotype distribution is reached by the age of 4-6 months, whereas 
adult activity is found by approximately l-3 years of age. Also, UDP-glucuronosyltransferase, 
responsible for the formation of glucuronide conjugates, seems to achieve adult activity by 618 
months of age (Leeder and Keams 1997). These data suggest that metabolism of 3,3’­
dichlorobenzidine by infants will differ from that in adults in extent, rate, or both. 
There are no biomarkers of exposure or effect for 3,3’-dichlorobenzidine that have been validated 
in children or adults exposed as children. There are no biomarkers in adults that identify previous 
childhood exposure. No studies were located regarding interactions of 3,3’-dichlorobenzidine 
with other chemicals in children or adults. No studies were located that examined possible 




No information was located regarding pediatric-specific methods for reducing peak absorption 
following exposure to 3,3’-dichlorobenzidine, reducing body burden, or interfering with the 
mechanism of action for toxic effects. In addition, no data were located regarding whether methods for 
reducing toxic effects of 3,3’-dichlorobenzidine used in adults might be contraindicated in children. 
There is no information regarding possible transgenerational effects of 3,3’-dichlorobenzidine in 
humans or animals. 
2.7 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They 
have been classified as markers of exposure, markers of effect, and markers of susceptibility 
(NASLNRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of 
biomarkers as tools of exposure in the general population is very limited. A biomarker of exposure is a 
xenobiotic substance or its metabolite(s), or the product of an interaction between a xenobiotic agent 
and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NRC 
1989). The preferred biomarkers of exposure are generally the substance itself or substance-specific 
metabolites in readily obtainable body fluid(s) or excreta. However, several factors can confound the 
use and interpretation of biomarkers of exposure. The body burden of a substance may be the result of 
exposures from more than one source. The substance being measured may be a metabolite of another 
xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different 
aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and 
environmental conditions (e.g., duration and route of exposure), the substance and all of its 
metabolites may have left the body by the time samples can be taken. It may be difficult to identify 
individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., 
essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 3,3’­
dichlorobenzidine are discussed in Section 2.7.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration 
within an organism that, depending on magnitude, can be recognized as an established or 
potential health impairment or disease (NAS/NRC 1989). This definition encompasses 
biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or 
pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction 
such as increased blood pressure or decreased lung capacity. Note that these markers are not often 
substance specific. They also may not be directly adverse, but can indicate 
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potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by 
3,3’-dichlorobenzidine are discussed in Section 2.7.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an 
organism’s ability to respond to the challenge of exposure to a specific xenobiotic substance. It 
can be an intrinsic genetic or other characteristic or a preexisting disease that results in an 
increase in absorbed dose, a decrease in the biologically effective dose, or a target tissue 
response. If biomarkers of susceptibility exist, they are discussed in Section 2.9, Populations That 
Are Unusually Susceptible. 
2.7.1 Biomarkers Used to Identify or Quantify Exposure to 3,3’-Dichlorobenzidine 
A test system that involves extracting dichlorobenzidine or its metabolite 
(monoacetyldichlorobenzidine) from urine and reacting it with Chloramine-T has been developed 
to screen for dichlorobenzidine exposure in workers (Hatfield et al. 1982). An amperometric 
method has been developed for the detection of 3,3’-dichlorobenzidine in the urine as a 
quantitative assay for the biological monitoring of people occupationally exposed to this 
substance or a metabolic precursor such as certain pigments. This method is based on the 
possibility of two electron oxidation at carbon electrodes by aromatic diamines (Trippel-
Schulte et al. 1986). 
Hemoglobin adducts have been detected in female Wistar rats orally administered single 127 or 
253 mg/kg doses of 3,3’-dichlorobenzidine (Birner et al. 1990). The investigators suggested that 
metabolically formed nitroso derivatives can result in the formation of a sulfinic acid amide with 
cysteine residues in hemoglobin (Birner et al. 1990). Hydrolysis yielded mainly 
3,3’-dichlorobenzidine; N-acetylated 3,3’-dichlorobenzidine was also detected. Using a more 
sensitive analytical method, Joppich-Kuhn et al. (1997) also detected 3,3’-dichlorobenzidine-
hemoglobin adducts in rats treated repeatedly with much lower doses (0.3-5.8 mg/kg/day) of 
3,3’-dichlorobenzidine in the drinking water. The limit of detection of the method 
was below 0.1 ng/g hemoglobin and was linear up to 150 ng/g hemoglobin. Although these 
methods have not yet been validated in an occupationally exposed population, they appear 
potentially suitable for use as a biomarker of human exposure to 3,3’-dichlorobenzidine. 
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2.7.2 Biomarkers Used to Characterize Effects Caused by 3,3’-Dichlorobenzidine 
For more information on biomarkers for renal and hepatic effects of chemicals, see ATSDR/CDC 
Subcommittee Report on Biological Indicators of Organ Damage (1990). For information on 
biomarkers for neurological effects, see OTA (1990). 
Currently no disease states in humans are clearly associated with exposure to 
3,3’-dichlorobenzidine. There is evidence that 3,3’-dichlorobenzidine is carcinogenic in animals 
(Golub et al. 1975; Osanai 1976; Pliss 1959, 1963; Sellakumar et al. 1969; Stula et al. 1975, 
1978) and that it is genotoxic in test systems (Ashby and Mohammed 1988; Cihak and 
Vontorkova 1987; Ghosal and Iba 1990; Shiraishi 1986). Hemoglobin adducts have been isolated 
from the blood of 3,3’-dichlorobenzidine-treated animals (Birner et al. 1990; Joppich-Kuhn et al. 
1997), although further studies are needed to determine the associations between blood levels of 
these adducts and specific adverse effects. 
2.8 INTERACTIONS WITH OTHER CHEMICALS 
In contrast to its effects on other mutagens and carcinogens, di-tert,-butylated hydroxytoluene 
(BHT), an antioxidant and a free radical scavenger-considered to be a cancer chemopreventative 
agent based on its ability to inhibit various phases of the carcinogenic process including the 
bioactivation and binding of carcinogenic chemical compounds to DNA-was shown to increase 
the mutagenicity of 3,3’-dichlorobenzidine to Salmonella TA98 by 21-32% and the covalent 
binding of 3,3’-dichlorobenzidine to added DNA by 32-76% (Ghosal and Iba 1992). 
A synergistic role for 3,3’-dichlorobenzidine and other aromatic amines in the development of 
bladder cancer has been suggested. This was proposed in a study in which no carcinomas were 
found in any rats administered one of the following: 0.03% 3,3’-dichlorobenzidine in the diet, 
0.001% BBN (N-butyl-N-(hydroxybutyl)nitrosamine) in drinking water, 0.0005% 
2-AAP (2-acetylaminofluorene) in the diet, or 0.04% FANFT (N-[4-(5-nitro-2-furyl)-2­
thiazolyllformamide) in the diet for a period of 40 weeks (Ito et al. 1983). However, when BBN 
and 3,3’-dichlorobenzidine were fed together at the same dose levels as above, there was a 
marked increase in papillary or nodular hyperplasia in the rat bladder and the appearance of one 
papilloma. Based on these findings, the authors suggested that 3,3’-dichlorobenzidine had a 
synergistic effect on the carcinogenicity of BBN. In rats sequentially administered BBN (0.01%), 
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FANFT (0.15%) 2-AAF (0.025%), and 3,3’-dichlorobenzidine (0.03%) for 4 weeks, the 
incidence ofbladder cancer after administration of the four chemicals was no different than after 
administration of the first three, suggesting no additive or antagonistic effect for 
3,3’-dichlorobenzidine (Ito et al. 1983). 
2.9 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population is defined as one which will exhibit a different or enhanced response to 
a chemical compared to most persons exposed to the same level of exposure. Reasons may 
include genetic makeup, age, health and nutritional status, and exposure to other toxic substances 
(e.g., cigarette smoke). For this chemical, these parameters may result in reduced detoxification 
or excretion of 3,3’-dichlorobenzidine, or compromised function of target organs affected by 
3,3’-dichlorobenzidine. Populations who are at greater risk due to their unusually high exposure 
to 3,3’-dichlorobenzidine are discussed in Section 5.6, Populations With Potentially High 
Exposure. 
No information was located that identified any human population that is exceptionally susceptible 
to the toxicity of 3,3’-dichlorobenzidine. See Section 2.6, Children’s Susceptibility, for a 
discussion of that topic. 
2.10 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic 
effects of exposure to 3,3’-dichlorobenzidine. However, because some of the treatments discussed 
may be experimental and unproven, this section should not be used as a guide for treatment of 
exposures to 3,3’-dichlorobenzidine. When specific exposures have occurred, poison control 
centers and medical toxicologists should be consulted for medical advice. 
2.10.1 Reducing Peak Absorption Following Exposure 
The only information in the literature regarding reducing the absorption of 3,3’-dichlorobenzidine 
was found in a Fact Sheet published by the State of New Jersey (State of New Jersey 1997). The 
recommendations source indicate that following eye contact, eyes should immediately be flushed 
with large amounts of water for at least 15 minutes, occasionally lifting upper and lower lids. It is 
also recommended that after skin contact contaminated clothing should be quickly removed and 
contaminated skin should be 
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immediately washed with large amounts of soap and water. A person exposed to 
3,3’-dichlorobenzidine in the air should be removed from the source of exposure promptly. 
Other information specific for 3,3’-dichlorobenzidine, aimed at minimizing exposure, was found 
in the HSDB database (HSDB 1997). This information indicates that full body protective clothing 
and gloves should be used by those employed in handling operations. Full face supplied air 
respirators of continuous flow or pressure demand should also be used. In addition, employees 
working with 3,3’-dichlorobenzidine (or its salts) within an isolated system, such as “glove box,” 
should wash their hands and arms upon completion of the assigned task and before engaging in 
other activities not associated with the isolated system. 
2.10.2 Reducing Body Burden 
There are no established methods for reducing the body burden of 3,3’-dichlorobenzidine. 
2.10.3 Interfering with the Mechanism of Action for Toxic Effects 
There are no known methods for interfering with the toxic effects of 3,3’-dichlorobenzidine. 
2.11 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation 
with the Administrator of EPA and agencies and programs of the Public Health Service) to assess 
whether adequate information on the health effects of 3,3’-dichlorobenzidine is available. Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology 
Program (NTP), is required to assure the initiation of a program of research designed to determine 
the health effects (and techniques for developing methods to determine such health effects) of 
3,3’-dichlorobenzidine. 
The following categories of possible data needs have been identified by a joint team of scientists 
from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if 
met would reduce the uncertainties of human health assessment. This definition should not be 




all data needs discussed in this section must be filled. In the future, the identified data needs will 
be evaluated and prioritized, and a substance-specific research agenda will be proposed. 
2.11 .l Existing Information on Health Effects of 3,3’-Dichlorobenzidine 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and 
animals to 3,3’-dichlorobenzidine are summarized in Figure 2-3. The purpose of this figure is to 
illustrate the existing information concerning the health effects of 3,3’-dichlorobenzidine. Each 
dot in the figure indicates that one or more studies provide information associated with that 
particular effect. The dot does not necessarily imply anything about the quality of the study or 
studies, nor should missing information in this figure be interpreted as a “data need.” A data need, 
as defined in ATSDR’s Decision Guide for Zdentifiing Substance-Specific Data Needs Related to 
Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as 
any substance-specific information missing from the scientific literature. 
Essentially no studies of human exposure to 3,3’-dichlorobenzidine were located by specific 
routes, except for occupational data on direct dermal effects following dermal exposure and a 
recent carcinogenicity study in which skin contact with 3,3’-dichlorobenzidine and other 
arylamines was found to be the most important exposure route (see Figure 2-3). Although there 
are studies of workers in the United States exposed to 3,3’-dichlorobenzidine, these reports are 
limited by the fact that exposure often involved other compounds, and both the route and extent 
of exposure are largely unknown. Dermal effects have also been investigated in experimental 
animals as well as ocular irritant properties of 3,3’-dichlorobenzidine exposure. There is 
no evidence to suggest that the non-ocular systemic toxicological effects of 
3,3’-dichlorobenzidine may be route- or species-specific. 
Additional information on health effects following dermal exposure is sparse. The majority of 
animal studies of 3,3’-dichlorobenzidine have focused on carcinogenic effects following oral 
exposure, whereas data on noncarcinogenic effects are limited. 
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2.11.2 Identification of Data Needs 
Acute-Duration Exposure. One study in humans showed that the compound may cause respiratory 
effects when inhaled and that application of 3,3’-dichlorobenzidine base causes skin irritation 
(Gerarde and Gerarde 1974). Thus, this limited information in humans is insufficient to conclusively 
identify target organs, other than the skin, following exposure by any route. Acute-duration exposure 
can cause eye damage (erythema, pus, cornea1 opacity) in rabbits following conjunctival application. 
However, the relevance of these findings for the general population is unknown since conjunctival 
application is not a typical route of exposure, and exposure by the inhalation route is unlikely. 
3,3’-Dichlorobenzidine can be lethal following oral and dermal exposure at very high doses. In most 
animal studies, comprehensive gross and histopathological evaluations have not been conducted and 
clinical signs have not been monitored.  Such studies may provide insight into systemic toxicity and 
potential health threat associated with acute-duration exposure. With the exception of effects caused 
by direct contact of 3,3’-dichlorobenzidine with the skin or the eyes, the limited pharmacokinetic data 
do not suggest route-specific target organs. The available data were inadequate for derivation of either 
inhalation or oral acute MRLs. 
Intermediate-Duration Exposure. No intermediate-duration studies in humans were located. 
Intermediate-duration oral studies have been performed in rats without adverse systemic effects, but 
these studies used only one dose level (Griswold et al. 1968; Ito et al. 1983; Osanai 1976; Pliss 1959, 
1963).  Organs and/or tissues from the reproductive, neurological, and immunological systems have 
not been examined in the available intermediate-duration studies; such information would be useful. 
No intermediate-duration inhalation or dermal studies were found. Animal studies evaluating 
toxicological parameters at several dose levels would provide dose-response data which could prove 
more predictive when assessing potential adverse effects in humans following intermediate-duration 
exposure. No oral intermediate MRL was derived because the available studies did not identify 
relevant noncancer effects. 
Chronic-Duration Exposure and Cancer. No studies were located that examined noncancer end points 
in humans following chronic exposure to 3,3’-dichlorobenzidine. Available chronic-duration oral 
studies provide information regarding systemic and carcinogenic effects in rats and dogs (Stula et al. 
1975, 1978). These studies employed one dose level and toxicological parameters measured were 
limited. The inadequacies of these studies precluded derivation of a chronic oral MRL. 
No chronic-duration animal inhalation or dermal exposure studies were located. Well conducted 
chronic-duration inhalation, dermal, 
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and oral studies involving low-dose exposure in animals might provide dose-response data on 
potential systemic effects of exposure in humans. The available data are insufficient to establish a 
relationship between the concentration of 3,3’-dichlorobenzidine and/or its metabolites in the body 
and the levels that are associated with adverse effects. Studies that provide data on the body burden of 
3,3’-dichlorobenzidine associated with toxicity may prove useful. 
Various studies have assessed the potential carcinogenicity of 3,3’-dichlorobenzidine in workers 
exposed to it (Gadian 1975; Gerarde and Gerarde 1974; MacIntyre 1975; Myslak et al. 1991; Ouellet-
Hellstrom and Rench 1996). However, many confounders have rendered the results inconclusive. A 
major difficulty in such studies is the simultaneous exposure to several potential or known 
carcinogens. The carcinogenicity of 3,3’-dichlorobenzidine has been well established in animals after 
oral administration of the compound (Osanai 1976; Pliss 1959, 1963; Sellakumar et al. 1969; Stula et 
al. 1975, 1978), but no information is available regarding inhalation and dermal exposure. There is 
suggestive evidence that 3,3’-dichlorobenzidine may cause cancer in animals when applied dermally 
since tumors were found in rats injected with the compound subcutaneously (Pliss 1963). Of particular 
interest would be additional studies, using relevant routes of exposure, to confirm the findings that 
3,3’-dichlorobenzidine causes cancer in offspring of rats injected with the chemical subcutaneously 
during pregnancy (Golub et al. 1975) 
Genotoxicity.  Available studies in animals and in bacterial systems show that 3,3’-dichlorobenzidine 
does alter genetic material (Ashby and Mohammed 1988; Bratcher and Sikka 1982; Cihak and 
Vontorkova 1987; Garner et al. 1975; Iba 1987a; Iba and Thomas 1988; Imaoka et al. 1997; Lang and 
Iba 1987; Lazear et al. 1979; Savard and Josephy 1986; Shiraishi 1986; Styles 1978). Studies 
involving more predictive indicator test systems may allow a better assessment of mutagenic potential. 
Reproductive Toxicity.  No studies were found regarding reproductive toxicity of 
3,3’-dichlorobenzidine.  Should data suggesting that reproductive organs are affected in a 90-day 
study become available, multigenerational reproductive studies in animals may be warranted. 
Developmental Toxicity.  No studies were found regarding developmental toxicity of 
3,3’-dichlorobenzidine in humans. Animal studies have shown that 3,3’-dichlorobenzidine and/or 
metabolites may be transferred across the placenta and or through maternal milk to the offspring and 
may affect the growth of the kidneys after parenteral exposure during pregnancy (Golub 1972; Shabad 




in the offspring (Golub et al. 1975). The effects of the compound on development following oral, 
inhalation, or dermal exposure have not been studied. Well conducted animal studies employing 
various dose levels and relevant exposure routes during critical developmental periods may provide 
information on potential fetotoxicity, embryotoxicity, and teratogenic effects in humans. Also, 
cross-fostering studies may help determine the relative impacts of in utero transfer of the chemical and 
transfer through nursing.  Further animal data may provide dose-response information if studies are 
conducted to determine what dose of 3,3’-dichlorobenzidine, or its metabolites, reaches the fetus. 
Immunotoxicity.  No studies were located assessing the potential effect on the immune system during 
3,3’-dichlorobenzidine exposure. Studies that examine antibody levels and responses to bacterial 
infections after exposure to 3,3’-dichlorobenzidine would provide valuable information on the 
immune system. Also, evaluation of morbidity among individuals exposed to 
3,3’-dichlorobenzidine in the workplace may provide important indirect evidence regarding their 
immune status. 
Neurotoxicity. Based on its chemical structure, 3,3’-dichlorobenzidine does not appear to be 
neurotoxicant, but the nervous system has not been carefully evaluated after exposure to this chemical. 
Workers exposed to 3,3’-dichlorobenzidine (and to other chemicals as well) complained of headache 
and dizziness (Gerarde and Gerarde 1974). A chronic-duration oral study in dogs reported convulsions 
in one of six dogs treated orally with 3,3’-dichlorobenzidine (Stula et al. 1978). Upon necropsy, the 
authors noticed slight neuronal degeneration in tissues (unspecified) of the nervous system from this 
dog. However, the effect was seen in only one of the six dogs and only one dose level was tested. The 
limited information available does not suggest that 3,3’-dichlorobenzidine is a neurotoxicant, and 
studies aimed exclusively to evaluate this end point seem unnecessary at this time. However, any 
future long-term toxicity study on 3,3’-dichlorobenzidine in animals should include histological 
evaluation of representative elements of the nervous system. Furthermore, evaluation of neurological 
end points in offspring from animals exposed during gestation would provide information that may be 
relevant to children of pregnant women exposed to 3,3’-dichlorobenzidine in the workplace. 
Epidemiological and Human Dosimetry Studies. The potential for occupational exposure exists in the 
use of 3,3’-dichlorobenzidine in the synthesis of 3,3’-dichlorobenzidine-based pigments for printing 
ink applications and to a lesser extent in paints. Workers exposed to 3,3’-dichlorobenzidine (and 





sore throat, caustic burns, headache, dizziness, and dermatitis (Gerarde and Gerarde 1974). The only 
one of these effects that appeared to be associated with 3,3’-dichlorobenzidine exposure with 
reasonable certainty is dermatitis, which was attributed to a manufacturing process change that 
resulted in exposure to dichlorobenzidine-freebase (Gerarde and Gerarde 1974). Studies of 
occupationally exposed individuals are complicated by the fact that there is usually simultaneous 
exposure to other chemicals. Based on available data, the potential for nonindustrial exposure to the 
general population by air, soil, or water is expected to be negligible. Epidemiological studies of people 
who live in areas where 3,3’-dichlorobenzidine has beendetected in groundwater, near industries 
releasing 3,3’-dichlorobenzidine, or near hazardous waste sites could provide information on whether 
3,3’-dichlorobenzidine exposure produces effects in humans. In the unlikely event that exposure of the 
general population (in the past or present) primarily to 3,3’-dichlorobenzidine is identified, individuals 
should be monitored for gastrointestinal, respiratory, dermal, and neurological effects (as reported 
earlier by Gerarde and Gerarde 1974). 
No studies were located that monitored human tissues for content of 3,3’-dichlorobenzidine or its 
metabolites. 3,3’-Dichlorobenzidine is excreted in urine. If 3,3’-dichlorobenzidine and metabolites can 
be detected and correlated with exposure, it may be possible to correlate urinary levels of 
3,3’-dichlorobenzidine or its metabolites, with systemic effects. 
Biomarkers of Exposure and Effect. 
Exposure.  A test system that involves extracting dichlorobenzidine or its metabolite 
(monoacetyldichlorobenzidine) from urine and reacting it with Chloramine-T has been developed to 
screen for dichlorobenzidine exposure in workers (Hatfield et al. 1982). In addition, an amperometric 
method has been developed for the detection of 3,3’-dichlorobenzidine in the urine as a quantitative 
assay for the biological monitoring of occupationally exposed persons to this substance. This method 
is based on the two electron oxidation at carbon electrodes by aromatic diamines (Trippel-Schulte et 
al. 1986). Hemoglobin adducts have been detected in female Wistar rats orally administered single 
doses of 127 or 253 mg/kg 3,3’-dichlorobenzidine (Birner et al. 1990) and to repeated doses of 0.3 
mg/kg/day (Joppich-Kuhn et al. 1997). Birner et al.(1990) suggested that metabolically formed nitroso 
derivatives can result in the formation of a sulfinic acid amide with cysteine residues in hemoglobin. 
Hydrolysis yielded mainly 3,3’-dichlorobenzidine; N-acetylated-3,3’-dichlorobenzidine was also 
detected. This method has not yet been validated in an occupationally exposed population. More 




as a biomarker of human exposure to 3,3’-dichlorobenzidine. Further studies to develop simpler, more 
sensitive biomarkers of exposure that are specific for 3,3’-dichlorobenzidine would be useful in 
monitoring exposure of people living near hazardous waste sites containing 
3,3’-dichlorobenzidine. 
Effect. There are no specific disease states in humans or animals that have been associated with 
exposure to 3,3’-dichlorobenzidine. Hemoglobin adducts have been isolated from the blood of 
3,3’-dichlorobenzidine-treated animals (Birner et al. 1990; Joppich-Kuhn et al. 1997). It is not known 
what relationship exists between adduct levels in the blood and 3,3’-dichlorobenzidine toxicity. 
Further research in animal models is needed to determine if these adducts could be correlated with 
effects of 3,3’-dichlorobenzidine exposure. Further studies to identify more sensitive toxic effects 
(noncancer) that are specific for 3,3’-dichlorobenzidine would be useful in monitoring effects in 
people living near hazardous waste sites containing 3,3’-dichlorobenzidine. 
Absorption, Distribution, Metabolism, and Excretion. Available data are insufficient to allow 
accurate evaluation of absorption, metabolism, or persistence of 3,3’-dichlorobenzidine in human 
tissues.  Additional studies to identify and quantify metabolites of 3,3’-dichlorobenzidine in humans 
and animals would be useful in establishing the relevance of animal studies in predicting human health 
effects. Metabolic handling of 3,3’-dichlorobenzidine in humans needs to be better characterized 
before urinary levels of the compound or its metabolites can be used to quantitate human exposure. 
Comparative Toxicokinetics. Pharmacokinetics studies have not been performed under conditions 
analogous to those of the carcinogenicity studies. Therefore, it is not possible to determine systemic 
levels of the compound associated with the reported effects. Pharmacokinetics data developed under 
exposure conditions associated with biological effects would markedly increase the possibility of 
improved species extrapolation for evaluating the true potency of 3,3’-dichlorobenzidine. 
Methods for Reducing Toxic Effects. There are no disease states in humans that are associated with 
exposure to 3,3’-dichlorobenzidine. Therefore, studies that further characterize means of assessing 
human exposures (biomonitoring) along with identification of programs designed to minimize this 
exposure would be effective for mitigation of potential effects resulting from accidental exposure in 
occupational settings or exposure to humans living near hazardous waste sites where 




Children’s Susceptibility.  The information on health effects of 3,3’-dichlorobenzidine in humans is 
derived exclusively from studies of occupational exposure (Gadian 197.5; Gerarde and Gerarde 1974; 
MacIntyre 1975; Myslak et al. 1991; Quellet-Hellstron and Rench 1996). Because of study limitations 
such as simultaneous exposure to other chemicals, no target organ or system has been identified for 
3,3’-dichlorobenzidine. In one occupational study it was reported that contact with the free base 
caused dermatitis (Gerarde and Gerarde 1974); it is reasonable to assume that children will respond in 
a similar manner under similar exposure conditions, although such exposure scenarios for children 
seem unrealistic. There is no information available to determine whether children and adults are 
equally susceptible to the toxic effects of 3,3’-dichlorobenzidine. No studies in animals have 
addressed this issue either, but given the unlikelihood of exposure to 3,3’-dichlorobenzidine by the 
general population, such studies do seem warranted at this time. 
There is no information on whether the developmental process is altered in humans exposed to 3,3’-
dichlorobenzidine. Studies in animals have been inadequate (Golub 1970; Golub et al. 1975; Shabad 
et al. 1972) and further well conducted research would be helpful to clarify whether the developmental 
process can be affected in animals exposed to 3,3’-dichlorobenzidine by a relevant route of exposure. 
This also includes information on whether 3,3’-dichlorobenzidine (or metabolites) can cross the 
placenta and/or be transferred to offspring via breast milk. There are no data to evaluate whether 
harmacokinetics of 3,3’-dichlorobenzidine in children are different from adults. There are no PBPK 
models for 3,3’-dichlorobenzidine, but a need for such a model is not apparent at this time. There is no 
information to evaluate whether metabolism of 3,3’-dichlorobenzidine in children is different than in 
adults, but there are some theoretical reasons to suspect that it might be different. 
Continued research into the development of sensitive and specific biomarkers of exposure and effect 
for 3,3’-dichlorobenzidine, and the validation of these biomarkers in occupationally exposed 
individuals would be valuable. Since at this point there are no validated biomarkers of exposure and 
effect in adults, it makes sense to focus efforts on occupationally exposed adults rather than children 
who are unlikely to be exposed.  There are no data on interactions of 3,3’-dichlorobenzidine with 
other chemicals in children or adults.  There are no pediatric-specific methods to reduce peak 
absorption for 3,3’-dichlorobenzidine following exposure, to reduce body burdens, or to interfere with 
3,3’-dichlorobenzidine’s mechanism of action, but it is reasonable to assume that exposure avoidance 
measures should be applied to children where needed. 
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Child health data needs relating to exposure are discussed in Section 5.8.1, Data Needs: 
Exposures of Children. 
2.11.3 Ongoing Studies
 




3. CHEMICAL AND PHYSICAL INFORMATION 
3.1 CHEMICAL IDENTITY
 
Information regarding the chemical identity of 3,3’-dichlorobenzidine is located in Table 3-l.
 
3.2 PHYSICAL AND CHEMICAL PROPERTIES
 






4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
3,3’-Dichlorobenzidine is commercially produced by reduction of o-nitrochlorobenzene through 
various reduction procedures to form a hydrazo compound, which is rearranged in the presence of 
mineral acids to form 3,3’-dichlorobenzidine (DCMA 1989; Sax 1987). Commercial supplies are 
usually provided in the form of the dihydrochloride salt because of its greater stability. 
According to the 1997 Directory of Chemical Producers (SRI 1997), only one company, Lomac, 
Inc. of Muskegon, Michigan, manufactures (that is, produces) 3,3’-dichlorobenzidine. By 
contrast, in 1986, there were approximately 10 suppliers of the chemical listed in the United 
States (NTP 1994). Current production volumes of 3,3’-dichlorobenzidine for individual 
companies are considered confidential business information and cannot be reported. The United 
States International Trade Commission (USITC 1984a) reported a 1983 production volume of 
3,3’-dichlorobenzidine-based dyes of over 18 million pounds in the United States. However, 
3,3’-dichlorobenzidine is no longer used to manufacture dyes in the United States (CPMA 1998). 
Consumption of 3,3’-dichlorobenzidine in the United States amounted to 9.9 million pounds in 
1987 (Hopmeier 1988). 
Table 4-l lists the facilities in each state that manufacture 3,3’-dichlorobenzidine or process the 
compound for further distribution, the range of maximum amounts of 3,3’-dichlorobenzidine 
on-site, and the activities and uses of the product. “Processing” means the further distribution of 
the compound either as the same physical compound, in a different form or physical state, or as 
part of another article or mixture (40 CFR 372.3). In 1996, there was one facility in the United 
States that manufactured or used 3,3’-dichlorobenzidine.  The data listed in Table 4-1 are derived 
from the 1996 Toxics Release Inventory (TR196 1998).  Only certain types of facilities were 
required to report. Therefore, this is not an exhaustive list. 
4.2 IMPORT/EXPORT 
Imports of 3,3’-dichlorobenzidine base and salts were 1.1 million pounds in 1983, while pigments 
derived from 3,3’-dichlorobenzidine were about 129,000 pounds in 1983 (USITC 1984b). 
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4.3 USE 
3,3’-Dichlorobenzidine is used primarily in the production of yellow, and some red and orange 
pigments for the printing ink, textile, paper, paint, rubber, plastic, and related industries (EPA 1979a). 
As of 1983, 7 specified pigments were commercially available. The yellow pigments derived from 
3,3’-dichlorobenzidine can be used as substitutes for lead chromate pigments (HSDB 1996). Little, if 
any, dye is prepared from this compound. The chemical also has application as a compounding 
ingredient for rubber and plastics (HSDB 1996), and can be used to test for the presence of gold 
(Searle 1976). 3,3’-Dichlorobenzidine is used in the manufacture of the raw material 
tetraminobiphenyl which is used to produce polybenzimidazole (PBI). PBI fiber is used in many 
protective clothing applications, such as firefighter’s apparel, welder’s garments, high-temperature 
gloves, and crash rescue garments (Celanese 1985). 
3,3’-Dichlorobenzidine is also used with 4,4’-methylenebis (2-chloroaniline) as a curing agent for 
liquidcastable polyurethane elastomers (HSDB 1996). 
4.4 DISPOSAL 
3,3’-Dichlorobenzidine is treated in the workplace as a controlled substance under OSHA. Therefore, 
strict requirements have been made to minimize exposure to the chemical in the workplace air and 
contact with the skin and eyes. Nonetheless, some releases may occur in wastewater effluents. 
One company which purchases 3,3’-dichlorobenzidine as the dihydrochloride salt in sealed fiber in 
drums rinses the empty drums with water, adds the rinse water to the product stream, then sprays the 
drums with a sodium hypochlorite bleach solution (converting the 3,3’-dichlorobenzidine to a 
quinone-type compound), and places them in polyethylene bags for disposal (London and Boiano 
1986). 
3,3’-Dichlorobenzidine is listed as a toxic substance under Section 313 of the Emergency 
Planning and Community Right to Know Act (EPCRA) under Title III of the Superfund 
Amendments and Reauthorization Act (SARA) (EPA 1995). Disposal of wastes containing 3,3’­
dichlorobenzidine is controlled by a number of federal regulations (see Chapter 7). The current 
recommended technologies specified for treating 3,3’-dichlorobenzidine-containing wastes (waste 
waters and nonwastewaters) prior to land disposal include wet air oxidation, chemical or 
electrolytic oxidation, and carbon adsorption and incineration (EPA 
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1986). Facilities which generate 3,3’-dichlorobenzidine-containing wastes, and owners and 
operators of hazardous waste treatment, storage, and disposal facilities must also comply with 
regulations promulgated under the authority of the Resource Conservation and Recovery Act 
(RCRA). 
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5.1 OVERVIEW 
3,3’-Dichlorobenzidine is currently used in the production of insoluble dyes and pigments. 
Almost all 3,3’-dichlorobenzidine is now manufactured outside the United States and is imported 
for on-site processing or for use as a reactant to synthesize pigments. “Processing” means 
preparing a chemical after its manufacture for commercial distribution either as the same physical 
compound, in a different form or physical state, or as part of another article (for instance, a 
mixture) containing the chemical (40 CFR 372.3). 
Use of the compound to synthesize soluble dyes ceased as of 1986, when better dyes from other 
sources were introduced. The distinction between dyes and pigments is not always clear. 
Pigments are almost without exception insoluble and exist as finely divided solid powders that are 
insoluble but wettable under the conditions of use. Dyes are almost always soluble organic 
substances used in coloring textiles or other fibrous substances. 
Release routes of 3,3’-dichlorobenzidine to the environment appear to be waste waters, sludges, 
and solid wastes where emissions are not properly controlled during the use of 
3,3’-dichlorobenzidine or during its chemical transformation to pigments. The compound has 
been found in water and soil at hazardous waste sites, a result of the improper land disposal of 
solid wastes. 
Concern for human health derives primarily from inhalation of airborne dust or skin contact 
during careless handling or accidental spillage in occupational settings or drinking of 
contaminated well water by persons living in the proximity of hazardous waste sites. However, 
occupational case reports suggest that risk to workers exposed to 3,3’-dichlorobenzidine through 
the use of 3,3’-dichlorobenzidine-based pigments may be minimal. No adverse health effects 
were reported among 20 workers engaged in the manufacture and handling of 
3,3’-dichlorobenzidine alone (concentration not specified) in a Japanese facility (DCMA 1989). 
No detectable levels of 3,3’-dichlorobenzidine or its monoacetyl metabolite (at a detection limit 
of 0.2 ppb) were seen in urine samples of workers who were exposed to pigments derived from 
3,3’-dichlorobenzidine on the day the samples were collected (Hatfield et al. 1982). The urine 
analysis results for workers with 
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high potential for pigment exposure suggest that these pigments are not metabolized in humans 
although, without pigment exposure data, this conclusion is somewhat tentative. 
The hydrochloric acid salt of 3,3’-dichlorobenzidine readily photolyses in water exposed to natural 
sunlight, but may not readily biodegrade in soil and acclimated sludges. It has a strong tendency to 
partition to soils and sediments, a property which reduces the potential for human exposure (Boyd et 
al. 1984; Chung and Boyd 1987; Sikka et al. 1978). Once partitioned to soil, the compound apparently 
binds further with humic substances to form humic-like materials that presumably would be 
non-hazardous (Sikka et al. 1978).  However, in a recent paper, Nyman et al. (1997) stated that 
dehalogenation of 3,3’-dichlorobenzidine to form benzidine (also a toxic substance) occurs in 
sediment/water mixtures under anaerobic conditions. The compound does not volatilize or hydrolyze 
in solution, but it may slowly oxidize (Banerjee et al. 1978; Callahan et al. 1979). 
3,3’-Dichlorobenzidine may be bioconcentrated by aquatic organisms (Appleton and Sikka 1980), but 
it is not certain if it is biomagnified by transfer through the food chain. 3,3’-Dichlorobenzidine 
accumulates in freshwater fish during aquatic exposure to either 5 ppb or 0.1 ppm concentrations of 
the chemical. After returning the fish to fresh, uncontaminated water, clearance of the compound from 
edible flesh was initially rapid (half-life of approximately 48 hours), but residues remained even after 
14 days (Appleton and Sikka 1980). Steady-state concentrations in fish from ambient (unspiked) water 
exposures would be expected to be very low. 
The reductive cleavage in vivo of azo dyes in general was first observed by Rinde and Troll (1975). 
Since then, several research groups have published articles that relate to the potential for human 
exposure to 3,3’-dichlorobenzidine that might arise via various chemical and biochemical mechanisms 
that degrade 3,3’-dichlorobenzidine-based synthetic dyes. A study by Hoffman and Schmidt (1993) 
found no evidence for metabolic cleavage of Pigment Yellow 17 to produced 3,3’-dichlorobenzidine 
in rats that inhaled the pigment. However, Zwirner-Baier and Neumann (1994), based on analysis of 
hemoglobin adducts from rats that drank the pigments, concluded that intestinal cleavage processes 
release very small amounts of 3,3’-dichlorobenzidine from Pigment Yellow 17 and Direct Red 46 
(0.6% and 3%, respectively, of the total dose administered over 4 weeks). In another study 
(Sagelsdorff et al. 1996), the lack of appearance of  3,3’-dichlorobenzidine from Pigment Yellow 13 
and 17 is shown, but a marked formation of  3,3’-dichlorobenzidine occurs from a soluble azo dye, 
C. I. Direct Red 46, which was an impurity in the pigments they studied. 
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In metabolism studies of azo dyes and pigments in the hamster, in viva cleavage of the benzidine-
based dye, Direct Black 38, to benzidine was shown by analysis of the urine. However, studies of the 
3,3’-dichlorobenzidine-based pigment, Pigment Yellow 12, showed no evidence for in vivo cleavage 
to release 3,3’-dichlorobenzidine (Nony et al. 1980). 
3,3’-Dichlorobenzidine has been identified in at least 32 of the 1,467 current or former EPA National 
Priorities List (NPL) hazardous wastes sites (HazDat 1998). However, the number of sites evaluated 
for 3,3’-dichlorobenzidine is not known. The frequency of these sites within the United States can be 
seen in Figure 5-l. The manufacture and use of 3,3’-dichlorobenzidine has been strictly regulated by 
OSHA since 1974. All work with the compound is done in closed systems and any residues are 
destroyed by chemical reaction. Such precautions, if conscientiously practiced, make it unlikely that 
significant quantities of 3,3’-dichlorobenzidine have been disposed of in landfills or at NPL sites after 
1974. 
NPL Superfund Records of Decision (RODS) were located for 24 of the 27 currently listed NPL sites 
where the HazDat database lists 3,3’-dichlorobenzidine as a contaminant. A ROD is a legally binding 
document that states the results of investigation and feasibility testing at hazardous waste sites and 
tells what techniques will be used to remediate the site. At four of the sites, 3,3’-dichlorobenzidine 
was verified as a contaminant. The RODS for the other 20 sites did not mention 3,3’­
dichlorobenzidine as a contaminant of concern (i.e., one that warrants development of cleanup criteria 
and a choice of remedy). Affected soil was removed from three of the four contaminated sites. Only 
one site, Bofors Nobel in Michigan, required development of a cleanup criteria (CPMA 1998). 
5.2 RELEASES TO THE ENVIRONMENT 
According to the Toxics Release Inventory (TRI), in 1996, a total of 2 pounds (1 kg) of 3,3’­
dichlorobenzidine was released to the environment from one processing facility (TR196 1998). 
Table 5-l lists amounts released from this facility. In addition, an estimated 250 pounds (118 kg) 
were released by manufacturing and processing facilities to publicly owned treatment works 
(POTWs), and an estimated 51,550 pounds (23,432 kg) were transferred offsite (TR196 1998). 
The TRI data should be used with caution because only certain types of facilities are required to 
report. Therefore, this is not an exhaustive list. 
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3,3’-Dichlorobenzidine has been identified in a variety of environmental media (air, surface 
water, groundwater, soil, and sediment) collected at 32 of the 1,467 current or former NPL 
hazardous waste sites (HazDat 1998). The frequency of these sites within the United States can be 
seen in Figure 5-l. 
5.2.1 Air 
The free base form of 3,3’-dichlorobenzidine is no longer utilized by industry in the United 
States. It is primarily supplied as the dihydrochloride salt (CPMA 1998). When it was used as the 
free base, it was handled as a powder or a moist paste (NIOSH 1980). 3,3’-Dichlorobenzidine is 
not a volatile chemical. A vapor pressure of 4.5x10x-9 mm Hg at 20 ºC has been reported (DCMA 
1989). Prior to OSHA 1974 regulations, benzidine and 3,3’-dichlorobenzidine were manufactured 
in open systems that permitted atmospheric releases of suspended particles at the work site 
(Shriner et al. 1978), but no historical data were located specifically for 3,3’-dichlorobenzidine 
emissions (atmospheric or in water). The absence of data may be attributed to analytical methods 
used at that time that could not distinguish benzidine from its derivatives or many other aromatic 
amines (Shriner et al. 1978). Under OSHA regulations adopted in 1974, only closed 
manufacturing systems are permitted, and atmospheric emissions are presumably reduced 
because of this regulation. 
Estimated releases of 2 pounds (0.9 kg) of 3,3’-dichlorobenzidine to the atmosphere from one 
facility in 1996, accounted for 100% of the estimated total environment releases (TR196 1998). 
These releases are summarized in Table 5-1. The TRI data should be used with caution because 
only certain types of facilities are required to report information to the Toxics Release Inventory 
only if they employ more than 10 full-time employees, if their facility is classified under Standard 
Industrial Classification (SIC) codes 20 through 39, and if their facility produces, imports, or 
processes 25,000 or more pounds of any TRI chemical or otherwise used more than 10,000 
pounds of a TRI chemical in a calendar year (EPA 1997). A member company of the Color 
Pigment Manufacturers Association, Inc., which monitors 3,3’-dichlorobenzidine under state 
regulations, reports that only de minimus values are found (CPMA 1998). 
3,3’-Dichlorobenzidine was not identified in any air samples collected at any of the 32 NPL 
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5.2.2 Water 
The free base form of 3,3’-dichlorobenzidine is sparingly soluble in water. The solubility of 
3,3’-dichlorobenzidinem-2HCl in water is 4 mg/L at a pH of 6.9 (Banerjee et al. 1978). A 
solubility of 3.1 mg/L is also quoted (CPMA 1998). 3,3’-Dichlorobenzidine may be released into 
the environment in waste waters generated by the production of dyes and pigments. 
No releases of 3,3’-dichlorobenzidine to the surface water were reported in 1996 (TR196 1998). 
Two hundred and fifty pounds (550 kilograms) were released to publicly owned treatment works 
(POTWs) (TR196 1998). These releases are summarized in Table 5-1. The TRI data should be 
used with caution because only certain types of facilities are required to report information to the 
Toxics Release Inventory only if they employ more than 10 full-time employees, if their facility 
is classified under Standard Industrial Classification (SIC) codes 20 through 39, and if their 
facility produces, imports, or processes 25,000 or more pounds of any TRI chemical or otherwise 
used more than 10,000 pounds of a TRI chemical in a calendar year (EPA 1997). As a result of 
secondary treatment processes in POTWs, only a small percentage of any 3,3’-dichlorobenzidine 
that might enter POTWs is subsequently released into surface water. 
3,3’-Dichlorobenzidine has been identified in surface water and groundwater samples collected at 
19 of the 32 NPL hazardous waste sites where it was detected in some other environmental media 
(HazDat 1998). 
5.2.3 Soil 
According to the Toxics Release Inventory, in 1996, there were no reported releases of 3,3’­
dichlorobenzidine to soil from any large processing facilities (TR196 1998). The TRI data should 
be used with caution because only certain types of-facilities are required to report information to 
the Toxics Release Inventory only if they employ more than 10 full-time employees; if their 
facility is classified under Standard Industrial Classification (SIC) codes 20 through 39; and if 
their facility produces, imports, or processes 25,000 or more pounds of any TRI chemical or 
otherwise used more than 10,000 pounds of a TRI chemical in a calendar year (EPA 1997). 
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3,3’-Dichlorobenzidine has been identified in soil and sediment samples collected at 18 of the 32 NPL 
hazardous waste sites where it was detected in some environmental media (HazDat 1998). 
5.3 ENVIRONMENTAL FATE 
Because 3,3’-dichlorobenzidine adsorbs to airborne dust particles or is otherwise bound to particulate 
matter, it is subject to dispersion, gravitational settling, and wash-out by rain. In water, 
3,3’-dichlorobenzidine is sparingly soluble, does not volatilize or hydrolyze, and may slowly oxidize 
in solution (Banerjee et al. 1978; Callahan et al. 1979; Mabey et al. 1982). 3,3’-Dichlorobenzidine 
may be strongly adsorbed to soils, clays, and sediments, depending on the pH of the soil-water system. 
It may be strongly bound by soil organic matter (Boyd et al. 1984; Chung and Boyd 1987; Sikka et al. 
1978). Although earlier research indicates that the compound does not appear to be readily 
biodegradable in soil or waste water sludges, recent work by Nyman (Nyman et al. 1997) indicates 
that more than 80% of 3,3’-dichlorobenzidine may be microbially degraded to benzidine under 
anaerobic conditions. 3,3’-Dichlorobenzidine is bioconcentrated by aquatic organisms under 
experimental conditions (Appleton and Sikka 1980), but it is not certain if it is bioaccumulated or 
transferred through the natural food chain. 
5.3.1 Transport and Partitioning 
In the atmosphere, 3,3’-dichlorobenzidine stays attached to dust particles or bound to particulate 
matter.  As such, suspended 3,3’-dichlorobenzidine is subject to atmospheric convection, dispersion, 
gravitational settling, and wash-out by rain. 
The Henry’s law constant for a compound is useful in estimating the partitioning of the compound 
between its vapor phase and aqueous media. At 25 ºC, a value of 5.11x10-11 atm-m3/mole has been 
estimated (SRC 1994). This very low value suggests that 3,3’-dichlorobenzidine essentially remains 
dissolved in water, and does not migrate from water into air. 
3,3’-Dichlorobenzidine in solution has a strong tendency to be adsorbed onto soils and sediments. The 
extent of adsorption of hydrophobic (sparingly water soluble) compounds has been shown to be highly 
correlated with the organic carbon content of the adsorbents (Hassett et al. 1983). When adsorption is 
expressed as a function of organic carbon content, an organic carbon-water partition coefficient (Koc) 
is 
3,3’-DICHLOROBENZIDINE 93 
5. POTENTIAL FOR HUMAN EXPOSURE
 
generated, which is a unique property of the compound and may be used to rank the relative mobility 
of organic contaminants in saturated soil-water systems. A Koc value for 
3,3’-dichlorobenzidine of 1,553 (based on an octanol-water partition coefficient (Kow) of 3,236) was 
calculated by Mabey et al. (1982).  This relatively high value implies that 
3,3’-dichlorobenzidine would exhibit “low” mobility in soil (see Roy and Griffin 1985). However, 
3,3’-dichlorobenzidine is not strictly a hydrophobic compound but can exist as a weak base in water, 
and exists in both neutral and cationic forms. Written as an acid-base reaction, the amine groups may 
be protonated as follows: 
3,3’-DCB +H2O ↔ 3,3’-DCBH+ + OH­
3,3’-DCBH’ + Hz0 ↔ 3,3’-DCBH22+  + OH­
pKa values reported for the conjugate acids (DCBH’ and DCBH,“) vary somewhat. Sikka (Sikka et al. 
1978) and Boyd (Boyd et al. 1984) reported that they are <4. Nyman (Nyman et al. 1997) reported 
pKa,1 and pKa,2 values of 1.6 and 3.2, respectively. Thus, in the pH range of most environmental 
situations (pH 6-8) the dominant state of 3,3’-dichlorobenzidine in water would be the non-ionic form. 
As pH increases, the proportion of cationic forms of 3,3’-dichlorobenzidine decreases, and the extent 
of adsorption to sediments via Coulombic interactions would also decrease and 3,3’-dichlorobenzidine 
adsorption would be dominated by hydrophobic processes. This expectation was demonstrated by 
Sikka and coworkers (Sikka et al. 1978), who found that the adsorption constant (Kf ) decreased with 
increasing pH; the decrease was more rapid in the range of pH 7-9. The adsorption data conformed to 
the Freundlich equation, Ca = KfCs1/n where Ca is the concentration of 3,3’-dichlorobenzidine adsorbed 
per mass of adsorbent, and Cs is the equilibrium concentration of 3,3’-dichlorobenzidine in solution. 
Kf and l/n are empirically derived constants. No correlation was found between Kf and the organic 
carbon content of the sediments (Boyd et al. 1984; Sikka et al. 1978). Similarly, the extent of 
benzidine adsorption does not correlate to the organic carbon content of soils and sediments (Graveel 
et al. 1986; Zierath et al. 1980). It was concluded that nonprotonated 3,3’-dichlorobenzidine is subject 
to hydrophobic bonding to some extent (Boyd et al. 1984). It is clear from these studies that 
adsorption constants for 3,3’-dichlorobenzidine cannot be accurately predicted for a given soil based 
only on a Koc value. 
The adsorption of 3,3’-dichlorobenzidine by soils and sediments may not be readily reversible (Boyd 
et al. 1984; Chung and Boyd 1987; Sikka et al. 1978). The extent of 3,3’-dichlorobenzidine desorption 
decreased with an increase in the age of the sample. Also, the adsorbed 3,3’-dichlorobenzidine was 
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resistant to extraction. After 24 hours of 3,3’-dichlorobenzidine-sediment contact, only 36% of the 
parent compound could be extracted by methanol. It is speculated that 3,3’-dichlorobenzidine forms 
covalent bonds with soil humic components (Sikka et al. 1978; Boyd et al. 1984). Experiments have 
indicated that covalent binding of ring-substituted anilines to humates is not a readily reversible 
reaction (Parris 1980).  3,3’-Dichlorobenzidine was highly immobile in soil column experiments 
(Chung and Boyd 1987). Water was passed through sandy soil (Entic Haplorthod) and 
3,3’-dichlorobenzidine-contaminated sewage sludge samples. Only small amounts of radioactive 
3,3’-dichlorobenzidine added to columns of sandy soil or sewage sludge were eluted with water over 
extended time periods. Extractable radioactivity from these soils and sludge samples decreased with 
time of chemical contact. There was greater adsorption of 3,3’-dichlorobenzidine to soil than to 
sludge, apparently as a result of the greater humus content of the soil samples, which suggested that 
the compound may favor migration from sludge to soil substrates (Chung and Boyd 1987). 
Since 3,3’-dichlorobenzidine is lipophilic, it may be concentrated from aqueous media by aquatic 
organisms. Bluegill sunfish were exposed to radiolabeled 3,3’-dichlorobenzidine in dynamic-flow 
experiments for 130-168 hours (Appleton and Sikka 1980) . Moderately low bioconcentration factors 
(BCF) of 495-507 were calculated for the whole fish. BCFs in fish (golden ide) of 610 and in green 
algae of 940 have been reported (Freitag et al. 1985). A BCF in edible portions of bluegill sunfish of 
114-170 has also been reported (EPA 1980b). Bioaccumulation by plants or terrestrial animals has not 
been studied. Assuming a log Kow (range, 3.02-3.78) (DCMA 1989; Mabey et al. 1982) 
3,3’-dichlorobenzidine is not likely to bioaccumulate appreciably. However, Law states that some 
bioaccumulation in aquatic organisms might be expected (Law 1995). The flesh of freshwater fish 
exposed to 5 ppb or 0.1 ppm concentrations of the chemical in water showed some accumulation. 
After returning the fish to clean water, clearance of the compound was rapid (a half-life of 
approximately 48 hours), but residues remained even after 14 days (Appleton and Sikka 1980). 
5.3.2 Transformation and Degradation 
5.3.2.1 Air 
3,3’-Dichlorobenzidine in the sunlit, ambient air atmosphere may react with photochemically 
produced hydroxyl radicals and ozone, but there are no quantitative data on reaction rates. The 
persistence of “all 
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benzidines” in the atmosphere has been estimated by assuming a hydroxyl radical concentration 
of 8x10-10 mole/L (an average value in a 24-hour day-night cycle) (EPA 1975). Treating the 
oxidation process as a first-order reaction, the rate constant was 7.2x1012/mole-hour and the 
corresponding half-life was 12 hours. This estimation approach was based on data on the rates of 
reaction of hydroxyl radicals with olefins, aromatics, and alkanes in the atmosphere. The 
estimated half-life of 3,3’-dichlorobenzidine in air has ranged from 1 to 60 days (EPA 1980b; 
Shriner et al. 1978). The most recently published value for the degradation half-life in air via 
reaction with OH radicals is 9.7 hours (SRC 1995a). The reason for this disparity among the half-
life estimates is not known. No other information on the fate of 3,3’-dichlorobenzidine in the 
atmosphere was located. 
5.3.2.2 Water 
The limited information that is available suggests that 3,3’-dichlorobenzidine may photolyze in 
water to yield benzidine, which is more photostable yet still toxic. It does not appear that the 
chemical is susceptible to any other transformations in water except protonation by acid-base 
reactions. 
There are no data to suggest that the hydrolysis of 3,3’-dichlorobenzidine is significant (Callahan 
et al. 1979). A hydrolysis rate constant of 0/mole-hour for 3,3’-dichlorobenzidine has been 
proposed (Mabey et al. 1982). 
It has been speculated that aqueous solutions of aromatic amines can be oxidized by organic 
radicals, but there are no actual data on reaction rates. Based on a study of reaction rate data for 
compounds with structures similar to 3,3’-dichlorobenzidine, an estimate of the half-life of 
aromatic amines in water is approximately 100 days, assuming a peroxy radical concentration of 
10-10 mole/L in sunlit, oxygenated water (EPA 1975). Based on the oxidation rates of similar 
compounds, the direct oxidation of 3,3’-dichlorobenzidine by singlet oxygen in solution may be 
treated as a first-order reaction, to arrive at an estimated reaction constant of <4x107/mole-hour 
(Mabey et al. 1982). The oxidation rate constant with peroxy radicals was estimated to be 
approximately 4x107/mole-hour. However, no information was located that demonstrates that 
3,3’-dichlorobenzidine is significantly oxidized in water. 
3,3’-Dichlorobenzidine was found to be extremely photolabile in water (Sikka et al. 1978; 
Banerjee et al. 1978). 3,3’-Dichlorobenzidine photolyzed yielding monochlorobenzidine, 
benzidine, and a number of 
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colored, water-insoluble products. In natural sunlight, the half-life of 3,3’-dichlorobenzidine in 
water was determined to be approximately 90 seconds. While 3,3’-dichlorobenzidine is very 
rapidly photolyzed under environmental conditions, the process may yield benzidine, a relatively 
photostable carcinogen (Banerjee et al. 1978). 
3,3’-Dichlorobenzidine in lake water samples was not metabolized by microorganisms over a 
4-week period (Sikka et al. 1978) although 1 lake sample of the 2 tested contained approximately 
5 million microorganisms per mL. The composition of the biological community was not 
described. Minor decreases in 3,3’-dichlorobenzidine concentrations were attributed to adsorption 
onto suspended sediment. 
5.3.2.3 Sediment and Soil 
Earlier reports gave little indication that 3,3’-dichlorobenzidine is significantly degraded in soil or 
that it is transformed to other substances. More recent research (Nyman et al. 1997) reports that 
sediment/water mixtures spiked with 3,3’-dichlorobenzidine display evidence of the chemical’s 
degradation. In the experiments reported by these authors, silty-clay to sandy sediments collected 
from a lake near Holland, Michigan, were spiked with 3,3’-dichlorobenzidine and incubated at 20 
°C for 12 months under anaerobic conditions. Time-course analysis of this mixture showed that 
dehalogenation of 3,3’-dichlorobenzidine to produce benzidine appears to take place through a 
transient intermediate, 3-monochlorobenzidine. Up to 80% of the 3,3’-dichlorobenzidine was 
transformed to benzidine over a l-year incubation period. No metabolites were observed in 
autoclaved samples, suggesting that dehalogenation is mediated by microbial activity. The final 
product, benzidine, shows more affinity for the solution (aqueous) phase and thus has a 
greater potential for transport in the environment. 
Unsubstituted benzidine may be oxidized at clay surfaces when mixed with some types of clay 
minerals (Tennakoon et al. 1974; Theng 197 1). Benzidine is oxidized to a monovalent radical 
cation by iron (III) in the silicate lattice and by aluminum at crystal edges. However, there is no 
experimental evidence that demonstrates that 3,3’-dichlorobenzidine is subject to the same type 
of surface oxidation at solid-liquid interfaces. 
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Activated sludge did not degrade 3,3’-dichlorobenzidine after weekly subculturing. The sludge 
was not described or chemically characterized. Observed decreases in 3,3’-dichlorobenzidine 
concentration were attributed to adsorption by the sludge. 
The results of seven laboratories conducting aerobic biodegradation experiments with 
3,3’-dichlorobenzidine have been summarized (Brown and Laboureur 1983). There was a clear 
dependence of the extent of degradation on the concentration of yeast extract added to the batch 
containers. The role of the extract was uncertain, but without it, no degradation was detected. The 
authors hypothesize that the yeast may be a food source to allow buildup of large concentrations 
of active bacteria that are able to break down the amines. The authors felt that these results 
showed the “inherent biodegradability” of 3,3’-dichlorobenzidine, but that the compound should 
not be classified as “readily biodegradable” (Brown and Laboureur 1983). Possible degradation 
mechanisms and degradation by-products were not discussed. 
3,3’-Dichlorobenzidine degraded very little when incubated with soil. In a study by Boyd et al. 
(1984), a Brookston clay loam soil (a typic Argiaquoll fine loamy, mixed mesic) containing 
[14C]-3,3’-dichlorobenzidine at concentrations of 40 and 4 mg/kg of dry soil was incubated 
aerobically and anaerobically in batch experiments (Boyd et al. 1984). Under aerobic conditions, 
3,3’-dichlorobenzidine degradation occurred at a very slow rate; accumulative 14CO2 production 
was approximately 2% after 32 weeks. Under anaerobic conditions, no gas evolution was 
detected after 1 year of incubation. The authors did not comment on the population or type of 
microorganisms in the soil sample (Boyd et al. 1984). Additional studies indicated that 3,3’­
dichlorobenzidine was very persistent in soil and sludge-amended soil (Chung and Boyd 1987). 
Biodegradation of [14C]-3,3’-dichlorobenzidine was evaluated during a 182-day incubation period 
in a sandy soil (Entic Haplorthod) amended with sewage sludge. The total amount of 
[14C]-3,3’-dichlorobenzidine recovered as 14CO2 was <2%. It should be noted that biodegradation 
when measured by 14CO2 evolution may provide a conservative estimate of the extent of 
decomposition. This technique does not account for carbon that is incorporated into the biomass 
or into soil organic matter, or for the compound being only partially metabolized (Graveel et al. 
1986). The disparity between the results of this work and the results of Nyman (Nyman et al. 
1997) is probably related to the nature of their respective biotic communities. 
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5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Reliable evaluation of the potential for human exposure to 3,3’-dichlorobenzidine depends in part 
on the reliability of supporting analytical data from environmental samples and biological 
specimens. In reviewing data on 3,3’-dichlorobenzidine levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not 
necessarily equivalent to the amount that is bioavailable. The analytical methods available for 
detection and measurement of 3,3’-dichlorobenzidine are detailed in Chapter 6. 
3,3’-Dichlorobenzidine was not detected in the ambient air at production facilities at detection 
limits of 0.1-5.0 ng/m3 (Narang et al. 1982; Riggin et al. 1983). The median concentration of 
3,3’-dichlorobenzidine in waste effluents (<10 ppb), groundwater (<10 ppb), surface water (<10 
ppb), and soils (<1 ppb) is very low, although significant contamination may be associated with 
hazardous waste sites (Staples et al. 1985). Moreover, the production and use of 
3,3’-dichlorobenzidine-based dyes has decreased to zero over the last 30 years, while 
environmental and health regulations have been implemented to reduce the release of 
3,3’-dichlorobenzidine to the environment. 
5.4.1 Air 
3,3’-Dichlorobenzidine does not naturally occur in the environment (IARC 1982a). 
3,3’-Dichlorobenzidine was not detected in ambient air of two dyestuff production plants at 
detection limits of 5 (Narang et al. 1982) and 0.1 ng/m3 (Riggin et al. 1983). More recent data on 
occupational exposure levels indicate the presence of levels ≤0.6-2.5 µg/m3 in 
3,3’-dichlorobenzidine production and pigment manufacturing plants in Germany (DCMA 1989). 
The concentration of 3,3’-dichlorobenzidine in the Canadian environment was estimated by 
Liteplo and Meek (1994) by applying the Level III Fugacity Computer Model of Mackay and 
Paterson (Mackay and Paterson 1991). Assuming that 1% of the total amount produced in and 
imported to Canada is released into various media in proportions similar to those given in the 
U.S. TRI, the average concentration of 3,3’-dichlorobenzidine in air, as estimated by the model, is 
7.6x10-16 µg/m3. 
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5.4.2 Water 
EPA’s computerized water quality database (STORET) was used to determine the median 
concentration of 3,3’-dichlorobenzidine in surface water, groundwater, and municipal and 
industrial inflow and outflow (Staples et al. 1985). The median concentration of 
3,3’-dichlorobenzidine detected in 12 of 1,239 samples of waste effluent collected from about 
1980 to 1984, was reported to be <10 ppb. The median concentration of 3,3’-dichlorobenzidine in 
both surface and groundwater was also reported to be <10 ppb.  The EPA reported that water 
samples collected from drinking-water wells near a waste disposal lagoon that contained 
3,3’-dichlorobenzidine-manufacturing wastes had concentrations of the chemical ranging from 
0.13 to 0.27 ppm (EPA 1980b). EPA indicated that 3,3’-dichlorobenzidine concentrations in 
waste waters from metal finishing operations were 0.07 ppb or less (EPA 1983c). Discharge 
concentrations from other industrial sources were at most 10 ppb. Using a Fugacity Computer 
Model, Liteplo and Meek estimated the concentration of 3,3’-dichlorobenzidine in Canadian 
water to be 3.4x10-7 ng/L (Liteplo and Meek 1994). Because the model does not address the 
possibility of bound residue in sediment, the concentration in water is certainly overestimated. 
Capillary gas chromatography/mass spectrometry (GC/MS) was used to identify, but not 
quantify, 3,3’-dichlorobenzidine in the dissolved phase (that is, smaller particles and dispersed 
colloids not retained by the filter) of water concentrates from the Besos River in Spain (Grifoll et 
al. 1992). Valls et al. identified 3,3’-dichlorobenzidine in urban wastewater in the same region 
(Valls et al. 1990). 
5.4.3 Sediment and Soil 
The estimated median concentration of 3,3’-dichlorobenzidine in sediments in the United States 
has been reported to be <l ppm on a dry sediment basis (Staples et al. 1985). Of the 34 sediment 
or soil measurements recorded in the STORET database, none of the samples contained 
detectable concentrations of 3,3’-dichlorobenzidine. 
5.4.4 Other Environmental Media 
There is a potential for 3,3’-dichlorobenzidine to occur in waste water sludges and industrial solid 
wastes. A 3,3’-dichlorobenzidine concentration of 16 ppm in municipal sludge from Michigan 
has been reported 
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(Chung and Boyd 1987). 3,3’-Dichlorobenzidine was detected at concentrations of 3.13 mg/kg 
dry sewage sludge in 2 of a total of 253 sewage treatment plants examined (Fricke et al. 1985). 
These plants were all in the United States (Arizona, Indiana, Michigan, Missouri, New Mexico, 
New York, and Texas). Concentrations up to 535 µg/L were detected in a communal sewage 
treatment plant (Lopez-Avila et al. 1981). The chemical was detected at 8.55 mg/kg in sewage 
sludge of an aeration basin in Muskegon, Michigan (Demirjian et al. 1984). 
Because the chemical has no agricultural or food chemical application, it is very unlikely that 
3,3’-dichlorobenzidine occurs in food in general. [14C]-3,3’-Dichlorobenzidine was found to 
rapidly accumulate in bluegill sunfish as a result of their exposure to water in which either 5 or 
100 µg/L of the chemical was intentionally added. Residues were distributed in both the edible 
and nonedible portions (Appleton and Sikka 1980). However, 3,3’-dichlorobenzidine was not 
detected in fish samples obtained from rivers near nine textile dyestuff manufacturers known to 
use 3,3’-dichlorobenzidine-based pigments (Diachenko 1979). 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Years ago, benzidine and its congeners such as 3,3’-dichlorobenzidine were likely to be found 
only in the vicinity of pigment plants (EPA 1980b; Shriner et al. 1978) where wastes may escape 
or be discharged. 3,3’-Dichlorobenzidine may also be found in locations where it is used in 
formulating other products such as rubber and plastic (HSDB 1996) or in producing 
polybenzimidazole (PBI) (Celanese 1985). However, 3,3’-dichlorobenzidine is no longer used to 
manufacture soluble dyes in the United States (CPMA 1998).  Based on available data, the 
potential for nonindustrial exposure via air, soil, or water is expected to be negligible. The 
greatest chance of exposure by the general public is from the improper land disposal of 
compounds. The significance of this exposure route can only be evaluated on a site-by-site basis. 
No uses of 3,3’-dichlorobenzidine in commonplace consumer products are known. In the past, the 
general public may have been exposed to minute amounts of 3,3’-dichlorobenzidine during the 
use of pressurized spray containers of paints, lacquers, and enamels containing traces of 
benzidine yellow, a pigment derived from 3,3’-dichlorobenzidine (Shriner et al. 1978). 
3,3’-Dichlorobenzidine-based pigments are normally used in printing ink applications; their use 
in paints is rare and, thus, its presence in present-day pressurized paint spray would not be 
expected (CPMA 1998). 
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Today the most likely possibilities for occupational exposure exist in the processing of 
3,3’-dichlorobenzidine in the synthesis of pigments, the compounding of PBI, and for workers in the 
garment, leather, printing, paper, and homecraft industries where benzidine-based pigments are used. 
However, there appears to be no information available on current levels of occupational exposure in 
the United States.  Since 1974, OSHA regulations have set strict standards for worker protection, 
required the use of closed manufacturing vessels, and prescribed methods to chemically destroy 
residues. Although there is limited evidence for in vivo cleavage of 3,3’-dichlorobenzidine-derived 
pigments to free 3,3’-dichlorobenzidine in animals, urinary tract data from pigment workers suggest 
that 3,3’-dichlorobenzidine-derived pigments are not significantly metabolized in humans. Less than 
0.2 ppb of 3,3’-dichlorobenzidine was detected in urine samples of 36 workers exposed to pigments 
derived from the compound (Hatfield et al. 1982). 
In Canada, the estimated daily intake of 3,3’-dichlorobenzidine by various segments of the population 
has been calculated. The calculations are based on the predicted levels of 3,3’-dichlorobenzidine in 
air, water, and soil, as well as on the estimated daily intake of each (air, water, soil) by Canadians 
(Government of Canada 1993). The predicted concentrations or human intake levels are not measured 
values but rather predicted values based on output from mathematical models using worst-case 
assumptions that do not take into consideration removal mechanisms such as photolysis, oxidation, or 
irreversible binding to substrates.  The total intake by adults (20 or more years of age) is predicted to 
be 7.4x10-9 ng/kg body weight/day. For infants up to 6 months of age (the group with the greatest 
predicted exposure on the basis of body weight), the total intake is estimated at 3.6x10-8 ng/kg body 
weight/day. 
5.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans and briefly 
considers potential pre-conception exposure to germ cells. Differences from adults in susceptibility to 
hazardous substances are discussed in Section 2.6, Children’s Susceptibility. 
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many  ways. 
Children drink more fluids, eat more food, and breathe more air per kilogram of body weight, and 
have a larger skin surface in proportion to their body volume. A child’s diet often differs from that of 
adults. The developing human’s source of nutrition changes with age: from placental nourishment to 
breast milk or formula to the diet of older children who eat more of certain types of foods than adults. 
A child’s behavior 
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and lifestyle also influence exposure. Children crawl on the floor; they put things in their mouths; they 
may ingest inappropriate things such as dirt or paint chips; they spend more time outdoors. Children 
also are closer to the ground, and they do not have the judgment of adults in avoiding hazards 
(NRC 1993). 
No specific references on exposures of infants or children to 3,3’-dichlorobenzidine were located. 
Young children may be exposed to 3,3’-dichlorobenzidine by ingesting paint chip debris, colorful 
objects or paints, and soil if the material contains the chemical. Mathematical models (using 
somewhat unrealistic worstcase assumptions) predict that the estimated total intake of 
3,3’-dichlorobenzidine by infants up to 6 months of age would be 3.6x10-8 ng/kg bodyweight/day, 
about 5 times greater than the estimate of 7.4x 10-9 ng/kg body weight/day for adults age 20 or older 
(Government of Canada 1993). 
Children sometimes put dirt in their mouths. Because the adsorption of 3,3’-dichlorobenzidine to soils 
and sediments may not be readily reversible (Boyd et al. 1984; Chung and Boyd 1987; Sikka et al. 
1978), the bioavailability of the compound is limited. A child who ingested contaminated dirt would 
be expected to incur less exposure as compared to that from other, more direct routes. 
Another potential exposure route for children is through exposure to clothing and tracked-in dirt 
brought in by parents who work in factories that produce 3,3’-dichlorobenzidine. A public health 
assessment study conducted in Michigan in 1981 (ATSDR 1996) found the compound in the homes of 
9 employees.  Samples collected from vacuum cleaner bags had up to 10.5 ppm and dryer lint 
contained up to 0.74 ppm. If these homes have not been adequately cleaned, exposure could continue. 
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
In addition to individuals who are occupationally exposed to 3,3’-dichlorobenzidine (see Section 5.5) 
there are several groups within the general population that have the potential for exposures to 
3,3’-dichlorobenzidine at levels above those of the general population. These groups include 
individuals living in proximity to sites where 3,3’-dichlorobenzidine was produced or sites where 
3,3’-dichlorobenzidine was disposed, and individuals living near one of the 32 NPL hazardous waste 
sites where 3,3’-dichlorobenzidine has been detected in some environmental media (HazDat 1998). 
3,3’-Dichlorobenzidine was not detected in fish samples obtained from rivers near nine textile 
dyestuff manufacturers known to use 3,3’-dichloro­
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benzidine-based pigments (Diachenko 1979), nor were there any fish consumption advisories for 
3,3’-dichlorobenzidine in 1996. Therefore, recreational and subsistence fishers are not at risk. 
NIOSH, in 1980, concluded that during the use of benzidine-based dyes, the greatest potential for 
exposurewould be expected to be by dermal absorption or inhalation by personnel who routinely 
handle dry powders (NIOSH 1980). However, EPA (1980b) has generalized that dermal 
absorption in the workplace is probably a minor route of 3,3’-dichlorobenzidine exposure, 
although dermatitis has occurred in workers in plants where 3,3’-dichlorobenzidine and 
3,3’-dichlorobenzidine-based pigments were manufactured. It may be that health risks with 
regard to 3,3’-dichlorobenzidine exposure depend on the specific operations of the individual 
plant and the extent of personal protective practices of the individual operator. 
5.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation 
with the Administrator of EPA and agencies and programs of the Public Health Service) to assess 
whether adequate information on the health effects of 3,3’-dichlorobenzidine is available. Where 
adequate information is not available, ATSDR, in conjunction with the NTP, is required to assure 
the initiation of a program of research designed to determine the health effects (and techniques 
for developing methods to determine such health effects) of 3,3’-dichlorobenzidine. 
The following categories of possible data needs have been identified by a joint team of scientists 
from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that, if 
met, would reduce the uncertainties of human health assessment. This definition should not be 
interpreted to mean that all data needs discussed in this section must be filled. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda 
will be proposed. 
5.8.1 Identification of Data Needs 
Physical and Chemical Properties.  It has been demonstrated that 3,3’-dichlorobenzidine is 
strongly adsorbed by soils and sediments, and that it may not readily desorb. Adsorption cannot 
be accurately predicted a priori; such data are soil-system specific and must be determined 
experimentally for each 
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system under study. Because there is some discrepancy regarding the volatility of the free base form 
of 3,3’-dichlorobenzidine (Gerarde and Gerarde 1974; CPMA 1998) research in this area is indicated. 
Production, Import/Export, Use, Release, and Disposal. According to the Toxics Release 
Inventory (TRI) report (TR196 1998), 3,3’-dichlorobenzidine is manufactured at one facility in 
Michigan. Three of the five facilities listed by TR196 that process the compound depend on imports 
for their supply.  The chemical is no longer used to produce dyes in the United States (better dyes 
based on other chemicals are available); its main use is in the production of pigments (DCMA 1989). 
It also finds some use in the formulation of rubber and plastic (HSDB 1996) and in the production of 
PBI (Celanese 1985). The compound is not used in the home or in the open environment; however, 
there is evidence that the compound can be brought into the home on the shoes and clothing of adults 
who work with 3,3’-dichlorobenzidine (ATSDR 1996) but the quantity that might be present is 
unknown. In the workplace, OSHA regulations require that the compound be handled in closed 
systems and that shipping containers be cleaned thoroughly (again, within a closed system) before 
disposal (DCMA 1989). The free base or salt form of the compound is not used in the home or in the 
general environment. It is handled only by industry to make pigments; thus there seems to be little 
chance the chemical could contaminate the food supply. No evidence of the compound in fish taken 
downstream from nine facilities known to handle 3,3’-dichlorobenzidine was found (Diachenko 
1979). Citations regarding disposal techniques for 3,3’-dichlorobenzidine are found in the Hazardous 
Substances Data Base (HSDB). Small quantities can be destroyed by chemical reaction, for example, 
with sodium hypochlorite solution, which converts 3,3’-dichlorobenzidine to a quinone-type 
compound. Incineration at high temperatures can be used to destroy work garments and miscellaneous 
solid wastes exposed to the compound. Presumably only small amounts would need to be disposed 
since the compound is mainly consumed by conversion to pigments. 
According to the Emergency Planning and Community Right-to-Know Act of 1986,42 U.S.C. Section 
11023, industries are required to submit chemical release and off-site transfer information to the EPA. 
The TRI, which contains this information for 1996, became available in May of 1998. This database 
will be updated yearly and should provide a list of industrial production facilities and emissions. 
Environmental Fate.  It is not known if 3,3’-dichlorobenzidine, like benzidine, is oxidized by clay 
minerals or if cations in water can have the same oxidizing effect. 3,3’-Dichlorobenzidine does not 
appear to biodegrade easily, but the few studies in this area did not state the type(s) or concentrations 
of 
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microorganisms used in each study. More systematic studies with other organisms may prove useful. 
A recent study (Nyman et al. 1997) provides evidence that in the span of a year up to 80% of 
3,3’-dichlorobenzidine can degrade to benzidine in anaerobic mixtures of sediment/water. Further 
research to identify the pathways and products of decomposition of 3,3’-dichlorobenzidine in various 
soils is needed. The toxicological profile for benzidine contains information on the environmental fate 
of that compound (ATSDR 1995). 
Bioavailability from Environmental Media. No information on the presence of 
3,3’-dichlorobenzidine in foods was located in the available literature. The Canadian Government’s 
Priority Substances List Assessment Report for 3,3’-dichlorobenzidine (Government of Canada 1993) 
also reports that no data on the levels of 3,3’-dichlorobenzidine in drinking water or foodstuffs were 
identified within either Canada or the United States. Because 3,3’-dichlorobenzidine has been found to 
bind strongly to soil constituents (Berry and Boyd 1985; Chung and Boyd 1987), Law (1995) 
concluded that it would also bind strongly to sedimentary material in the marine aquatic environment 
and thus may have limited bioavailability. 
Food Chain Bioaccumulation. 3,3’-Dichlorobenzidine is bioconcentrated by aquatic organisms under 
experimental conditions. Whole-fish BCFs of around 500, with equilibration occurring in 96-168 
hours, have been published (Appleton and Sikka 1980). In view of the n-octanoywater partition 
coefficient for 3,3’-dichlorobenzidine, limited bioaccumulation could be expected (Law 1995) 
because the retention time of the chemical in exposed fish is short (Appleton and Sikka 1980). The 
ability of aquatic organisms to concentrate the compound could present a human health hazard if 
contaminated fish were eaten. However, 3,3’-dichlorobenzidine was not found in fish taken from 
waters in the vicinity of dye or textile manufacturing plants on the Buffalo and Delaware rivers in the 
United States (Diachenko 1979). It was concluded that monitoring for 3,3’-dichlorobenzidine in 
marine waters of the United Kingdom is unwarranted at present (Law 1995). 
Exposure Levels in Environmental Media. There were no quantitative data on current 
atmospheric levels of 3,3’-dichlorobenzidine emissions or on the chemical’s potential to act as a 
surface contaminant of soil environments. It is difficult to determine 3,3’-dichlorobenzidine levels in 
the aquatic environment because the concentrations tend to be at or below analytical detection limits. 
In general, it may only be possible to ascertain fully the environmental fate of 3,3’-dichlorobenzidine 
as analytical advances permit the routine determination of very low concentrations. Moreover, 
determination of the nature and environmental fate of breakdown products of 3,3’-dichlorobenzidine 
would be useful. 
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Reliable monitoring data for the levels of 3,3’-dichlorobenzidine in contaminated media at hazardous 
waste sites are needed so that the information obtained on levels of 3,3’-dichlorobenzidine in the 
environment can be used in combination with the known body burdens of 3,3’-dichlorobenzidine to 
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous 
waste sites. 
Exposure Levels in Humans.  It has been speculated that the 1974 OSHA regulations have reduced 
workplace air levels of 3,3’-dichlorobenzidine (CPMA 1998). However, it would be important to 
conduct exposure studies to monitor air levels in the workplace to confirm this premise. The need for 
more information on the extent of air, water, and soil contamination by industrial plant emissions or 
waste sites containing 3,3’-dichlorobenzidine continues. There is little information on exposure of 
children to 3,3’-dichlorobenzidine (or products derived from the compound). The compound has a 
very limited distribution and is not present in consumer goods (other than in insoluble pigmented 
forms). This information is necessary for assessing the need to conduct health studies on these 
populations. 
Exposures of Children.  There is no available information on exposure of children to 
3,3’-dichlorobenzidine (or products derived from the compound). The compound has a very limited 
distribution and is not present in consumer goods (other than in insoluble pigmented forms). Thus, 
there is no pressing need to gather data related to children’s exposure. However, given sufficient 
resources, the topic of inadvertent take-home exposure by occupationally exposed parents could be 
explored. A public health assessment (ATSDR 1996) found measurable levels of 
3,3’-dichlorobenzidine (10.5 ppm in vacuum cleaner bags and 0.74 ppm in clothes dryer lint) in the 
homes of workers who were employed in manufacturing or processing the compound. 
Exposure Registries. No exposure registries for 3,3’-dichlorobenzidine were located. This substance is 
not currently one of the compounds for which a subregistry has been established in the National 
Exposure Registry. The substance will be considered in the future when chemical selection is made 
for subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related 
to exposure to this substance. 
5.8.2 Ongoing Studies
 





The purpose of this chapter is to describe the analytical methods that are available for detecting, 
and/or measuring, and/or monitoring 3,3’-dichlorobenzidine, its metabolites, and other 
biomarkers of exposure and effect to 3,3’-dichlorobenzidine. The intent is not to provide an 
exhaustive list of analytical methods.  Rather, the intention is to identify well-established methods 
that are used as the standard methods of analysis. Many of the analytical methods used for 
environmental samples are the methods approved by federal agencies and organizations such as 
EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods 
presented in this chapter are those that are approved by groups such as the Association of Official 
Analytical Chemists (AOAC) and the American Public Health Association (APHA). 
Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits, and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
Methods for the determination of 3,3’-dichlorobenzidine and its metabolites in biological 
materials are summarized in Table 6- 1. 
The compound 3,3’-dichlorobenzidine has been measured most often in urine and serum using 
gas chromatography (GC) (Bowman and Nony 1981; Bowman and Rushing 1981; Hoffman and 
Schmidt 1993; Joppich-Kuhn et al. 1997; Nony and Bowman 1980; Nony et al. 1980) and high 
performance liquid chromatography (HPLC) (Birner et al. 1990; Bowman and Nony 1981; 
CPMA 1998; Nony and Bowman 1980; Nony et al. 1980; Zwirner-Baier and Neumann 1994). A 
method for 3,3’-dichlorobenzidine in fish using GC (Diachenko 1979) has been reported. GC 
methods usually relied upon selective detection of the fluorinated derivatives while HPLC 
methods relied on absorbence or electrochemical detection. In addition, one method of analysis in 
urine used a spectrophotometric approach (Roberts and Rossano 1982). Several of the reported 
methods can also be used to determine the mono- and di-acetylated metabolites. The studies of 
Birner et al. (1990), Joppich-Kuhn et al. 1997, and Zwirner-Baier and Neumann (1994) reported 
the determination of 3,3’-dichlorobenzidine and monoacetyl-3,3’-dichlorobenzidine following 
hydrolysis of the analyte-hemoglobin adducts (the adduct is a marker of exposure). Although 
most of these methods have been developed using animal samples, they should also be applicable 
to the determination of 3,3’-dichlorobenzidine and its metabolites in samples of human origin. 






have been reported, although the hemoglobin adduct method of Joppich-Kuhn et al. (1997) reported a 
limit of detection of less than 0.1 ng/g (ppb). These sensitive methods are potentially useful for the 
assessment of human exposure to 3,3’-dichlorobenzidine. 
6.2 ENVIRONMENTAL SAMPLES 
Methods for the determination of 3,3’-dichlorobenzidine in environmental samples are  summarized in 
Table 6-2. 
The determination of 3,3’-dichlorobenzidine in environmental samples is most commonly achieved by 
GC/mass spectrometry (GC/MS) (Diachenko 1979; EPA 1982b, 1986a, 1984a; Greenberg et al. 1992) 
and HPLC (Armentrout and Cutie 1980; EPA 1982a; Morales et al. 1981; NIOSH 1994; Riggin and 
Howard 1979). Sample preparation typically employs liquid-liquid or liquid-solid extractions for 
water, waste water, soils, sediments, and solid waste. Supercritical fluid extraction has also been 
shown to provide good recovery of 3,3’-dichlorobenzidine from a spiked, dried soil (Oostdyke et al. 
1995). Lopez-Avila et al. (1996) demonstrated that microwave-assisted extraction using a hexane-
acetone solvent system gave recoveries from spiked (5 mg/kg), standard soil of 96%. The same 
solvent system in Soxhlet extraction resulted in only 47% recovery. 
Solid phase extraction followed by capillary zone electrophoresis with UV absorbence detection has 
been shown to be applicable to the isolation and determination of 3,3’-dichlorobenzidine in water at 
ppm levels (Cavallaro et al. 1995). 
For the HPLC determination of 3,3’-dichlorobenzidine in water, a relatively complicated 
procedure may be used (EPA 1982a) in which the analyte is extracted into chloroform, back-
extracted with acid, neutralized, and extracted with chloroform. The chloroform is exchanged to 
methanol and concentrated using a rotary evaporator and nitrogen blowdown, then brought to a 5 
mL volume with an acetate buffer. HPLC with electrochemical detection is used, providing for a 
method detection limit of 0.13 µg/L; single operator accuracy and precision for 30 analytes of 5 
different types of water samples over a spike range of l-5 µg/L gave an average recovery of 65% 
and a standard deviation of 9.6% (EPA 1982a). The more complicated the matrix, the more 
extensive the sample preparation methods generally need to be. In certain circumstances (i.e., 






analysis step without prior treatment (Armentrout and Cutie 1980). GC separation methods can be 
applied also to the extracts obtained for HPLC analyses. Detection of the free amine, in addition 
to fluorinated derivatives, has been demonstrated by GC methods. 
Dichlorobenzidine and its salts are collected from air matrices using adsorption/filtration 
approaches (Morales et al. 1981; NIOSH 1994) and recovered from the adsorbent using methanol 
containing a small amount of triethylamine (TEA). The addition of TEA converts any salt to the 
corresponding amine, thus rendering it soluble in the organic solvent. Limits of detection in the 
low µg/m3 (low to sub-ppb) range have been reported. The compound 4,4’-methylenebis(2­
chloroaniline) was reported to interfere with 3,3’-dichlorobenzidine (Morales et al. 1981; NIOSH 
1994). 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation 
with theAdministrator of EPA and agencies and programs of the Public Health Service) to assess 
whether adequate information on the health effects of 3,3’-dichlorobenzidine is available. Where 
adequate information is not available, ATSDR, in conjunction with the NTP, is required to assure 
the initiation of a program of research designed to determine the health effects (and techniques 
for developing methods to determine such health effects) of 3,3’-dichlorobenzidine. 
The following categories of possible data needs have been identified by a joint team of scientists 
from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if 
met would reduce the uncertainties of human health assessment. This definition should not be 
interpreted to mean that all data needs discussed in this section must be filled. In the future, the 
identified data needs will be evaluated and prioritized, and a substance-specific research agenda 
will be proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. Methods for the determination 
of 3,3’-dichlorobenzidine in urine and serum have been reported (Birner et al. 1990; Bowman and 
Nony 1981; Bowman and Rushing 1981; Hoffman and Schmidt 1993; CPMA 1998; Nony and 
Bowman 1980; Nony et al. 1980; Zwirner-Baier and Neumann 1994). Some of the methods have 




suitable for the determination of the acetylated metabolites (Bowman and Nony 198 1; Nony and 
Bowman 1980; Nony et al. 1980). The methods of Birner et al. (1990), Joppich-Kuhn et al. 
(1997), and Zwirner-Baier and Neumann (1994) permit the analysis of hemoglobin adducts of 
3,3’-dichlorobenzidine and its monoacetyl metabolite. Limits of detection for 
3,3’-dichlorobenzidine in urine and serum were reported to be as low as 1 to 5 ppb (Bowman and 
Rushing 1981; Hoffman and Schmidt 1993; Roberts and Rossano 1982), with detectable 
concentrations of the acetylated metabolites somewhat higher. Most of these studies were 
performed with samples from rats; the methods should be tested to determine if they are 
applicable to samples of human origin. In addition, the levels of these biomarkers associated with 
exposures to 3,3’-dichlorobenzidine of toxicological concern should be defined in order to 
increase their utility. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods have been described for the determination of 3,3’-dichlorobenzidine in air, with 
reported limits of detection of 0.5 µg/m3 (NIOSH 1994) and 3 µg/m3 (Morales et al. 1981). 
Methods for the analysis of 3,3’-dichlorobenzidine in water and waste water have also been 
described, with reported detection limits of 16.5 µg/L (ppb) (EPA 1982b; Greenberg et al. 1992), 
50 µg/L (ppb) (EPA 1984a), 3 ppb (Armentrout and Cutie 1980), 0.13 µg/L (ppb) (EPA 1982a), 
and 50 to 100 ng/L (ppt) (Riggin and Howard 1979). The only method found for 
3,3’-dichlorobenzidine in food (fish) reported a limit of detection of less than 20 ppb (Diachenko 
1979). It does not appear that additional methods for the determination of 3,3’-dichlorobenzidine 
in air or water are needed. Additional methods for 3,3’-dichlorobenzidine in foods are needed. If 
MRLs were established, the needs could be defined more precisely. 
6.3.2 Ongoing Studies 
No ongoing studies in which new methods for the determination of 3,3’-dichlorobenzidine are 
being developed were found in a search of the Federal Research in Progress database 
(FEDRIP 1998). 
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The national and state regulations and guidelines pertaining to 3,3’-dichlorobenzidine in air, 
water, and other media are summarized in Table 7- 1. 
There is no oral reference dose (RfD) for 3,3’-dichlorobenzidine. The health effects data for 
3,3’-dichlorobenzidine were reviewed by the EPA RfD/RfC Work Group and determined to be 
inadequate for derivation of an inhalation RfC (IRIS 1998). 
The EPA has determined that 3,3’-dichlorobenzidine is a probable human carcinogen, B2 
classification (IRIS 1998). The International Agency for Research on Cancer (IARC) has 
classified 3,3’-dichlorobenzidine as a Group 2B carcinogen-possibly carcinogenic to humans 
(IARC 1987). The American Conference of Governmental Industrial Hygienists (ACGIH) 
classifies 3,3’-dichlorobenzidine as A3, which indicates that the chemical is carcinogenic in 
experimental animals when administered at a relatively high dose (ACGIH 1997). The National 
Toxicology Program (NTP) of the U.S. Department of Health and Human Services has 
determined that 3,3’-dichlorobenzidine and its salt may reasonably be expected to be 
cancer-causing agents (NTP 1998). 
3,3’-Dichlorobenzidine is on the list of chemicals subject to the requirements of the Emergency 
Planning and Community Right-to-Know Act of 1986 (EPCRA) (EPA 1988a). Section 3 13 of 
Title III of EPCRA requires owners and operators of certain facilities that manufacture, import, 
process, or otherwise use the chemicals on this list to report annually their release of those 
chemicals to any environmental media (U.S. Congress 1986). 
3,3’-Dichlorobenzidine is one of a number of carcinogenic compounds regulated by OSHA. To 
control exposures to 3,3’-dichlorobenzidine in workplace air and to protect the health of workers, 
OSHA’s regulatory standards provide strict guidelines for manufacturing, processing, 
repackaging, handling, using, and storing the compound (OSHA 1996). These standards also 
include the requirements for personal protective equipment, training, labeling, posting, and 
engineering controls. In addition to engineering controls such as continuous local exhaust 
ventilation and workplace practices such as full body protective clothing, the employer must 
maintain medical surveillance records (OSHA 1996). OSHA requires that initial medical 
screening and regular medical examinations be made available to any employee who is 
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exposed to 3,3’-dichlorobenzidine at potentially hazardous levels. The employer must also 
provide a training program that informs its employees of the carcinogenic hazards of 
3,3’-dichlorobenzidine, the nature of the operation involving the chemical that could result in 
exposure, decontamination procedures,and specific emergency procedures to be used if exposure 
does occur (OSHA 1996). OSHA also regulates 3,3’-dichlorobenzidine under the Hazard 
Communication Standard (HCS) and as a chemical hazard in laboratories (NTP 1998). The HCS 
has established uniform requirements to make sure that the hazards of all chemicals imported 
into, produced, or used in workplaces are evaluated and that information on the hazards they pose 
is transmitted to affected employers and exposed employees (OSHA 1998). 
EPA regulates 3,3’-dichlorobenzidine under the Clean Air Act (CAA) and has designated 
3,3’-dichlorobenzidine as a hazardous air pollutant (HAP) (EPA 1994; U.S. Congress 1990). The 
major source category for which the national emissions standards for new stationary sources are 
applicable to 3,3’-dichlorobenzidine emissions is the synthetic organic chemicals manufacturing 
industry (SOCMI)-equipment leaks (EPA 1994). 
3,3’-Dichlorobenzidine is regulated by the Clean Water Effluent Guidelines in Subchapter N of 
Title 40 of the Code of Federal Regulations. Electroplating is the point source category for which 
3,3’-dichlorobenzidine is controlled as a total toxic organic (EPA 1981). The point source 
categories for which 3,3’-dichlorobenzidine has a specific regulatory limitation are steam electric 
power generation (EPA 1982) and metal finishing (EPA 1983a). The EPA has proposed a 
reportable quantity of 10 pounds for 3,3’-dichlorobenzidine for its water quality criteria for the 
protection of human health (IRIS 1998). 
The Resource Conservation and Recovery Act (RCRA) identifies 3,3’-dichlorobenzidine as the 
hazardous constituent in various hazardous wastes. It is the regulated constituent in hazardous 
wastes assigned the waste code U073 (EPA 1988b). 
Under the Comprehensive Environmental Response, Compensation, and Liability Act 
(CERCLA), owners of vessels or facilities are required to immediately report releases of 
3,3’-dichlorobenzidine equal to or greater than the reportable quantity of 1 pound (0.454 kg) 
(EPA 1985). It is subject to the requirements under the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (IRIS 1998). 
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Although the Food and Drug Administration (FDA) classifies 3,3’-dichlorobenzidine as a 
carcinogen, the agency has not enacted regulatory guidelines (NTP 1998) or issued advisories 
specifically targeting 3,3’-dichlorobenzidine as being a danger in the food supply. 
EPA has selected 3,3’-dichlorobenzidine and its mixtures for priority consideration for testing 
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Absorption-The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure-Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption-The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) 
to the surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)-The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at 
equilibrium. 
Adsorption Ratio (Kd)-The amount of a chemical adsorbed by a sediment or soil (i.e., the solid 
phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the 
solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical 
sorbed per gram of soil or sediment. 
Benchmark Dose (BMD) -is usually defined as the lower confidence limit on the dose that 
produces a specified magnitude of changes in a specified adverse response. For example, a 
BMD10 would be the dose at the 95% lower confidence limit on a 10% response, and the 
benchmark response (BMR) would be 10%.  The BMD is determined by modeling the dose 
response curve in the region of the dose response relationship where biologically observable data 
are feasible. 
Benchmark Dose Model-is a statistical dose-response model applied to either experimental 
toxicological or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF) -The quotient of the concentration of a chemical in aquatic 
organisms at a specific time or during a discrete time period of exposure divided by the 
concentration in the surrounding water at the same time or during the same period. 
Biomarkers-are broadly defined as indicators signaling events in biologic systems or samples. 
They have been classified as markers of exposure, markers of effect, and markers of 
susceptibility. 
Cancer Effect Level (CEL)-The lowest dose of chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed 
population and its appropriate control. 
Carcinogen-A chemical capable of inducing cancer. 
Case-Control Study-A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group of people with a specified and well-defined 
outcome is identified and compared to a similar group of people without outcome. 
Case Report-describes a single individual with a particular disease or exposure. These may 




Case Series-describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research but are not actual research 
studies. 
Ceiling Value-A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure-Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study-A type of epidemiological study of a specific group or groups of people who have 
had a common insult (e.g., exposure to an agent suspected of causing disease or a common 
disease) and are followed forward from exposure to outcome. At least one exposed group is 
compared to one unexposed group. 
Cross-sectional Study-A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs-substance-specific informational needs that if met would reduce the uncertainties of 
human health assessment. 
Developmental Toxicity-The occurrence of adverse effects on the developing organism that may 
result from exposure to a chemical prior to conception (either parent), during prenatal 
development, or postnatally to the time of sexual maturation. Adverse developmental effects may 
be detected at any point in the life span of the organism. 
Dose-Response Relationship-The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity- Any toxic effect on the conceptus as a result of prenatal 
exposure to a chemical; the distinguishing feature between the two terms is the stage of 
development during which the insult occurs. The terms, as used here, include malformations and 
variations, altered growth, and in utero death. 
Environmental Protection Agency (EPA) Health Advisory-An estimate of acceptable drinking 
water levels for a chemical substance based on health effects information. A health advisory is 
not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, 
and local officials. Epidemiology-refers to the investigation of factors that determine the 
frequency and distribution of disease or other health-related conditions within a defined human 
population during a specified period. 
Genotoxicity-a specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of 
specific alteration of the molecular structure of the genome. 
Half-life-a measure of rate for the time required to eliminate one half of a quantity of a chemical 




Immediately Dangerous to Life or Health (IDLH)-The maximum environmental concentration of 
a contaminant from which one could escape within 30 minutes without any escape-impairing 
symptoms or irreversible health effects. 
Incidence--The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified 
time period. 
Intermediate Exposure-Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles. 
Immunological Effects-are functional changes in the immune response. 
Immunologic Toxicity- The occurrence of adverse effects on the immune system that may result 
from exposure to environmental agents such as chemicals. 
In Vitro-Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo-Occurring within the living organism. 
Lethal Concentratioq(LO) (LCLO) -The lowest concentration of a chemical in air which has been 
reported to have caused death in humans or animals. 
Lethal Concentratioq(50) (LC50)--A calculated concentration of a chemical in air to which 
exposure for a specific length of time is expected to cause death in 50% of a defined experimental 
animal population. 
Lethal Dose(50) (LD50) -The lowest dose of a chemical introduced by a route other than inhalation 
that has been reported to have caused death in humans or animals. 
Lethal Dose(50) ( LD50)-The dose of a chemical which has been calculated to cause death in 50% 
of a defined experimental animal population. 
Lethal Tlme(50) (LT50)-A calculated period of time within which a specific concentration of a 
chemical isexpected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)-The lowest exposure level of chemical in a 
study, or group of studies, that produces statistically or biologically significant increases in 
frequency or severity of adverse effects between the exposed population and its appropriate 
control. 
Lymphoreticular Effects-represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.  Malformations-Permanent structural changes that may 
adversely affect survival, development, or function. 
Minimal Risk Level (MRL) -An estimate of daily human exposure to a hazardous substance that 
is likely to be without an appreciable risk of adverse noncancer health effects over a specified 




Modifying Factor (MF)-A value (greater than zero) that is applied to the derivation of a minimal 
risk level (MRL) to reflect additional concerns about the database that are not covered by the 
uncertainty factors. The default value for a MF is 1. 
Morbidity-State of being diseased; morbidity rate is the incidence or prevalence of disease in a 
specific population. 
Mortality-Death; mortality rate is a measure of the number of deaths in a population during a 
specified interval of time. 
Mutagen-A substance that causes mutations. A mutation is a change in the DNA sequence of a 
cell’s DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy-The gross examination of the organs and tissues of a dead body to determine the cause 
of death or pathological conditions. 
Neurotoxicity-The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)-The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen 
between the exposed population and its appropriate control. Effects may be produced at this dose, 
but they are not considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)-The equilibrium ratio of the concentrations of a 
chemical in n-octanol and water, in dilute solution. 
Odds Ratio-a means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among 
subjects who were not exposed to the risk factor). An odds ratio of greater than 1 is considered to 
indicate greater risk of disease in the exposed group compared to the unexposed. 
Organophosphate or Organophosphorus Compound-a phosphorus containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)-An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an &hour shift of a 40 hour workweek. 
Pesticide-general classification of chemicals specifically developed and produced for use in the 
control of agricultural and public health pests. 
Pharmacokinetics-is the science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism. Utilizing computational techniques, it provides the means of studying 




Pharmacokinetic Model - is a set of equations that can be used to describe the time course of a 
parent chemical or metabolite in an animal system. There are two types of pharmacokinetic 
models: data-based and physiologically-based. A data-based model divides the animal system 
into a series of compartments which, in general, do not represent real, identifiable anatomic 
regions of the body whereby the physiologically-based model compartments represent real 
anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model - is a type of physiologically-based 
doseresponse model which quantitatively describes the relationship between target tissue dose 
and toxic end points. These models advance the importance of physiologically based models in 
that they clearly describe the biological effect (response) produced by the system following 
exposure to an exogenous substance. 
Physiologically Based Pharmacokinetic (PBPK) Model - is comprised of a series of 
compartments representing organs or tissue groups with realistic weights and blood flows. These 
models require a variety of physiological information: tissue volumes, blood flow rates to tissues, 
cardiac output, alveolar ventilation rates and, possibly membrane permeabilities. The models also 
utilize biochemical information 4such as air/blood partition coefficients, and metabolic 
parameters. PBPK models are also called biologically based tissue dosimetry models. 
Prevalence-The number of cases of a disease or condition in a population at one point in time. 
Prospective Study--a type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study. A group is followed over time. 
q1*-The upper-bound estimate of the low-dose slope of the dose-response curve as determined by 
the multistage procedure. The ql* can be used to calculate an estimate of carcinogenic potency, 
the incremental excess cancer risk per unit of exposure (usually µg/L for water, µg/kg/day for 
food, and µg/m3 for air). 
Recommended Exposure Limit (REL)-A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40­
hour workweek. 
Reference Concentration (RfC)-An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive 
subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects 
during a lifetime. The inhalation reference concentration is for continuous inhalation exposures 
and is appropriately expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)-An estimate (with uncertainty spanning perhaps an order of magnitude) of 
the daily exposure of the human population to a potential hazard that is likely to be without risk 
of deleterious effects during a lifetime. The RfD is operationally derived from the No-Observed­
Adverse-Effect Level (NOAEL- from animal and human studies) by a consistent application of 
uncertainty factors that reflect various types of data used to estimate RfDs and an additional 
modifying factor, which is based on a professional judgment of the entire database on the 




Reportable Quantity (RQ)-The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). 
Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount established 
by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are 
measured over a 24-hour period. 
Reproductive Toxicity-The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the 
related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the 
integrity of this system. 
Retrospective Study-A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to casual factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk-the possibility or chance that some adverse effect will result from a given exposure to a 
chemical. 
Risk Factor-An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic, that is associated with an increased occurrence of disease or other health-
related event or condition. 
Risk Ratio--The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed. 
Short-Term Exposure Limit (STEL)-The American Conference of Governmental Industrial Hygienists 
(ACGIH) maximum concentration to which workers can be exposed for up to 15 min continually. No 
more than four excursions are allowed per day, and there must be at least 60 min between exposure 
periods. The daily Threshold Limit Value - Time Weighted Average (TLV-TWA) may not be 
exceeded. 
Target Organ Toxicity-This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single 
limited exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen - A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)-An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect. 
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)-An allowable exposure concentration averaged over a normal &hour 
workday or 40-hour workweek. . 
Toxic Dose(50) (TD50) - A calculated dose of a chemical, introduced by a route other than inhalation, 




Toxicokinetic-The study of the absorption, distribution and elimination of toxic compounds in the 
living organism. 
Uncertainty Factor (UF)-A factor used in operationally deriving the Minimal Risk Level (MRL) 
or Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are 
intended to account for (1) the variation in sensitivity among the members of the human 
population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the 
uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, 
and (4) the uncertainty in using Lowest-Observed-Adverse-Effect Level (LOAEL) data rather 
than No-Observed-Adverse-Effect Level (NOAEL) data. A default for each individual W is 10; if 
complete certainty in data exists, a value of one can be used; however a reduced UF of three may 
be used on a case-by-case basis, three being the approximate logarithmic average of 10and 1. 





ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 
U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act 
(SARA) [Pub. L. 99-4991, requires that the Agency for Toxic Substances and Disease Registry 
(ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of 
priority, a list of hazardous substances most commonly found at facilities on the CERCLA 
National Priorities List (NPL); prepare toxicological profiles for each substance included on the 
priority list of hazardous substances; and assure the initiation of a research program to fill 
identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available 
toxicological information and epidemiologic evaluations of a hazardous substance. During the 
development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable 
and sufficient data exist to identify the target organ(s) of effect or the most sensitive health 
effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily 
human exposure to a hazardous substance that is likely to be without appreciable risk of adverse 
noncancer health effects over a specified duration of exposure. MRLs are based on noncancer 
health effects only and are not based on a consideration of cancer effects. These substance-
specific estimates, which are intended to serve as screening levels, are used by ATSDR health 
assessors to identify contaminants and potential health effects that may be of concern at 
hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect 
level/uncertainty factor approach. They are below levels that might cause adverse health effects in 
the people most sensitive to such chemical-induced effects. MRLs are derived for acute (l-14 
days), intermediate (15-364 days), and chronic (365 days and longer) durations and for the oral 
and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not 
derived because ATSDR has not yet identified a method suitable for this route of exposure. 
MRLs are generally based on the most sensitive chemical-induced end point considered to be of 
relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or 
birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL 




MRLs are intended only to serve as a screening tool to help public health professionals decide 
where to look more closely. They may also be viewed as a mechanism to identify those hazardous 
waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of 
uncertainty because of the lack of precise toxicological information on the people who might be 
most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects 
of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this 
uncertainty consistent with the public health principle of prevention. Although human data are 
preferred, MRLs often must be based on animal studies because relevant human studies are 
lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more 
sensitive to the effects of hazardous substance than animals and that certain persons may be 
particularly sensitive. Thus, the resulting MRL may be as much as a hundredfold below levels 
that have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews 
within the Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup 
reviews, with participation from other federal agencies and comments from the public. They are 
subject to change as new information becomes available concomitant with updating the 
toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously 
published levels. For additional information regarding MRLs, please contact the Division of 
Toxicology, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road, Mailstop E­
29, Atlanta, Georgia 30333. 
A-3 3,3’-DICHLOROBENZIDINE 
APPENDIX A 
MINIMAL RISK LEVEL (MRL) WORKSHEET 






Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language. Its 
intended audience is the general public especially people living in the vicinity of a hazardous 
waste site or chemical release. If the Public Health Statement were removed from the rest of the 
document, it would still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern. 
The topics are written in a question and answer format. The answer to each question includes a 
sentence that will direct the reader to chapters in the profile that will provide more information on 
the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects and 
illustrate graphically levels of exposure associated with those effects. These levels cover health 
effects observed at increasing dose concentrations and durations, differences in response by 
species, minimal risk levels (MRLs) to humans for noncancer end points, and EPA’s estimated 
range associated with an upper- bound individual lifetime cancer risk of 1 in 10,000 to 1 in 
10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate 
data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide 
reliable, quantitative estimates of No-Observed-Adverse- Effect Levels (NOAELs), Lowest-
Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures. 
Representative examples of LSE Table 2-l and Figure 2-l are shown. The numbers in the left 
column of the legends correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 2-1 
(1)	 Route of Exposure One of the first considerations when reviewing the toxicity of a 
substance using these tables and figures should be the relevant and appropriate route of 
exposure. When sufficient data exists, three LSE tables and two LSE figures are 
presented in the document. The three LSE tables present data on the three principal routes 
of exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3, respectively). 
LSE figures are limited to the inhalation (LSE Figure 2-l) and oral (LSE Figure 2-2) 
routes. Not all substances will have data on each route of exposure and will not therefore 
have all five of the tables and figures. 
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(2)	 Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15-364 
days), and chronic (365 days or more) are presented within each relevant route of exposure. 
In this example, an inhalation study of intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3)	 Health Effect The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer. 
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the “System” column of the LSE table (see key 
number 18). 
(4)	 Key to Figure Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the 2 “18r” data points in Figure 2-l). 
(5)	 Species The test species, whether animal or human, are identified in this column. Section 2.5, 
“Relevance to Public Health,” covers the relevance of animal data to human toxicity and 
Section 2.3, “Toxicokinetics,” contains any available information on comparative 
toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are 
extrapolated to equivalent human doses to derive an MRL. 
(6)	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column. This permits comparison of NOAELs and LOAELs 
from different studies. In this case (key number 18), rats were exposed to 1,1,2,2­
tetrachloroethane via inhalation for 6 hours per day, 5 days per week, for 3 weeks. For a more 
complete review of the dosing regimen refer to the appropriate sections of the text or the 
original reference paper, i.e., Nitschke et al. 1981. 
(7)	 System This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  “Other” refers to any systemic effect (e.g., a decrease in body weight) not 
covered in these systems.  In the example of key number 18, 1 systemic effect (respiratory) 
was investigated. 
(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at 
which no harmful effects were seen in the organ system studied. Key number 18 reports a 
NOAEL of 3 ppm for the respiratory system which was used to derive an intermediate 
exposure, inhalation MRL of 0.005 ppm (see footnote “b”). 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the 
study that caused a harmful health effect. LOAELs have been classified into “Less Serious” 
and “Serious” effects. These distinctions help readers identify the levels of exposure at which 
adverse health effects first appear and the gradation of effects with increasing dose. A brief 
description of the specific endpoint used to quantify the adverse effect accompanies the 
LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less serious 
LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs. 




(11)	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset 
of carcinogenesis in experimental or epidemiologic studies. CELs are always considered 
serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the 
text may report doses not causing measurable cancer increases. 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are 
found in the footnotes. Footnote “b” indicates the NOAEL of 3 ppm in key number 18 
was used to derive an MRL of 0.005 ppm. 
LEGEND 
See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures 
help the reader quickly compare health effects according to exposure concentrations for particular 
exposure periods. 
(13) 	 Exposure Period The same exposure periods appear as in the LSE table. In this example, 
health effects observed within the intermediate and chronic exposure periods are 
illustrated. 
(14) 	 Health Effect These are the categories of health effects for which reliable quantitative 
data exists. The same health effects appear in the LSE table. 
(15) 	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on 
the log scale “y” axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure 
is reported in mg/kg/day. 
(16) 	 NOAEL In this example, 18r NOAEL is the critical endpoint for which an intermediate 
inhalation exposure MRL is based. As you can see from the LSE figure key, the open-
circle symbol indicates to a NOAEL for the test species-rat. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 
0.005 ppm (see footnote “b” in the LSE table). 
(17) 	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The 
diamond symbol refers to a Cancer Effect Level for the test species-mouse. The number 
38 corresponds to the entry in the LSE table. 
(18) 	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels 
are derived from the EPA’s Human Health Assessment Group’s upper-bound estimates 
of the slope of the cancer dose response curve at low dose levels (q1*). 






Chapter 2 (Section 2.5) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of 
existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to 
present interpretive, weight-of-evidence discussions for human health end points by addressing the 
following questions. 
1. What effects are known to occur in humans? 
2 . What effects observed in animals are likely to be of concern to humans? 
3 . What exposure conditions are likely to be of concern to humans, especially around
 hazardous waste sites? 
The section covers end points in the same order they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, 
chronic). In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) 
are also considered in this section. If data are located in the scientific literature, a table of genotoxicity 
information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, 
using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess 
cancer potency or perform cancer risk assessments. Minimal risk levels (MRLs) for noncancer end 
points (if derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to 
public health are identified in the Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). 
These MRLs are not meant to support regulatory action; but to acquaint health professionals with 
exposure levels at which adverse health effects are not expected to occur in humans. They should help 
physicians and public health officials determine the safety of a community living near a chemical 
emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs 
are based largely on toxicological studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 
2.5, “Relevance to Public Health,” contains basic information known about the substance. Other 
sections such as 2.8, “Interactions with Other Substances,” and 2.9, “Populations that are Unusually 
Susceptible” provide important supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology the Environmental Protection Agency (EPA) 




To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best 
judgment, represents the most sensitive human health effect for a given exposure route and 
duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative 
or qualitative) is available for all potential systemic, neurological, and developmental effects. If 
this information and reliable quantitative data on the chosen endpoint are available, ATSDR 
derives an MRL using the most sensitive species (when information from multiple species is 
available) with the highest NOAEL that does not exceed any adverse effect levels. When a 
NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive 
an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty 
factors of 10 must be used both for human variability to protect sensitive subpopulations (people 
who are most susceptible to the health effects caused by the substance) and for interspecies 
variability (extrapolation from animals to humans). In deriving an MRL, these individual 
uncertainty factors are multiplied together. The product is then divided into the inhalation 
concentration or oral dosage selected from the study. Uncertainty factors used in developing a 
substance-specific MRL are provided in the footnotes of the LSE Tables. 







